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ABSTRACT

DEVELOPMENT OF A PHARMACEUTICAL TABLET AUTHENTICATION
SYSTEM USING SPECTROSCOPIC TECHNIQUES IN COMBINATION WITH
MULTIVARIATE CHEMOMETRIC METHODS

By
Md Nayeem Hossain
May 2020

Dissertation supervised by James K. Drennen, III, Ph.D.

The spread of falsified drugs is increasing worldwide. Currently, 10%-30% of drugs
in the world are falsified. Unfortunately, the supply chain system of developing countries
(from manufacturers to customers) is not well monitored and suffers the highest rates of
fraudulent activities. Also, the rise of product procurement from the internet increases the
chance of American consumers' exposure to poor quality drugs. To combat this horrendous
activity, surveillance of pharmaceutical materials is required in the supply chain system.
Spectroscopic techniques (e.g., Near-Infrared and Raman spectroscopies) can be a potential
solution to authenticate samples in different locations; they are non-destructive, safe, rapid,
portable, and affordable. However, before deploying these techniques in the field, rigorous
method development is required with the help of chemometrics. The chemometric tools to
be used should declare the test sample as either target class (authentic samples) or noniv

target class (alternate class or falsified samples). One challenge of method development is
the sensitivity of spectrometers toward unwanted variabilities including moisture, batch to
batch variabilities, raw material variabilities, etc. Initial research for this dissertation
observed that the traditional chemometric methods, which are based on distribution
assumptions, provided a high number of false negatives due to violation of distribution
assumptions in the presence of unwanted variations. It was demonstrated that adding
samples from different seasons in the calibration set created binominal or multimodal
distributions due to moisture variations - which violated the assumptions of the principal
component analysis based soft independent modeling of class analogy (SIMCA) method.
Hence, the support vector data description (SVDD) method—which has no distribution
assumption—is proposed for use as a class modeling approach for authentication purposes.
Implementing the SVDD algorithm improved model performance by reducing false
negatives relative to the traditional multivariate class modeling approach (i.e., SIMCA). In
addition, while developing the SVDD method, this dissertation suggested using different
non-target class samples produced by competitor manufacturers or synthetic samples
generated in the laboratory using design of experiment (DOE) as test or validation set to
decrease false positives. This work also evaluated several commercially available products
in two local pharmacies using portable spectrometers to validate the practical usefulness of
the proposed methods. To summarize, the research performed for this dissertation has
demonstrated the value of critical prior knowledge regarding pharmaceutical products,
pharmaceutical manufacturing/processing, analytical methodology, and advanced
chemometric techniques in a unique way to develop a successful spectroscopic
authentication system.
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1 Chapter 1: Introduction
1.1

Background, Statement of Problem

A sound authentication process is vital to protect pharmaceutical materials from
falsification or any fraudulent activities. According to the World Health Organization (WHO), the
term “falsified medicines” can be defined as “Medical products that deliberately/fraudulently
misrepresent their identity, composition or source. Such deliberate/fraudulent misrepresentation
refers to any substitution, adulteration, or reproduction of an authorized medical product or the
manufacture of a medical product that is not an authorized product” [1]. Specifically, composition
refers to the raw material or final dosage form in accordance with applicable specifications
authorized/recognized by national or regional regulatory bodies. In May 2017, the WHO published
this definition of falsified products to bring harmony among the member countries and replaced
the word “counterfeit medicine” which was widely used [1].

Protection of pharmaceutical materials from fraudulent activities is becoming increasingly
critical as falsified products are more widely distributed. Currently, 10%-30% of drugs in the world
are falsified [2]. Unfortunately, the supply chain system of developing countries (from
manufacturers to customers) is not well monitored, and suffers the highest rates of fraudulent
activities [3, 4]. Also, the rise of product procurement from the internet increases the chance of
American consumers' exposure to poor quality drugs [2].

A variety of techniques have developed to eliminate such fraudulent activities. Among
these, visual inspections or image analysis have been used as the very first step of the identification
1

process. However, many counterfeiters and producers of falsified products can evade sophisticated
visual tests [5]. Therefore, a variety of analytical tools have been used to reveal the different
chemical compositions of falsified products from authentic samples. Among these analytical
methods, several rapid screening tools provide an effective way to increase the number of products
that can be subjected to chemical testing before reaching patients or consumers [6]. Handheld and
portable instrument platforms provide an opportunity to implement the screening process in more
locations (e.g., in different locations of the supply chain including rural hospitals, clinics,
drugstores, etc.). Spectroscopic techniques offer a number of advantages for screening
pharmaceutical products, including rapidity, portability, etc. In particular, Near-Infrared (NIR)
and Raman spectroscopies have been demonstrated to be valuable tools [7]. These spectroscopic
techniques are fast and easily deployable to different inspection sites, facilitating detection of
falsified drug products in developing countries to reduce the life-threatening prevalence of this
scourge [8-10]. Also, these spectroscopic techniques can be applied in the developed world to
advance internet-of-things (IoT) based smart applications.

However, the use of such spectroscopic techniques is not straightforward due to the
multivariate nature of the data and the significant variety of potential factors influencing the
analytical measurements. Therefore, rigorous method development is required, usually involving
advanced chemometric methods, before deploying such analytical techniques in the field. These
analytical systems should declare the test sample as either target class (authentic samples) or nontarget class (an alternate class, or falsified samples). All practical methods should offer good
performance in terms of limiting both false negatives (identification of samples as false samples
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when, in fact, they are authentic samples), and false positives (identification of samples as
belonging to the target class when they are actually false samples).

Two types of chemometric techniques have been well described in the literature for
authentication methods, including spectral matching (SM) and class modeling (CM) techniques
[11]. Most of the current portable spectrometers come with some variety of SM algorithm. These
algorithms facilitate the comparison of two spectra, including a reference spectrum collected from
a genuine or authentic material and a spectrum of the unknown material under study [12, 13].
These two spectra are used to calculate spectral correlation or spectral distance. If these correlation
or distance values match with a target threshold value, the unknown samples are declared as
genuine or authentic samples. Research showed that the SM method was successful when samples
included chemical differences, providing sufficient spectral uniqueness to allow detection [14, 15].
For example, the SM method was used to identify placebo samples and samples containing the
wrong API. However, this method struggled to differentiate samples containing identical APIs
and similar excipient compositions, resulting in high false positives [16].

A variety of class-modeling techniques can also be applied for authentication. Multivariate
methods such as SIMCA and its extended version, data driven SIMCA, etc. have been used for
spectroscopic identification of pharmaceutical samples. The primary premise of these methods is
to develop a target class using representative samples from an authentic source. A calibration
model is developed from the target class, which is comprised of spectral data containing API and
excipient information. Class-modeling (CM) estimates a decision boundary which is formed
around the data at a specific significance level. This boundary is developed based on certain
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assumptions regarding the data (e.g., normal distribution, 𝜒 2 distribution, etc.) [17-19]. The
pharmaceutical literature reveals several studies proposing that CM techniques are more powerful
than the SM method in separating samples containing similar compositions using portable
spectrometers [15, 20]. Critical considerations for the analytical method developer include
identifying an appropriate sample of target class product, adequately defining boundary conditions
for the target class, and selecting suitable non-target samples. CM methods will not be successful
without suitable training samples.

To achieve desirable performance, CM methods must account for the anticipated chemical
and physical variations to be encountered in the target class of product; NIR and Raman
spectroscopies are sensitive to different physical and chemical factors such as moisture variation,
tablet hardness, component particle size, instrument drift, etc. This is particularly important for the
implementation of spectroscopic methods in the field, as samples will be collected in various
locations. Therefore, models must include this variability at the outset, or must be updated with
new authentic samples over time to include new sources of variation. To limit the demands of
calibration updates that might be required due to such new target class variability, different spectral
preprocessing techniques are applied to remove or limit the spectral effect of this variability. While
different data processing techniques reduce the unwanted effect of these variabilities, adding new
samples over time to update the model by including such target class variability is sometimes
considered the most effective approach.

Defining appropriate boundary conditions for the target class is a critical aspect of defining
a suitable set of “good” product samples for model development. A test sample is assigned to the
4

target group if the computed distances of tested samples to model is shorter than a predefined
threshold value based on a mathematical boundary. However, several challenges arise during this
boundary formation. As analysts may be required to update the model by adding samples
containing recently evolved variations into the calibration sample set, these newly added samples
are often considered as extreme objects or outliers. Moreover, this may violate the assumptions of
the model by forming clusters or binomial distribution in the model space. Therefore, the caveat
of defining boundary condition is—without prior knowledge of the shape of the underlying
distribution of samples, satisfactory boundary formations may not be achieved.

A CM method can also be developed without relying on distribution assumptions. Unlike
the traditional CM methods used for the authentication, forming a decision boundary based on
boundary samples of the calibration set includes all of the samples produced during the model
update or after the risk-assessment. Support vector machine (SVM) based methods are a viable
approach for establishing a boundary through the identification of boundary samples. Here, an
algorithm developed by Tax et al. is proposed as a method for development of a spectroscopic
authentication system for pharmaceutical products [21]. This method is often identified as a
support vector data description (SVDD), which has shown similar performance to the one-class
support vector machine (OC-SVM) developed by Schölkopf et al [22]. The proposed SVDD
method has been applied for detection of machine faults, outlier detection, etc., but has not yet
been evaluated for analyzing pharmaceutical samples using spectroscopic data, particularly for the
authentication purpose.
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After developing a calibration model using an appropriate decision boundary, an analyst
should use a complex sample set to test or validate the model performance. Particularly, to validate
the model’s capability of rejecting falsified samples, it is critical to evaluate samples from alternate
classes. These samples are used to test the specificity of the method, which is the portion of
alternate class samples that are correctly identified as negative or outlier samples with respect to
the target class. In practice, alternate class samples may be very similar to the target class;
therefore, alternate class test samples must include samples that are ‘highly similar’ to the target
class. Usually, these ‘highly similar’ samples are those which contain the same API and similar
excipient composition and are manufactured using similar techniques. Therefore, the choice of the
alternate class test samples is essential for assessing false positives (FP). Legitimate generic
versions of the target class drugs that are manufactured by various producers can be used to test
the FPs as such drugs should contain identical API and may contain similar excipient
compositions. These non-target class samples should be used to optimize the boundary condition
of the proposed SVDD model. This avoids the unnecessary acceptance of non-target class samples
during boundary optimization and decreases FPs.

Because the analyst will not always have access to the competitors’ products during method
development, selecting an alternative strategy such as preparing samples using statistical design
of experiment (DOE) may be a suitable approach to overcoming the limitations associated with
inaccessible samples. Various challenging samples can be generated by altering the chemical
composition of target class samples using DOE. Moreover, depending on the analytical technique
to be used, the chemical compositions of non-target class samples may be unique based on the
inherent sensitivity to the chemical compositions. Utilizing both NIR and Raman spectroscopic
6

techniques could prove the value of using different non-target class samples for different
techniques.

1.2

Hypothesis and Specific Aims

The proposed hypothesis is:

Development of a support vector machine based algorithm with pertinent calibration and
validation sets enables a multivariate spectroscopic authentication method that provides a
superior system for both NIR and Raman spectroscopy compared to traditional multivariate
methods of classification (e.g., SIMCA).

Given the central hypothesis, the objectives of this dissertation are to:

1. Demonstrate the development of a robust authentication system using NIRS and a SVM
based algorithm in the presence of moisture variations.
2. Demonstrate the use of Raman spectroscopy and the SVDD algorithm for authentication
in the presence of moisture variations.
3. Demonstrate model development for the detection of ‘highly similar’ non-target class
samples collected from different developing countries (produced by various
manufacturers).
4. Demonstrate the application of DOE concepts to generate ‘highly similar’ samples for
testing of NIR and Raman spectroscopic systems.
5. Demonstrate portable NIR spectrometers as an onsite screening tool for rapid testing of
pharmaceutical samples.
7

In summary, the objectives of this dissertation were achieved by obtaining two figures of
merit as described in Figure 1-1:

Figure 1-1: Two primary goals of an authentication method, associated
challenges of each goal and steps taken to address the challenges.

The first two objectives addressed opportunities to improve the sensitivity of models
(decreasing false negatives) used for pharmaceutical authentication by addressing the critical
quality attributes and material attributes relevant to a robust authentication of pharmaceutical
samples. These parameters are crucial for both NIR and Raman techniques. In Chapters 2 and 3,
respectively, the work defines how a machine learning based algorithm can be used to improve
model performance of NIR and Raman spectroscopy and compared with an existing multivariate
method.

The next two chapters, Chapters 4 and 5, asses the model's ability to reject non-target class
samples by decreasing false positives (objectives 3 and 4). In Chapter 4, the document discusses
the analysis of a variety of highly similar samples, collected from across the globe and
manufactured by different companies. These were used to assess the performance of spectrometers
and models for pharmaceutical tablet authentication. Because a competitor’s product may not
8

always be available, the work of Chapter 5 demonstrated the use of laboratory generated tablets as
non-target class samples. Since the spectral response of different analytical techniques is unique
for any composition, unique non-target class samples are likely to be required in model
development for each different analytical technique. Finally, Chapter 6 describes the use of
portable spectrometers for sample analysis in the field. Two spectrometers were used to scan
pharmaceutical samples in local pharmacies.

The novelty of the work should be apparent due to 1) the requirement of applying critical
prior knowledge regarding pharmaceutical products, pharmaceutical manufacturing methods,
analytical methodology, and chemometric techniques, and 2) the application of a specific modern
approach to calibration development for a new application.

9

1.3

Literature Review of Falsified Drug Detection

Different chemometric methods have been used for the qualitative and quantitative
analyses of NIR and Raman spectral data to detect various types of falsified products. This
literature review compiles the details of such previously described work. Critical evaluation of
these chemometric methods is provided to define the inherent limitations. Finally, directions are
provided to develop an accurate and robust spectroscopic method for the authentication of
pharmaceutical products.

1.3.1

Analytical Method Development to Detect Falsified Drugs

Figure 1-2: Method development strategies for a pharmaceutical product
authentication system

Analyical method development starts with setting the goals of the analysis. This guides the
subsequent method development steps (see Figure 1-2). In this case, to protect pharmaceutical
products from any falsification activities, the analytical system should have the capabilities to
separate genuine products from falsified products. This target will be effectively achieved if
analysts are aware of the many potential falsified products. The pharmaceutical literature has
reported many approaches to falsifying both pure components and finished dosage forms [2]. Such
falsification frequently involves different counterfeit product composition. This includes, but is
10

not limited to, intentional adulteration of pharmaceutical ingredients, tablets prepared without
active pharmaceutical ingredient (API) (e.g., using only excipients), tablets manufactured using
the wrong API, and tablets generated with the correct API, but different compositions of excipients
(see Figure 1-3). Different types of falsified products are also compiled in Table 1-1.

Figure 1-3: Types of falsified products

NIR or Raman spectroscopy have been used successfully to detect different approaches to
falsification; examples of these counterfeiting activities are discussed in Section 1.3.2 (Step 2 in
Figure 1-2). Selection of analytical techniques to detect such falsification activities also depend on
the fundamental capability of the analytical techniques itself, which is further discussed in this
section [23, 24]. Both NIR and Raman spectroscopy will typically require multivariate modeling
approaches for the development of a suitable calibration model, discussed in Section 1.3.3 (Steps
3-4 in Figure 1-2). Development of a robust model will reduce the need to update a calibration
over time (discussed in Section 1.3.4). Finally, the chemometric approaches proposed in this
dissertation are provided in Section 1.3.5
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Table 1-1: Overview of representative pharmaceutical authentication studies using NIR and Raman spectroscopy,
including model development details regarding preprocessing, number of samples, cross-validation, robustness studies.

Category of falsified
products*

Analyzed medicine, brand
name in parenthesis.

Analytical techniques
and types (L- Lab
based, P- Portable)

Product origin(s)/ Source

Reported chemometric approaches and
relevant comments - preprocessing,
internal validation (type, split ratio),
external validation, model validation,
robustness testing, performance &
validation parameter.

Pure material

309 different USP materials

Raman L

USP material

peak match, correlation, and PP: first
derivative

[25]

Adulterants in the
raw material

DEG in glycerin, melamine
in lactose

Raman P

Lab based experiment

Spectral correlation method, PLS. PP:
Savgol 1st Derv, SNV, MNCN, CV:
LOOCV, Sensitivity, Specificity, RMSEP

[11]

Adulterant detection
in Tablet

glibenclamide

NIR-L, solid-phase
fluorescence
spectrometry

Brazil

SIMCA, PLS-DA, UPLS-DA; WS:GA,
SPA; Type I, Type II error.

[26]

Tablet without API.

chloroquine, ciprofloxacin
HCl, hydroxychloroquine,
levofloxacin, metronidazole,
quinine sulfate

Raman P

Commercially purchased
sample, simulated counterfeit

Spectral correlation, PP: SavGol (first
derivative, 2nd order, W-31-point),
wavelength selection to the API specific
regions

[27]

Tablet without API.

artesunate

-

PLSDA, Ncal=112, Ncounter=55, CV, PP:
mean-centering.

[28]

South-East Asia
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Ref.

Category of falsified
products*

Analyzed medicine, brand
name in parenthesis.

Analytical techniques
and types (L- Lab
based, P- Portable)

Capsule without API

miltefosine

NIR-L, LC-MS/MS

Product origin(s)/ Source

Bangladesh

Reported chemometric approaches and
relevant comments - preprocessing,
internal validation (type, split ratio),
external validation, model validation,
robustness testing, performance &
validation parameter.

Ref.

Spectral investigation

[29]

[30]

Tablet without API,
Tablet with wrong
API

artesunate

Raman L.

Vietnam, Laos PDR, Burma,
China, Ghana, Thailand-Burma
border

Spectral peak identification- assigned to
the corresponding functional groups, PCA,
K-mean clustering, Ncal- 50. PP: SavGol,
SNV (to remove fluorescence).
Robustness issue: API has strong
fluorescence background.

Tablet with wrong
API

atorvastatin

NIR L and Raman L,
LC-MS

Dutch Health Care
Inspectorate

PCA, PLS-DA, Robustness issue: Effect of
storage condition was tested

[31]

Tablet with wrong
API

acyclovir, amoxicillin,
cephalexin, ciprofloxacin,
doxycycline, levofloxacin

Raman-P

Commercially purchased,
counterfeit product was lab
based (simulated).

Raman barcode, PP: SavGol to remove
fluorescence.

[32]

Tablet without API,
Tablet with right API
but different
excipient
compositions

sibutramine

NIR L, Raman L, LCMS

Internet, Korea, Egypt, Libya,
Turkey, Syria, Philippines,
Thailand

Spectral analysis, PCA analysis.

[33]

Tablet without API,
Tablet with right API
but different
excipient
compositions

aspirin, ampicillin, KCL,
ampicillin, enalapril, (wide
variety of falsified drug)

NIR L

Brazil

PCA/SIMCA, N=50, CV: LOOV, PP:
SavGol (5 w, 2nd polynomial).
Robustness: effect of humidity alteration,
sample position and sample face (for
tablets) on model performance was tested.

[34]

Tablet without API,
Tablet with right API
but different
excipient
compositions

sildenafil citrate (Viagra)

NIR L, TLC, UV,
HPLC-DAD, HPLCDAD-MS

Netherlands

SavGol (2nd derivative) SC, PCA.

[35]
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Category of falsified
products*

Analyzed medicine, brand
name in parenthesis.

Analytical techniques
and types (L- Lab
based, P- Portable)

Product origin(s)/ Source

Reported chemometric approaches and
relevant comments - preprocessing,
internal validation (type, split ratio),
external validation, model validation,
robustness testing, performance &
validation parameter.

Tablet without API,
Tablet with right API
but different
excipient
compositions

sildenafil (Cialis)

Raman L, HPLC

Medsafe, intercepted at New
Zealand's International Mail
Centre

SIMCA, PLS-DA, SVM. PP= LBC, MSC.
N=250. Split: Cal-67%. Test-33%. CV,
Quantitative modeling: PCR, PLS

[36]

[37]

Ref.

Tablet without API,
Tablet with right API
but different
excipient
compositions

sildenafil

Raman L

China, Mexico.

PCA-HCA, PP: SavGol (13W), NCal=19,
NTest=9, Robustness: Baseline-corrected
before presentation, to eliminate the
influence of broad fluorescence
background

Tablet with right API
but different
excipients
composition

sildenafil

Raman L

Federal Agency for Medicines
and Health Products in
Belgium (AFMPS/FAG)

PCA (different wavelength range), LDA,
K-NN, SIMCA. CV: LOOCV. Ncal= 26,
Ntest= 12.

[38]

[13]

Tablet with right API
but different
excipient
composition

not specified

NIR P

Not specified

SC, PCA, PP: SNV, SavGol (2nd, W-5,
2nd order), unit vector normalization.
Robustness: lamp change, lot-to-lot
variabilities

Tablet with right API
but different
excipient
composition

atorvastatin calcium

Raman P, PXRD, X-Ray
tomography

India, Thailand, Pakistan,
Germany

Characteristic peaks around 1600 cm-1 was
used to determine whether Atorvastatin
was present or not.

[39]

Tablet with right API
but different
excipient
composition

trimethoprim, metronidazole

NIR

Not specified

PCA, SIMCA

[40]

Tablet with right API
but different
excipient
composition

antimicrobial, antispasmodiccoated, film coated, crushed wide varieties of counterfeit
product

NIR L, NIR Imaging

Not specified

PCA/SIMCA, PP: MSC, N=10

[41]
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Category of falsified
products*

Analyzed medicine, brand
name in parenthesis.

Analytical techniques
and types (L- Lab
based, P- Portable)

Product origin(s)/ Source

Reported chemometric approaches and
relevant comments - preprocessing,
internal validation (type, split ratio),
external validation, model validation,
robustness testing, performance &
validation parameter.

Tablet with right API
but different
excipients
compositions

calcium channel blocker

NIR P

Not specified

Correlation coefficient, SIMCA

[15]

Liquid ampoule with
right API different
compositions

dexamethasone

NIR-L, HPLC-DADMS, CE-UV

Not specified

SNV, SIMCA, PP: SNV, N=30

[42]

Injectable

doxofylline, Levofloxacin,
HPLC

Raman P

China

SC, CLS models., N(Dox)= 60,
N(Lev)=60.

[43]

[44]

[45]

Expired tablets

paracetamol

Raman P

China

Spectral Correlation; PP: max–min
normalization (MN), SavGol (1st and 2nd
deriv), N=120, CV: 7-round crossvalidation, SIMCA, PLS-DA, SVM, k-NN.
(SVM proved robust compared other
methods.)

Seized products

Not specified

NIR L, Raman L

Not specified

PCA, HCA, k-NN, PLSD-DA, SVM,
ANN, CV: venetian blinds, 9 splits.

Ref.

Note: USP: United Sates of Pharmacopeia; DEG: Diethylene glycol; PP: Preprocessing; Savgol: Savitzky–Golay; Ncal: Number of calibration sample; SIMCA: Soft independent
modelling by class analogy; PLS-DA: Partial Least Squares Discriminant Analysis; UPLS-DA: Unfolded Partial Least Squares with Discriminant Analysis; WS: Wavelength
selection; GA: Genetic algorithm; SPA: successive projections algorithm; Ncounter: Number of counterfeit samples; CV:Cross validation; LC-MS/MS: Liquid chromatographymass spectroscopy; LOOV: Leave one out of validation; TLC: Thin layer chromatography; HPLC-DAD: High-performance liquid chromatography with diode-array detection;
SC: Spectral correlation; SVM: Support vector machine; LBC: linear baseline correction; MSC: multiplicative scatter correction; PCR: principal component regression; PLS:
Partial least squares; regression; HCA: hierarchical cluster analysis; LDA: Linear discriminant analysis; K-NN: k-nearest neighbors; PXRD: Powder X-Ray Diffraction; CE:
Capillary electrophoresis; CLS: Classical Least Squares.* The mentioned category of falsified products are an approximation to give readers an idea of the types of products.
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1.3.2

Analytical Tools

1.3.2.1 Near Infrared Spectroscopy

Near-infrared spectroscopy (NIRS) is based on the absorption of electromagnetic radiation
in the range of 700 nm to 2500 nm, which includes overtone and combination bands of the
fundamental vibrations observed in the mid-infrared region [46]. NIRS is a useful analytical tool
due to its non-destructive nature and flexible sample interface. These properties provide extensive
opportunities for qualitative and quantitative prediction of critical components of pharmaceutical
products, managing critical process parameters and for assuring that products meet real-time
release criteria [47].

Detecting falsified pharmaceutical materials is one of the potential applications of NIRS.
Typically, this application is based on the comparison of the presence or absence of spectral
features of genuine products. A significant number of studies have been undertaken by NIRS for
the authentication of medicines. Significantly, medicines which are critical for treating diseases
prevalent in low and middle income countries, including antimalarial, antimicrobial, and
antispasmodic [28, 41] medicines, were successfully authenticated using NIRS [48]. While NIR
applications for detecting falsified drugs began in the laboratory, successful results led regulatory
bodies to use NIRS directly in the field. Initiatives using mobile van laboratories in rural areas of
China and India have set examples for other regions [49]. Advances in instrumentation technology
has led to dramatic reductions in the size of NIR spectrometers, with handheld devices now
available [50]. These spectrometers are light-weight and do not need any dedicated vehicle to
mount them onto. Typically, these spectrometers are available with sizes 20x10x5 cm (~8x4x2 in.)
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or smaller, and weights of just 1 kg (~2 lbs) or less. A good review of different hand-held
spectrometers will be found in Crocombe et al. [51]

In addition to the single point NIR spectrometer, another important spectral collection
mode of NIRS is hyperspectral chemical imaging (NIR-CI). This enables the collection of
additional information from pharmaceutical products such as the surface distribution of APIs,
excipients, powders and granules [52]. NIR-CI was shown to be superior to single-point NIRS in
some cases because it combines the capability of spectroscopy with the potential of visualization
of API and excipients in the falsified products [52]. Furthermore, NIR-CI can be useful to measure
both potency and the quality of the formulation, even without knowing the exact composition of
the drug, which is critical when falsified products are collected without prior information [53].

1.3.2.2 Raman Spectroscopy

Raman spectroscopy, a molecular spectroscopy, generates a polarization in the molecule
resulting in in-elastically scattered photons [54]. The spectrum observed from a Raman
spectrometer is a measure of the amount of energy a photon has lost (Stokes Raman scattering) or
gained (anti-Stokes Raman scattering) which is frequently expressed as wavenumber shift. Stokes
Raman scattering is most commonly measured because this is of higher intensity than anti-Stokes
scattering (due to the lower probability of the molecule being in an excited vibrational state).

Raman spectroscopy has demonstrated value as a method in the array of techniques for
pharmaceutical analysis [47, 55]. The advent of several configuration of Raman spectrometers
(backscattering, transmission, surface enhanced Raman (SER), and imaging systems) have opened
opportunities for the evaluation of different types of falsified samples [30, 31, 37, 56-58]. A
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primary advantage of Raman spectroscopy is the significant selectivity, which allows
identification of different APIs, excipients and impurities present in the pharmaceutical materials
[25, 59]. Packaging materials, including dyes, markers, etc., can also be authenticated with Raman
spectroscopy, adding to the list of advantages for this method in the fraud detection process [60,
61]. However, there are other possible ways to authenticate pharmaceutical packaging materials,
which are out of the scope of this review.

Like NIRS, application of Raman spectroscopy has also spread from benchtop to fieldbased use at the point of sample collection [62, 63]. Although the portable Raman spectrometer is
relatively new, it shows promise for detecting falsified and unapproved drugs [64]. Moreover,
similar to NIRS, the imaging configuration of Raman spectroscopy was also successfully used to
gain an understanding of the spatial distribution of formulation components of tablets [38, 65, 66].

Although both Raman and NIR spectroscopy have been proven effective for the detection
of falsified medicine, they are not without limitations. NIRS suffers from a lack of specificity issue
due to the absence of sharp peak features (due to broad overtones and combination bands) which
necessitates the careful use of multivariate chemometric methods. On the other hand, Raman
spectroscopy for chemical analysis suffers from relatively low sensitivity and interference from
fluorescence [59]. In spite of their relative advantages and limitations, both techniques have been
used successfully to detect falsified products (Table 1-1). Understanding these the potential of each
method facilitates selection of the appropriate analytical tool for development of suitable product
authentication systems.
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Table 1-2: Some features and shortcomings of NIR and Raman spectroscopy. Italics
indicate disadvantages
NIR

Raman

Advantages
Advantages
• Noninvasive
• Noninvasive
• Sensitive to the Physical factors
• Sharper peak features
including
particle
size
and
• Less sensitive to the physical factors
compression force
• Typically, API has strong
• Pharmaceutical excipients have strong
Raman signal.
NIR signal
• Penetration is higher for NIR light
Disadvantages
Disadvantages
• Fluorescence interferences
• Wide bandwidth
• Pharmaceutical excipients exhibit less
• Weak fingerprints of API and
Raman signal relative to the API
excipients
Penetration depth is lower (and often
insignificant for coated dosage forms)
1.3.3

Chemometric Techniques for Model Development and Relevant Applications

Numerous chemometric techniques have been used to extract the relevant chemical and
physical information from the collected NIR and Raman spectra of falsified samples. These
chemometric techniques can be divided into three categories:

i) spectral matching methods

ii) exploratory analysis, and

iii) supervised techniques

As mentioned, various types of fraudulent activities (formulation approaches to
counterfeiting) will generate unique spectral characteristics. The chemometric techniques to be
reviewed have been applied for detecting different scenarios anticipated in counterfeiting. Uses of
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these chemometric techniques are discussed below, with a description of theory and relevant
applications. Criticisms of each method will be provided to give the reader an understanding of
their limitations for the application of authentication.

1.3.3.1 Spectral Matching Method
1.3.3.1.1 Theory

Historically, spectral features of known components have been used to accomplish
qualitative identification of pharmaceutical samples. This would involve assigning absorbance
bands to corresponding functional groups of the expected component. Then, the presence or
absence of these spectral bands in the sample spectra could be used to distinguish between genuine
and falsified products [12]. However, this method requires recognition of the distinct peaks and
may not be suitable for automatic detection by non-specialist analysts in the field. To simplify a
field analyst’s work, spectral matching (SM) algorithms have been used to compare spectra of
unknown test samples to a reference spectrum collected from genuine material. SM algorithm
compare the proximity between vectors of a reference (or genuine) sample and an unknown sample
to determine sample identity [67].

Proximity is computed by calculating distance and spectral correlation. Distance is also
often described as SD, a spectral dissimilarity (i.e., the greater the distance, the less similar the
objects are), which is measured based on following relations: the sum of least squares (Equation l
), and the sum of absolute value differences (Equation 2) [68].
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1

(𝐿𝑖𝑏𝑚 − 𝑈𝑛𝑘𝑛𝑚 )2
𝑆𝐷1 = √(100 ∗ ∑
)
𝑁
1
𝑆𝐷2 = ( ) ∑ |𝐿𝑖𝑏𝑚 − 𝑈𝑛𝑘𝑛𝑚 |
𝑁

2

Here N is the number of data points, and 𝐿𝑖𝑏𝑚 and 𝑈𝑛𝑘𝑛𝑚 is the 𝑚𝑡ℎ absorption value in
the library spectrum and the unknown spectrum, respectively. As 𝑆𝐷1 and 𝑆𝐷2 calculate
dissimilarity between the spectra, their minimum value is 0 for identical spectra. On the other hand,
spectral correlation (𝑆𝐶), which is often mentioned as a similarity, is the equivalent of measuring
the cosine of the angle between two spectra.

𝑆𝐶 = 100 ∗ √[(𝐿𝑖𝑏𝑚 ∙ 𝑈𝑛𝑘𝑛𝑚 )2 ]/[(𝐿𝑖𝑏𝑚 ∙ 𝐿𝑖𝑏𝑚 )(𝑈𝑛𝑘𝑛𝑚 ∙ 𝑈𝑛𝑘𝑛𝑚 )]

3

Here, 𝑆𝐶 measures the similarity between the spectra; and 𝑆𝐶 values range from 0 (poorest
match possible) to 1 (perfect match).

Generally, the SM method can be employed for identification and verification. Before
applying the SM method for identification, a reference library is developed using authentic
samples. An unknown sample is systematically compared with spectra in the reference library by
using equations 1-3. The corresponding reference spectrum, which has minimum distance or
maximum correlation with the unknown sample, is declared as the potential target sample (e.g.,
target product or target manufacturer). This approach is often referred to as a library search. For
verification purposes (e.g., to verify whether the claimed component is present in the sample or
not, or if the test sample is an authentic product) the 𝑆𝐷 or 𝑆𝐶 value is directly calculated using
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target reference spectra. A verification test uses empirically defined target threshold values,
usually 0.95, to assign a “Pass” or “Fail” determination to the sample under study [69, 70].

1.3.3.1.2 Applications of Spectral Matching Method

The application of a spectral matching methods to the chemical analysis was reviewed
nearly two decades ago by Penchev [67]. The author evaluated the performance of SM methods
using infrared spectroscopy. Since 1996, the use of this chemometric technique in the
pharmaceutical industry has continued, with increased interest in its application using other
analytical tools, such as Raman and NIR spectroscopic methods [14, 71, 72].

McCreery [25] in 1998, was one of the first to use Raman spectroscopy with a SM method.
His work involved testing the identity of pure pharmaceutical materials. First, a reference library
was prepared using 309 United State Pharmacopeia (USP) standard compounds. Then, a total of
26 unlabeled vials were scanned blindly and used as a test set. After that, the developed reference
library was used to calculate SM values for each of the test samples. The highest matching value
obtained from the reference library was declared the identity of the test sample, and around 96%
of the test samples were accurately identified. Authors noted that the use of the right preprocessing
method was critical for getting a successful result, as it affected matching values significantly [25].
Although the components were successfully identified in the McCreery study, it is important to
understand that the library search method relies on the listed components already presented in
library and provided the best probable compound as the possible target sample.

While detecting pure components using spectroscopy, it is also required to study whether
the SM method is able to detect contaminants in the sample. As mentioned earlier, to verify
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whether the contaminant is present in the sample, the matching value of the test sample to the
claimed compound is calculated directly using SM algorithm. This accurate detection of
contaminants is of particular importance when dealing with pharmaceutical excipients because
they are susceptible to economically motivated adulteration with substances having comparable
physical, chemical, and/or spectroscopic properties. The result is not only financial loss for the
patient, but these adulterants can also cause severe health risks. For example, several adverse
events have been reported due to adulteration of glycerin with diethylene glycol (DEG) [73] and
melamine in baby formula [74]. Therefore, when an analyst uses a spectral matching method to
identify the presence of active components, the method should also be sensitive to the presence of
contaminants.

Several studies using Raman spectroscopy have been conducted to address the SM method
sensitivity for distinguishing adulterants while detecting the presence of anticipated raw materials.
[72, 75, 76]. Various adulterants (e.g., DEG in glycerin, melamine in lactose, and DEG in
polyethylene glycol) were successfully identified using a spectral matching method [11]. However,
the limit of detection by the SM method depends on the intrinsic spectral properties of the
materials. For example, glycerin and DEG are spectrally very close and the SC value of glycerin
gradually changes as the amount of DEG in the test set increases (see Figure 1-4A). Rodriguez and
colleagues published a method to measure the detection limit of impurities while using SM method
[72]. Experiments were conducted for a range of DEG in glycerin compositions; 𝑆𝐶 was calculated
for each of the compositions, and a polynomial line was drawn using 𝑆𝐶 values. From this line,
the authors estimated the exact DEG compositions that would be expected to cause the 𝑆𝐶 test to
deliver a failed result. In Figure 1-4B, it can be observed that while changing DEG composition,
𝑆𝐶 remained unchanged until the composition reached 10%. Afterwards, the 𝑆𝐶 value begins to
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drop noticeably, crossing the 0.95 threshold when DEG is around 18%. Therefore, the authors note
that if glycerin contains DEG below a content of 18%, contaminated samples will be misidentified
as the pure sample. Additional studies are required to justify this detection limit, as the threshold
value of 0.95 used by this study is an arbitrary value; there is no probabilistic interpretation
associated with this. While setting the detection limit, other validation criteria such as sample
repositioning analyst to analyst variability, etc., should also be considered. Other factors which
may also affect the method quality include intra- and inter-day variability. Setting threshold values
based on probability statistics would enhance confidence in the limit of detection.

Another potential solution to detect DEG might be to use unique spectrometric methods.
For example, DEG and glycerin may have different spectral features in the NIRS, which will be
more effective for detecting DEG in glycerin. Of course, thorough investigations would be
required to develop NIRS methods for detecting adulterants.
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Figure 1-4: (A) The Raman spectra for a series of glycerin-DEG samples. From
bottom to top, the spectral correlation value diminishes as the DEG amount
increases. (Glyc- glycerin; DEG- diethylene glycol). (B) Quantifying the effect of
increasing DEG on Raman spectra for the glycerin–DEG system. The red dotted
line is the threshold value (0.95) to pass the test. The spectral correlation value is
expected to drop below the threshold when glycerin samples contain 18% DEG or
more. Figures obtained from Rodriguez et al [77], Copyright (2014) with
permission from American Chemical Society.
The SM method has also been applied to detect falsified tablets. One potential approach is
to detect API in tablets using a pure component spectral library. Since 50% of tested falsified
products do not have the claimed API, or contain the wrong API [27], such a method can screen
this type of falsified product. Loethen et al. [27] attempted to detect falsification in antimicrobial
and antimalarial tablets acquired from multiple manufacturers. The spectral library was prepared
using the antimicrobial and antimalarial pure components. Results showed that all the samples
acquired from different manufacturers had a correlation value higher than 0.95 with the claimed
API while lab-based products, which did not contain any API, had low SC values (see Figure 15). According to this method, samples manufactured by any company can be authenticated using
a pure component library, eliminating the need to collect sample spectra from each manufacturer
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while developing a reference library. Therefore, this method would appear promising for detecting
the presence of the declared API.

Figure 1-5: SC values were calculated for drug product spectra compared to the
API library spectra. The numbers in parenthesis ( ) are the number of
manufacturers in the sample set. Adapted from Loethen et al [27], Copyright
(2015) with permission from Society of Public Analysts (Great Britain),
Chemical Society (Great Britain), Society for Analytical Chemistry, Society of
Public Analysts (Great Britain), Royal Society of Chemistry (Great Britain).

Though detecting API in the finished dosage form is an efficient process, this approach has
more potential for Raman spectroscopy due to the presence of sharp API features relative to that
for excipients. While Raman offers sharper absorbance bands, NIRS has an advantage of more
significant excipient signals compared to Raman, due to the presence of C-H and C=O bonds in
the excipients. Ultimately, it is assumed that excipient signal will be overlapping with API peaks,
making Loethen’s method impractical for NIRS. Additionally, samples evaluated by the Loethen
group were relatively high-dose formulations. Low-dose drugs with overlapping API and excipient
bands would provide difficulty in extracting the API signal using a SM method.
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Rather than using the SM method with pure component libraries, some researchers have
used the method to compare authentic samples with test samples allowing both NIR and Raman
spectroscopy to be used for authentication of various finished dosage forms [14, 35, 78-80].
Because samples spectra would contain the data from each component, this method can be used to
authenticate whether a solid dosage form contains the correct formulation. However, using sample
spectra also has barriers. One limitation is the sensitivity of the analytical method. Studies have
shown that, since different generic samples of a specific therapeutic group will often contain
similar formulations (i.e., excipient compositions are often very similar to each other), both NIRS
and Raman were unable to differentiate generic products from different manufacturers using the
SM method [14, 15]. Therefore, cautions application of this method is recommended for
authentication purposes.

1.3.3.1.3 Limitations of Spectral Matching Method

While the SM method has been useful for authentication of pure materials and finished
products, the method has many limitations. The biggest drawback is that there is no specific
direction established for setting a threshold value while using spectral correlation algorithms.
Many studies used a threshold of 0.95 to determine whether two spectra are matched [13, 15, 35,
79, 80]. However, this value does not imply any probability or assurance statistics. Moreover, in
different studies, this threshold was determined on a system-by-system basis to suit the desired
application and the pass/fail decision was taken based on that unique threshold. Several examples
are provided in Table 1-3, where different applications demonstrated the unique threshold values.
For example, to differentiate the products produced from different manufacturers, threshold values
were set to 0.99 for NIRS and 0.95 for Raman spectroscopy.

27

Table 1-3: Variation of spectral correlation method in different scenarios
Analytical technique

Applications

NIR

Differentiating batches
Differentiating
manufacturers
Differentiating batches
Differentiating
molecules
Differentiating
manufacturers
Differentiating expired
products
Differentiating liquid
injectable

NIR
NIR
Raman
Raman
Raman
Raman

Spectral Correlation
Threshold
0.9999

Ref.
[80]

0.99

[15]

0.996

[13]

0.92

[14]

0.95

[27]

0.996-0.998

[44]

0.95

[43]

Additionally, the threshold can be affected by many external factors such as spectral noise,
environmental temperature, operator variability, etc. Unfortunately, most of the studies which
applied the SM method did not validate that the developed method would perform consistently
over time, since they did not consider the fluctuation of these external factors [72]. While
developing a spectral library, spectra should be collected more rigorously to avoid the effect of
this external variability. If an effect is observed, the relative standard deviation of the measurement
should be reported.

Another limitation of this method is illustrated when it is used to test high quality falsified
medicines. High quality falsified medicines are commonly produced with a recipe that is similar
to the genuine product and manufactured with modern equipment [15, 16, 40]. Most often, one or
two excipients vary in the high quality fake products, compared to the genuine products. This
causes minimal spectral differences between samples, which is insufficient to separate falsified
product and genuine samples by the SM method.[14, 15]
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Moreover, the effect of excipient variation on the correlation value will vary for different
analytical techniques. As Raman spectroscopy offers lower spectral absorbance for excipients
compared to NIR spectroscopy, small changes in formulation may be more difficult to detect using
Raman spectroscopy [31, 45]. However, a comprehensive comparative study between Raman and
NIR spectroscopy has not been conducted to fully understand the effect of formulation changes on
the SM method. Therefore, further studies are required to understand the effect of different spectral
features of the commonly used excipients on the SM method.

1.3.3.2 Exploratory Methods of Data Analysis

Exploratory methods of data analysis have been used to measure similarity or dissimilarity
of samples without any prior information regarding their identity. These types of analyses are often
called as unsupervised methods, as the analysis procedure does not have affiliation with the group
or the source of the data. Principal component analysis (PCA) and clustering analysis (CA) are
two of the most often applied methods for exploratory data analysis.

1.3.3.2.1 Theory

Principal component analysis (PCA): The PCA method projects multivariate spectra into
low-dimensional space, highlighting the variabilities present in spectral data, although not
specifically identifying the cause of such variability [81, 82]. Spectral variability arising from
unique sample characteristics (physical or chemical) can often be visualized by this technique.
PCA decomposes the multivariate response arranged in an X matrix into a product of two new
matrices as indicated in the following equation:
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𝑋 = 𝑇𝑘 𝑃𝑘𝑇 + 𝐸

4

Where 𝑇𝑘 is the matrix of scores which represent how samples relate to each other, 𝑃𝑘 is
the matrix of loadings which contain information about how variables relate to each other, k is the
number of factors included in the model and E is the matrix of residuals, which contains the
information not retained by the model. Falsified products often have different chemical profiles or
are produced by different manufacturing conditions which are discernable by this data
decomposition mechanism [41]. Additionally, PCA is convenient to use for other chemometric
methods, such as clustering analysis, SIMCA, support vector machines etc., which will be
discussed in subsequent sections. The reader is referred to the works of Wold et al. [81] and
Martens & Naes [82] for a more detailed discussion of PCA.

Clustering method (CA): Clustering involves the partitioning of a dataset of ‘n’ objects in
such a way that objects in the same group (cluster) are more homogeneous to each other than to
those in other groups. Clustering analysis is accomplished using the entire spectra or using scores
of the principal components computed with the previously described PCA models. Grouping of
multivariate data is based on a similarity criterion. Many concepts and definitions of how to score
the chemical or physical similarity between two samples or variables have been proposed in the
literature [83, 84]. Among these, Euclidian distance, Mahalanobis distance, and correlation
coefficient are commonly used to calculate similarity indices [84, 85]. These similarity indices
are used to cluster the data in two ways: i) partition clustering and ii) hierarchical clustering. The
partitioning method uses similarity indices to separate the dataset into user defined groups,
whereas hierarchical clustering establishes a data hierarchy. It should be noted that while clustering
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methods may identify patterns in the data, but a conclusion about sample identity (whether falsified
or genuine) should not be drawn from such method.

1.3.3.2.2 Applications of Exploratory Methods

PCA: PCA has been successfully applied to visualize the difference of genuine and
falsified samples. Dégardin et al. [86] presented a large and complicated NIR data set which
included 29 different pharmaceutical product families. Some of the product families have similar
spectral signatures as they used similar excipients. Moreover, low dosage forms resembled the
spectral signatures of placebo samples. However, while PCA was applied to this dataset, the first
two PC scores enabled visualization of only two groups, while PC 3 and PC 4 helped to observe
at least eight other groups. Consequently, after considering additional PCs, most product families
were discernable (See Figure 1-6). Therefore, transforming raw spectra to a lower dimension made
these samples statistically different. This is advantageous for falsified drug detection, as falsified
products often contain unique formulations in comparison to genuine samples [63].
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Figure 1-6: Results of the PCA applied to the calibration spectra pretreated with
SNV. Each color represents one of the 29 product families. Figure obtained from
Dégardin et al. [86], Copyright (2016) with permission from Elsevier.
Since falsified drugs are typically manufactured without the benefit of Current Good
Manufacturing Practice (cGMP), the poor quality of these products is typically reflected in higher
inter- and intra-tablet variabilities of components. Inter-batch variability will also be more
significant than is typical for genuine products [41, 80, 87, 88]. These variabilities can usually be
distinguished by NIRS or Raman spectroscopy using the PCA method. Rodionova et al. [41]
showed that the spread of scores (generated from spectral data) in falsified products was higher
relative to that of the genuine samples (see Figure 1-7A). Here, single point spectrometers were
used to visualize these inter-tablet variabilities.
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To demonstrate intra-tablet variabilities, a NIR-CI imaging system was used in other
studies. Statistical parameters of score distributions (mean, standard deviations, skewness) showed
significant differences between genuine and falsified medicines [89, 90]. Figure 1-7B shows a PC
image of the falsified (left) and genuine samples(right).

Figure 1-7: (A) PCA scores plot of genuine tablets (dots) and falsified tablet
(squares). Tablets were also cut and the internal surface scanned; genuine and
falsified samples are displayed in open dots and squares B) NIR Hyperspectral
imaging of counterfeit (left) and original tablet (right). Figures obtained from A)
Rodionova et al. [41], Copyright (2005) and B) Wilczyński et al. [90], Copyright
(2016), with permission from Elsivier.
Compared to NIRS, Raman spectroscopy may demonstrate greater sensitivity towards the
variation of API between genuine and falsified products. Neuberger et al. [91] systematically
investigated the capability of Raman to differentiate chemically dissimilar samples. Raman
spectroscopy distinguished samples with different coating levels, varying amount of drug loading,
and different excipients using PCA. Also, Raman spectroscopy successfully detected the
degradation of aspirin over time due to changes in storage conditions [91].

Additionally, by analyzing the loadings plot of PCA analysis, it is possible to discern
probable reasons for score variations. Ryder et al. [92] showed that the loading plot was correlated
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with narcotic components, which might have been attributed to the API variation. The character
of a loadings plot may provide information related to the presence of a certain molecule, which is
especially critical when samples are seized by law enforcement without any packaging or details
regarding sample origin [92].

Along with chemical content, the physical structure of the samples often provides useful
information to detect falsified products, since it is difficult for fraudulent manufacturers to follow
exact manufacturing steps such as blending, granulation, compression, etc. NIR spectra are
sensitive towards the physical characteristics of the sample, and this can make NIR measurement
information-rich. For example, samples manufactured at two different sites can be distinguished
using NIRS [35]. Vrendenbregt et al [35] demonstrated that similar tablets from two manufacturing
sites (Europe and the USA) were statistically separated by PCA. In another study, acetaminophen
tablets prepared in the United Kingdom and Malaysia were also identified accurately using PCA
[80]. Neuberger et al. [95] aimed that Raman is not adequately sensitive to detect physical
differences (e.g., density variability associated with compression force, mixing quality), which
ultimately created minimum PCA variations among these samples (see Figure 1-8). However, this
study did not consider other physical factors such as particle size variations, tablet size, etc., which
might have effects on Raman spectra. Therefore, further studies are required to investigate whether
falsified and genuine samples are differentiable based on the physical factors of the samples using
Raman spectroscopy.
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Figure 1-8: Score plot of PC1 and the PC2 of the samples which were prepared
using different compression force. (very low = black, low = red, optimal = blue
and high = green). Figure obtained from Nuremberg et al. [91], Copyright (2015)
with permission from Elsevier.

Cluster Analysis (CA): It is known that the global spread of falsified drugs is most likely
funded by organized criminal activity involving manufacturers, wholesalers, distributors and local
sellers. Hence, there is significant possibility that some falsified products are manufactured from
common sources [33]. Investigating the source of such falsified drugs will be helpful in finding
the origin of criminal activities. Various types of cluster analysis facilitate the development of
dendrograms, which may provide an opportunity to visualize the clusters of the seized samples
ultimately help to separate genuine from falsified drugs.
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Figure 1-9: Dendrogram computed using Euclidean distance and average linkage
method. NIR spectra were collected from capsules and SNV preprocessed. Figure
obtained from Been et al. [45], Copyright (2011) with permission from Elsevier.
Been et al. [45] used a large database of samples which were seized from 27 different
regions and a hierarchical clustering method was applied to form a dendrogram by computing
Euclidean distances to separate the underlying groups (see Figure 1-9). Authors found that 12 types
of chemical profiles existed among these seized samples; the unique profiles were later confirmed
by the reference method. This cluster formation was beneficial for profiling newly acquired
samples. New samples were projected to these 12 groups and the distances between the test sample
and different clusters were calculated. The cluster which provided the minimum distance was the
suspected source of the seized sample. Therefore, cluster analysis helps to efficiently investigate
the sources of different falsified products [42, 45, 53, 56].

1.3.3.2.3 Limitations of Exploratory Methods

Though PCA is one potential approach to identifying falsified samples, certain challenges
exist for the application of this algorithm. One of the drawbacks is that a large number of samples
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are required to build an effective model. Preparation of a sufficiently large reference library can
be difficult for the PCA method. Unfortunately, there is no clear direction as to how many samples
should be used for method development and the number of samples needed for PCA analysis varies
across studies [88, 93]. Additionally, the boundary design, which is often 95% equal frequency
ellipses, varies depending on the nature and quality of samples used in calibration development
[31, 40, 89, 91]. As PCA explains the variation between groups, it is challenging to separate sample
groups when intra-group variation is higher than inter-group variability. Therefore, representative
samples should be collected from the pool of genuine samples for the development of the PCA
method.

Cluster analysis is useful to understand the types of seized samples. However, the most
significant challenge for the analyst is setting an appropriate threshold value, as the actual number
of potential sample groups is unknown to the analyst. Arbitrarily setting a threshold value often
results in an over-classification or under-classification problem. This becomes more critical when
the same source of sample has high batch-to-batch variability. Therefore, samples from the same
source may be classified into two different clusters. Even genuine samples can be clustered into
two groups if they are stored under unique conditions [94].

As there is generally no reference information used for the unsupervised method, careful
interpretation of PCA or CA results is required. While in typical pharmaceutical applications of
NIRS or Raman spectroscopy, it is comparatively straightforward to gain an understanding of the
score variability because samples are relatively well characterized, for falsified sample detection
the samples are obtained without much detail about the source. To ensure the correct interpretation
of the visualized differences of PCA or CA, the data collection should be consistent across the
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samples. For example, if repositioning error dominates in the spectral pattern, it is difficult for the
analyst to make conclusions about the source of variation in the scores.

1.3.3.3 Supervised Techniques
1.3.3.3.1 Theory

Supervised techniques are the most applicable methods for false product identification
since they provide direct decisions about the test samples (whether it is falsified/genuine).
Supervised techniques are mainly classified into two categories: class-modeling and
discrimination. Class-modeling (also known as the soft classification approach) allows samples to
be assigned to one or multiple groups. However, discrimination methods (also known as hard
classification methods) always allow a sample to be considered as a member of only one group
from the pool of groups being considered. This is illustrated in Figure 1-10, where examples of
B

both the class-modeling and discrimination approaches are shown for a data set where objects are
described by two variables and grouped into three classes (blue, green and brown). When a classmodeling technique is applied, each class space is separated by a specific boundary from the rest
of the data space (Figure 1-10A). Considering three unknown subjects (T1, T2, T3), T2 is considered
as class 2, whereas here T3 is considered as an unclassified object, and T1 falls outside the model
boundary, and therefore cannot be considered at all.
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B

A

Figure 1-10: Example of both class-modeling (A) and discrimination (B) on a data
set including 52 objects described by two variables and grouped into three classes
(blue, green, and brown circle). Figures adapted from Ballabio et al. [83], Copyright
(2009) with permission from Elsevier.
In the case of discrimination, T1, T2 and T3 must be classified into three classes (see Figure
1-10B). These objects are projected into data space and assigned to the category corresponding to
the hyperspace where they are placed. T1 and T2 are assigned to class green, even if T1 is far from
the green samples, while T3 are recognized as blue [83, 95].

The outcome of these two supervised classification methods is assessed by two important
figures of merit: sensitivity and specificity [83, 96-98]. Sensitivity is defined as the percentage of
samples correctly classified to the class of interest. Authentication methods should be able to
identify the genuine samples correctly, reflecting the sensitivity of the model. Specificity is defined
as the percentage of samples correctly rejected, since it is also important to recognize different
types of falsified products, and reject them [99]. These two parameters are calculated by the
following formulas:

Sensitivity= 𝑇𝑃/(𝑇𝑃 + 𝐹𝑁)

5
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Specificity= 𝑇𝑁/(𝑇𝑁 + 𝐹𝑃)

6

where TP, TN, FP and FN are true positive, true negative, false positive and false negative,
respectively [99]. A visual tool that compares sensitivity with (1-specificity), is the so-called
receiver operating characteristic (ROC) curve, which has been applied in spectroscopic
classification methods [96, 100]. By calculating the area under the ROC curve, it is possible to
derive a summary performance parameter for sensitivity and specificity that may serve as adequate
figures of merit for model comparisons.

An assortment of multivariate modeling approaches has been developed to be used both as
class-modeling and discriminant methods. Here, some of the most commonly applied techniques
are briefly discussed. More detailed information on the considered techniques can be found in the
technical literature [18, 84, 96, 97].
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1.3.3.3.1.1 Class-Modeling Approach: SIMCA

SIMCA is a PCA based approach where calibration samples are used to develop a PCA
model. After decomposing the data and reducing it to lower dimension, a decision boundary is
formed. Over the years, different versions of SIMCA models have been developed based on unique
approaches to boundary formation around the training set. These different versions are based on
two distances: 1) score distance (SD): determined by computing the distance in PC space between
an unknown sample and a target group, referred to as Hotelling’s 𝑇 2, and 2) orthogonal distance
(OD): determined by calculating the unknown sample’s squared residual distance to the model
space, known as the 𝑄 residual [17, 18, 82, 101-104].

The 𝑄𝑖 statistic is defined as the sum of squares of the residuals and can be calculated
according to Equation 2, where 𝑒𝑖 is the residual of sample i after applying the SIMCA model.

The Hotelling’s 𝑇 2 measures the information of each sample within the PCA or SIMCA
model and is calculated by means of Equation 1, where 𝑡𝑖 is the 𝑖-th row of the 𝑇𝑘 , the 𝑛 by 𝑘
matrix of 𝑘 score vectors from the PCA model, and matrix of 𝑘 scores vectors from the PCA
model of 𝑛 number of target class samples and 𝛬−1 is a diagonal matrix containing the inverse of
the eigenvalues associated with the 𝑘 eigenvectors (principal components) retained in the model.

The 𝑄𝑖 statistic is defined as the sum of squares of the residuals and can be calculated
according to Equation 2 where 𝑒𝑖 is the residual of sample i after applying the SIMCA model.
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𝑇𝑖2 = √𝑡𝑖 𝛬−1 𝑡𝑖𝑇

7

𝑄𝑖 = 𝑒𝑖 𝑒𝑖𝑇

8

Figure 1-11: Graphical representation of Hotelling’s 𝑇 2 and 𝑄 residual. Threshold
boundary based on 𝑇 2 versus 𝑄 residual. The acceptance area is the squared space
in the graph, where samples plotted at any point outside of this area are rejected.
According to this threshold, nearly every sample will be accepted, with only the
green sample being rejected. A more flexible boundary could be applied as shown
by the semi-circular area. Then, both green and red samples will be accepted. Figure
is adapted from López et al.[100], Copyright (2014) with permission from Elsevier.

A sample is assigned to a target class if the computed distances are shorter than a predefined
2
threshold value. These threshold values are based on 𝑇𝑙𝑖𝑚
and 𝑄𝑙𝑖𝑚 , which are the confidence

interval for the model under consideration. Confidence limits for SD (that is referred to as 𝑇 2 in
2
2
the PLS_Toolbox and related literature) are given from Hotelling’s 𝑇 2 to obtain 𝑇𝑙𝑖𝑚
, i.e. (𝑇𝑙𝑖𝑚
=

𝐹𝑘,𝑛−𝑘 𝑘(𝑛 2 − 1)/(𝑛 − 𝑘)) considering 𝑘 and 𝑛 –𝑘 degrees of freedom, where 𝑘 is the number
of PCs and 𝑛 is the number of calibration samples for the target class. The χ2 distribution is used
for the squared residuals and confidence limits for the orthogonal distance (OD, that is also referred
to as 𝑄 in the PLS_Toolbox and related literature) are computed by the Jackson and Mudholkar
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(JM) approximation. Wolf et al. developed SIMCA model based on 𝑄 residual. Candolfi et al.
proposed a SIMCA model which is based on the Mahalanobis distance; details will be found in
the relevant literature [68, 105].

A more recent approach is to consider both Hotelling’s 𝑇 2 and 𝑄 residual. According to
this approach, boundaries are defined considering the reduced statistics. The reduced Hotelling’s
𝑇 2 (𝑇𝑟2 ) and the reduced 𝑄 statistic (𝑄𝑟 ) values can be calculated from the ratio between the
corresponding statistic of the sample 𝑖 and the corresponding limit at α = 0.05. Here, samples must
have values under 1 for both statistics to be considered ‘‘within the model’’ which was defined by
the square boundary in the Figure 1-11. A newer version used by PLS toolbox takes the distance
defined by Equation 9 [17, 18]. In this case, the boundary considered as ‘‘within the model’’ forms
a semi-circle with a radius of √2, which is mentioned as d in the Equation 9.

𝑑 = √( 𝑄

𝑄
𝑙𝑖𝑚

2

𝑇2

2

) + (𝑇 2 )

9

𝑙𝑖𝑚

A variety of methods are proposed to develop an acceptance area are based on different
distribution assumptions of OD and SD. Pomerantsev proposed to use the χ2 distribution for both
of these parameters. This method is referred to as data-driven SIMCA (DD-SIMCA) [106].
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1.3.3.3.1.2 Discrimination Analysis: PLS-DA

Figure 1-12: Partial least squares discriminant analysis (PLS-DA) model for two
classes, where X is a matrix containing spectral data, Y are dummy variables
categorized as genuine (Group A) and falsified samples (Group B). Adapted from
Brereton et al. [107], Copyright (2014) with permission from John Wiley and Sons.
Partial least-squares discriminant analysis (PLS-DA) is derived from PLS regression to
develop a model that predicts the class number for each sample. While developing a PLS-DA
calibration model, the number of groups and the samples that belong to each group are defined
with dummy variables. For example, if a data set contains just two classes, Y can be set up easily
by assigning samples in one of the classes as 1 if the samples are in the class, and 0 if it is not. This
membership is paired with a training set (X block), and PLS is implemented in the usual way
(Figure 1-12). During the calibration process, the PLS-DA method is trained to compute
membership values and assigned a class membership. It is reasonable that the model does not
predict perfectly, so a limit must be set, for example, 0.5, above which the sample is estimated as
1 and below which the sample is estimated as 0. For spectroscopic product authentication system
development, PLS-DA can give good insight to the underlying reason for discrimination via
weight and loadings. Also, it is a popular technique due to the advantages of wavelength selection
and noise reduction associated with the PLS algorithm. A more detailed discussion of the PLS-DA
algorithm is available elsewhere [107-109].
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1.3.3.3.2 Applications of Supervised Classifications:

SIMCA: PCA analysis utilizing both Raman and NIR spectroscopy can separate diverse
samples based on physico-chemical differences (e.g., composition differences, API amount
differences, etc.). SIMCA, using PCA, is an effective method for detecting falsified drugs. Scafi
and colleagues [34] demonstrated the use of SIMCA to detect 12 types of falsified products of
different compositions. Scafi used PCA, constructed from NIR spectral data generated from the
genuine samples. Then, falsified products were projected onto these PCA models, and distances
were calculated for each falsified sample showing clear separation. Here, it is important to mention
that this method only rejected samples declared as falsified products. Further reference analysis
could provide better understanding of the specific nature of these falsified samples relative to the
genuine samples.

In another study, Storme-Paris and co-authors [20] used SIMCA, noting that the SIMCA
method distinguished tablets with small differences of composition Raman spectral data. In their
study, falsified and genuine products varied by 1.0 - 2.5% API (%w/w), and the SIMCA method
was successfully able to identify the falsified products.

SIMCA was used in a later study with NIR and Raman to overcome some of the limitations
of the spectral matching method, detecting a small amount of impurities in the raw materials. This
study detected a contaminant (DEG) in glycerin up to 5% w/w; three times lower concentration
range than using the spectral matching method [11]. It is important to note that although SIMCA
provides certain advantages, this method is only providing information about whether the sample
is pure or has some adulterants. Additional investigation may provide information about the types
of chemicals present in the sample.
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Figure 1-13: (A) Score plots for PCA analysis: (a) PC1 vs. PC2. (Different color
and shape represent different groups of samples, (B) Result of the Test sets is
displayed. Here, SIMCA model is developed from the target class (yellow-round).
Figure adapted from Zontov [15], Copyright (2016) with permission from Elsevier.
Liquid dosage forms have also been authenticated using SIMCA. One example is the
authentication of dexamethasone ampules [40]. This study used two genuine batches (G1 and G2)
of 4% dexamethasone 21-phosphate, and a batch of falsified product (F2) in 1 mL closed
transparent glass ampoules. NIR spectra were collected through the vials. The performance of this
approach was evaluated with reference testing by CE-UV, GC-MS, and HPLC-DAD. SIMCA
analysis of NIRS data demonstrated comparable performance to the reference techniques.

SIMCA has also been used to detect high quality falsified products. However, to detect this
type of product, adjustment of the decision boundary improved the model performance,
demonstrated using DD-SIMCA. Figure 1-13A shows, when products contained the same API but
have one or two different excipients, PC scores generated from different products were closely
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grouped. This tight representation of scores also reflects the similarity of the formulation of the
scanned samples. In Figure 1-13B it was observed that, if method developed using one group
(yellow-round), and all the other groups (green- triangle, red-triangle, brown-square, bluediamond) projected onto the developed model, then initially developed model rejected two of its
test samples (yellow-round). This decreases the sensitivity of the model by tuning the confidence
interval. The authors moved the boundary from 1 to 2, which changed the acceptance area of the
model. This change avoided rejection of two genuine samples and improved the sensitivity of the
model [15, 16, 110-113]. Despite this successful result, risks of changing boundaries may be high
without using an independent validation set to test the consistency of the result. Without an
independent validation, it is difficult to predict if the model will be adequately sensitive to accept
other batches of genuine samples consistently. Also, enhancing the model with representative
genuine samples from different batches would reduce this concern. Above all, this study
emphasized the importance of considering a change in the decision boundary to enable detecting
high quality falsified products [17, 111].

Though there are advantages of using SIMCA, it is also highly sensitive towards small
variation of external factors which can decrease the performance of the method. For example,
operator and instrument variabilities caused spectral perturbation, which often projected genuine
test samples outside the PCA space, causing degradation of model performance [114, 115]. This
introduces new challenges, especially when the analyst needs to transfer the model from one
instrument to another instrument [116]. Some of these issues can be resolved by removing
unwanted variables, which have small discriminant power [117].

Selection of appropriate

preprocessing methods may help to reduce some of this variability. For example, offset or baseline
drifts are removed by derivative, standard normal variate (SNV), or multiplicative scatter
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correction (MSC) algorithms [18]. Calibration transfer and method algorithms are useful when
analysts are required to use multiple instruments. The following studies provide direction for
analysts who must transfer spectroscopic methods [116, 118, 119].

Another essential model parameter is selection of the appropriate number of PCs to use for
calibration development. Rodionova et al [16] developed two SIMCA models by selecting a
different number of PCs. Here, a model developed using three PCs successfully separated samples
prepared in the different seasons, whereas the model developed including only two PCs did not
[15, 105]. Proper statistical approaches should be followed in selecting PCs. One way to select the
appropriate number of PCs is via cross-validation (CV) [82]. Finally, selecting the proper number
of PCs avoids unnecessary rejection of genuine samples (false negative) or incorrect authentication
of falsified products (false positive). Analysts should be careful about both factors, as rejecting
falsified samples are important from a patient’s perspective, but, similarly, accepting genuine
samples is critical from a manufacturer’s perspective. Further discussion about selecting principal
components can be found in Bro el al. [120]

PLS-DA: PLS-DA successfully identified falsified tablets containing the wrong API in an
example by Piender et al [31]. Lovastatin is occasionally used in falsified products instead of
atorvastatin. For discriminating lovastatin from atorvastatin, Piender et al [31] demonstrated PLSDA as a useful technique for discriminating the two active components. Moreover, investigations
of the regression vector of PLS-DA analysis demonstrated the important features which helped to
distinguish the differences (Figure 1-14) [31, 45, 121]. Similarly, tadalafil and sildenafil were
separated using the PLS-DA method. Another potential application for the PLS-DA method is to
detect adulterated products [26]. However, it is important to note that, while developing a
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calibration method, samples containing the expected amount of impurities should be added into
the model as an alternate class of the pure sample. Otherwise, impure samples may be accepted as
pure samples, which will give false positive result.

Figure 1-14: Class prediction plot (A) and regression vector(B) of the PLS-DA
model of NIR spectra based on three LV’s to discriminate counterfeits (•) from
genuine tablets (▼). Figure obtained from Peinder [31]. Copyright (2008) with
permission from Elsevier.

PLS-DA is also useful for identifying expired products which are often repackaged and
resold, resulting in a major public health risk. Qun et al.[44] used both expired and non-expired
products to develop the PLS-DA calibration model, where expired products and non-expired
products are used as two classes. Then expired products were detected by using an independent
test set [20, 36, 44]. The success rate of detecting the expired product in this study was possible
due to a change in the expired tablet’s matrix. Raman spectroscopy was sensitive to the change of
the tablet matrix. However, this might not be true in other cases. Therefore, before implementing
the PLS-DA method to detect expired products, analysts should carefully investigate whether the
expiration of the product creates any change in the sample spectra. PCA can also be an important
tool to understand the variabilities among the expired and non-expired products before developing
PLS-DA method. It is also suggested that manufacturers store their expired products and develop
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a reference library. This will be helpful to develop an authentication system to detect expired
products in the future.

Similar to SIMCA, proper wavelength selection and preprocessing methods also help to
improve PLS-DA classification model performance [36]. For example, baseline removal by a
derivative method minimizes spectral changes associated with the tablet geometry, physical
differences in tablet faces, and sample position relative to the probe beam [34]. Theoretical and
experimental evidence showed that elimination of useless predictors (wavelengths which are not
carrying important information) increases the anticipated performance of PLS-DA [121, 122]. Li
et al [121] showed that classification of five different manufacturers of anisomide tablets was
successfully accomplished by appropriate variable selection method. Here, iterative PCA (iPCA)
was successfully applied to find the superior spectral regions to predict and classify falsified
products. However, wavelength selection is not always necessary. In fact, Fernandes et al [26]
demonstrated cases where false sample identification was less effective with wavelength reduction
as there is a risk of inadvertently removing an essential wavelength region [44, 121].

1.3.3.3.3 Limitations of Supervised Techniques

It is evident from the literature that SIMCA and PLS-DA are often used for the same
application, and their performance has been compared [20, 45]. However, this comparison is not
necessarily reasonable, since different models use varying amounts of information. In the case of
PLS-DA, the algorithm uses information regarding several classes and develops a decision
boundary based on the existing classes; whereas SIMCA develops a decision boundary based on
only one (its own class).
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Depending on the different scenarios, PLS-DA and SIMCA should be used carefully. For
example, SIMCA is one of the best choices when the variabilities of falsified samples are not
possible to be sampled sufficiently. By using genuine samples, a target class can be developed,
and any new unknown sample which is dissimilar from the genuine samples is projected outside.
However, when an analyst develops a PLS-DA model, the model assigns class membership based
on the variability modeled from available samples. Then, predicted unknown samples are assigned
to any of the classes, even if they have very different compositions. This leads to an incorrect
recognition of new samples [123].

On the other hand, when the potential variability of falsified samples has a limit, PLS-DA
is applicable. For instance, when the types of impurities found in falsified samples are expected,
then the discriminant techniques may perform better than class-modeling. Since data from genuine
and impure samples have different directions in the score space, effective boundaries around
different groups’ scores form easily. For the above reasons, PLS-DA and SIMCA should be
selected depending on the target sample.

Supervised classification methods provide only diagnostic results (in class or out of class),
but other specific information, such as types of impurities, whether a sample contains any harmful
content, or whether a tablet contains any API or not, is not typically identified using this method.
Therefore, while developing authentication systems, the analyst should consider a variety of
chemometric techniques to enhance the potential for a successful authentication method (see Table
1-4).
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Table 1-4: Comparison of different chemometric methods:
Data
Analysis
Method

Spectral
matching

Exploratory
analysis

Method

Spectral
correlations
Spectral
Distance

Aim

Similarity and
dissimilarity
measurement
between spectra

PCA

Projection and
visualization of
data in a
low- dimensional
space

Clustering
method

Partitioning data
into clusters

ClassModeling:
SIMCA

Genuine
samples are
used to develop
class and
unknown
sample is
classified based
on its distance
to the class

Discriminant
analysis:
PLS-DA

Covariance
between data
and class
membership is
stablished to
develop
classifications

Supervised
techniques

Relevant applications and comments
•
•
•

Prescreening of raw material identification
Impurities/adulterant detection
Detection of API or excipients in the
finished dosage form.
• Must determine a useful threshold.
• For NIRS broad overtones and combination
bands reduce the usefulness of this
applications.
• Physico-chemical differences of the
genuine and falsified products captured by
spectroscopic techniques.
• PCA forms data clusters, which are related
to the sample variance. Examples:
composition differences between genuine
and falsified products, variance observation
between genuine and falsified samples.
• Link developed between seized samples
from different regions based on differences.
The class-modeling approach is useful for detecting
unknown falsified samples:
• Finished falsified dosage forms which are
highly similar to genuine products, and
difficult to separate by spectral matching
method, are easily identifiable.
• Drugs containing the wrong active
substance and or the correct active
substance with wrong dose are detectable.
Adulterated raw materials (API and
excipients) may be detectable.
• Rigorous method development is required.
• Classification methods are developed from
two or more classes, for example, a) the
original drugs with expired date and b)
drug developed from different APIs.
• Directions in the data space that
discriminates the two or more medicine
classes can be directly developed from this
method.
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1.3.3.4 Other Methods

Raman Barcode: Lawson and colleagues developed an interesting method to screen
whether seized finished products contain API or not, which they stated as “Raman barcode”
method [32, 64]. A barcode is developed from API spectra and finished products by replacing zero
intensity to every wavelength shift except the wavelength shift that represented Raman peaks. The
identity of API was ensured by comparing the percentage of nonzero overlap between the target
API barcode and finished drug product barcode (Figure 1-15). This method was successfully
applied to test 18 different original products acquired from the market and nine simulated falsified
products. A Raman barcode was applied only for high dose drug products with the assumption that
excipients are Raman inactive. However, this conjecture restricted the use of this method only for
Raman spectroscopy, as NIRS demonstrates high excipients signal. Additionally, this method was
only applied for samples containing a single API and was not tested for the tablets which contained
multiple APIs. Overlapping of different API peaks increases the risk of detection of a specific API.
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Figure 1-15: Generation of Raman Barcode. All peaks denoted with a green circle
are included in the barcode spectrum. Figure obtained from Lawson et al. [32],
Copyright (2016) with permission from American Chemical Society.

Machine Learning Method (Support Vector Machine): A Support Vector Machine
(SVM) is developed by constructing the best separation hyperplane to maximize the margin
between different groups. The widest margin between the two groups is identified using several
samples residing in the boundary, which are called support vectors. This margin can be linear or
nonlinear depending on the type of kernel function that is applied. Finding the optimal hyperplane
requires optimization of the model parameters. Details of the methods are discussed elsewhere
[124, 125].

SVM can handle some of the challenges usually related to a) large datasets [86], b) samples
which are collected using a limited spectroscopic wavelength range[63], and c) calibration transfer
[116]. For example, newly developed pocket size spectrometers span a limited wavelength range
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compared to full size spectrometers, creating sensitivity challenges in terms of detecting product
identity. However, falsified products can be successfully separated from genuine products using
SVM even with limited wavelength range. SVM is also less affected by small spectral perturbation
when compared to SIMCA, which makes it a better algorithm for calibration transfer [116, 126].
However, careful optimization of SVM parameters are required before implementation.

Though classical SVM has been applied for falsified drug detection, other forms of the
SVM algorithm, such as the support vector data description (SVDD) method, can also be useful
for class-modeling. The advantage of SVDD is that it does not require two classes of samples
during method development. Therefore, it is more suitable to use class-modeling techniques for
analysis of pharmaceutical samples. In this dissertation project, SVDD was explored as a potential
class-modeling technique for falsified drug detection.

Multivariate Quantitative Analysis: Hyperspectral chemical imaging systems use different
multivariate regression methods to quantify the composition of falsified products. In most cases,
compositions of the seized samples are generated without knowing actual formulations. Different
algorithms, for example, classical least-squares (CLS) and multivariate curve resolution (MCR)
methods, are useful to determine the compositions. Details of such algorithms are found elsewhere
[66].
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Figure 1-16: PLS predicted images of (a) genuine tablet; (b) falsified tablet– red
pixels indicate higher concentration and blue pixels indicate lower concentration of
the target component [89], Copyright (2010) with permission from Elsevier.
Lopes and co-authors [89] implemented Classical Least Squares to quantify pure
components of falsified and genuine samples. Concentration maps of each pure material, including
the API (lamivudine) and the excipients microcrystalline cellulose, sodium starch glycollate, rice
starch and talc, were estimated using CLS [89]. Imaging of predicted concentration of the
components showed apparent differences in the sample (see Figure 1-16) [127].

1.3.4

Challenges and Considerations of Routine Spectroscopic Authentication Methods

Many sources of variability impacting the spectra of pharmaceutical samples occur during
the life-cycle of a spectroscopic technique. Some examples include manufacturing process
variability, analytical instrument variability, and environmental fluctuations. Sample variability is
introduced through raw material inconsistencies or through the impact of a manufacturing process
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on material variability. Lot-to-lot variations of incoming raw materials introduce new physical and
chemical variations to which both Raman and NIR spectra have been shown to be sensitive [128,
129]. However, the significance of variabilities on spectral quality depends on the sampling
configuration, collection modalities, etc. [130-132]. For Raman spectroscopy, the effect of particle
size variation in tablets between backscatter and transmission mode were compared. As the Raman
backscatter mode generates most of the signal from the tablet surface, it was relatively less
impacted by the variation in particle size relative to the transmission mode [133]. Tablet surface
roughness also affected the impact of particle size on the spectra for the backscatter mode.
However, in transmission mode, photon propagation characteristics were more influenced by
particle size variations due to the scattering coefficient and optical path length [1, 133-135]. A
change of size, shape or density of tablets due to the changes in the manufacturing process also
generate spectral variabilities [134, 136, 137]. Physical factors are very critical for NIRS, as this
method is highly sensitive to physical variations of the samples mentioned above [138-144]. These
sources of variability are well known, but their effect on the model is not always well characterized.
One way to test the effect of such physical variation is to develop calibration models with and
without these variations in the model, and then determine whether including the variabilities
improves the model performance.

Another challenging source of variability that analysts often encounter with the
spectroscopic method development and deployment is environmental variability; for example,
relative humidity often varies from the warehouse, where materials are stored, to the
manufacturing facilities where samples are analyzed. The impact of relative humidity and extreme
temperatures on model performance is critical to product quality and must be considered during
method development [34]. Figure 1-17 demonstrates the spectral variability two samples scanned
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using NIRS over the duration of a one year period .The variability was due to moisture variations
of the testing period. This highlights the importance of including moisture variability in a NIRS
model development [71, 91, 145-147].

Figure 1-17: PCA plots (PC1/PC2) and the related 95% confidence intervals of two
lubricant spectra recorded five times over a 1-year period. Figures obtained from
Vredenbregt [148], Copyright (2003) with permission from Elsevier.
For Raman spectroscopy, although water has a weak Raman scattering, it was found that
for tablets exposed to high humidity and temperature, the spectral baseline demonstrated variation.
As chloroquine has broad fluorescence background, moisture variability caused spectral artifacts
in the form of baseline variations, which is associated with fluorescence quenching [146]. This
caused failure of the detection method. Fluorescence quenching also happens due to long laser
exposure to samples. It was reported that due to the fluorescence background, obtaining reliable
Raman spectra was an issue [147]. Using a 1064 nm laser can decrease fluorescence background,
but requires longer exposure time to acquire similar S/N compared to 785 nm [149, 150].
McCreery showed that among 308 reference samples, around 8% of compounds showed a
fluorescence background, and 3% of compounds were misidentified using the SM method [25].
However, the effect of moisture on different supervised models needs to be investigated more
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rigorously for Raman Spectroscopy. Also, the suitability of baseline removal algorithms for
removing this unwanted effect should be carefully evaluated.

Two recommendations are proposed to fill the gap in current literature regarding
authentication method development. First, before developing a multivariate calibration model, a
thorough investigation should be conducted to identify and understand the possible risks that may
occur throughout the life-cycle of the method [151, 152]. Introducing systematic risk assessment
based on previous experiences can be helpful to achieve this goal. For example, using Ishikawa
diagrams and Failure Mode and Effects Analysis (FMEA) can be beneficial for developing a robust
authentication model. Such risk assessment techniques were used to develop robust quantitative
modeling in past studies [153, 154]. It is recommended that even for qualitative modeling to detect
falsified drugs, risk assessment approaches may be quite practical. In Figure 1-18, an Ishikawa
diagram showed critical factors for NIR and Raman spectroscopic techniques to detect falsified
samples.
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Figure 1-18: Ishikawa diagram for a risk assessment of a NIR spectroscopic techniques of
pharmaceutical tablets.
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Second, using an independent validation set over time to validate model performance will
be helpful. This will also ensure long-term model performance [109, 151, 155].

1.3.5

Project Description

In this dissertation project, detailed investigations were conducted to demonstrate an
optimized spectroscopic authentication method using class-modeling techniques for the detection
of falsified pharmaceutical samples.

Appropriate prior knowledge of the pharmaceutical product, the manufacturing process,
the spectroscopic technique, and the mathematical algorithm for calibration were required to
develop and validate a sensitive, selective, and robust method. For a proper spectroscopic
authentication system, the method was validated using independent sample sets, and the developed
method met two validation criteria: 1) acceptance of genuine products and 2) rejection of falsified
products.

The first validation parameter was that the model must accept authentic samples. To ensure long
term model performance, proper risk assessment was investigated during method development.
This risk assessment explored a variety of critical factors, including the effect of variability in
materials, environmental conditions, manufacturing variability, and analytical instrument
parameters. To understand the effect of these factors on the multivariate model performance,
further studies were conducted. When it was found that certain factors were a risk for the model
performance, inclusion of these factors improved the long-term model performance and decreased
the burden of updating the model over time. Also, this work demonstrated that the typical current
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method, e.g., SIMCA, had certain limitations that may be resolved with more modern algorithms,
in particular, a SMV based algorithm.

The research project generated simulated falsified samples to test the capability of the
analytical technique and to test the second validation criteria, i.e., rejection of falsified product. A
variety of falsified sample characteristics were simulated in the lab. Specifically, the models were
tested against falsified samples which contained the appropriate API but different excipient
compositions. This was the most difficult condition of falsified samples to detect. To evaluate the
ability of the analytical techniques and the developed chemometric model, a systematic variation
of excipients was required in the formulations. Statistical method such as design of experiment
(DOE) is a valuable tool to explore the spectroscopic capability to identify different falsified
products. DOE is also helpful to understand which falsified samples are spectrally similar in
comparison to genuine samples, and which pose a risk on the developed method. Carefully
developed DOE, accomplished with appropriate prior knowledge, minimized the risk of model
failure. Using samples created at small scale, in the laboratory, reduced the burden of sample
preparation and made the model development efficient.

A detailed discussion of these strategies is offered in the following chapters.
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2 Chapter 2: Evaluation of SVDD and SIMCA methods as
Class-Modeling Techniques using Near-Infrared
Calibration Sets of Pharmaceutical Tablets Containing
Moisture Variation
2.1

Introduction

Protection of pharmaceutical materials from fraudulent activities is becoming increasingly
critical due to the growing distribution of falsified products. The rise of procurement of internet
products by American consumers increases the chance of exposure to these falsified products [6].
Currently, 10%-30% of drugs in the world are falsified [156, 157] and pharmaceutical tablets are
the most common type of falsified products.

The primary method of pharmaceutical tablet falsification is to vary the chemical
composition. This includes, but is not limited to, tablets prepared without active pharmaceutical
ingredient (API), tablets manufactured using the wrong API and tablets generated using the correct
API but different excipient compositions. Implementation of tools to monitor the chemical
composition of pharmaceutical products during distribution from manufacturers to customers can
reduce fraudulent activities [3, 4].

Near infrared spectroscopy (NIRS) offers the ability to rapidly determine the chemical
content of pharmaceutical tablets. In studies utilizing NIRS, antimalarial, antimicrobial,
antispasmodic and other medicines were successfully authenticated [28, 34, 96]. In these studies,
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medications were collected from around the world and tested in the laboratory. Further progress
in instrumentation technology has led to opportunities for NIRS to be implemented as portable,
even handheld spectrometers, for the detection of falsified products in the field. These
spectrometers allow screening for the quality of medicines in multiple locations (e.g., in different
locations of the supply chain including rural hospitals, clinics, drugstores, etc.) [51].

However, developing authentication methods using NIRS is challenging due to sample
constraints and the multivariate nature of the collected data. Only authentic samples are available
during method development, as it is impracticable to produce or collect all types of falsified
samples. Additionally, rigorous chemometric methods are required to statistically compare an
authentic sample’s NIR spectrum with an unknown sample’s spectrum to determine whether the
unknown sample is genuine or falsified.

Two types of chemometric techniques are highlighted in the literature for authentication of
pharmaceutical tablets: 1) spectral matching (SM) and 2) class-modeling (CM) techniques [11].
SM compares two spectra, including a reference NIR spectrum from an authentic tablet and an
unknown spectrum from a sample. The spectral correlation or spectral distance is calculated
between these two spectra and, if these values fall within a target threshold, the unknown sample
is declared to be genuine [158]. Research has shown that the SM method is successful when
samples have large chemical differences providing sufficient spectral uniqueness [14]. For
example, the SM method was used to identify placebo samples and samples containing the wrong
API. However, this method struggled to separate samples containing identical APIs and similar
excipient compositions or what would be considered high quality falsified products [15].
Moreover, most current portable spectrometers provide limited sensitivity and selectivity relative
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to research instruments, and insufficient spectral resolution to distinguish the differences between
authentic and falsified samples. Regardless, SM is a popular technique included in most of the
current portable spectrometers due to its rapid and relatively simple assessment of authenticity.

Class-modeling (CM) is another chemometric technique that can be applied for the purpose
of authentication. Multivariate methods such as SIMCA and its extended versions have been used
for spectroscopic class-modeling techniques for authentication. The primary premise of these
methods is to develop a target class using representative samples from an authentic source. A
calibration model is developed from the target class, comprised of NIR spectral data containing
API and excipient information. CM estimates a decision boundary which is formed around the
calibration data at a specific significance level. For example, the boundary of different versions of
SIMCA is developed based on the distribution assumptions such as normal, 𝜒 2 , etc. [17-19].
Several studies have compared the performance of SM and CM, and proposed that CM techniques
are more effective than the SM method. In these studies, portable spectrometers successfully
separated pharmaceutical tablets containing similar compositions [15, 20].

The CM methods require two critical considerations: suitable target class samples and the
establishment of appropriate boundary conditions. A typical target class includes authentic
samples; however, it does not necessarily include the variabilities that have a critical impact on
NIR spectra. For example, a CM method using NIRS data based on a target class including
authentic samples from one batch may consider an authentic sample from a different batch to be
falsified because batch-to-batch variability is not considered in the original calibration. Batch-tobatch variability can have a severe impact on the performance of NIR prediction models,
potentially due to small physical and/or chemical differences in the samples from unique batches.
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Specific sources of small chemical and physical changes between authentic samples include raw
material variability and environmental (i.e., temperature, relative humidity) fluctuations.
Specifically, environmental variability is of high concern because authentic samples are often
produced in different manufacturing sites around the world with varying relative humidity
conditions. NIR spectra are highly sensitive to moisture; thus, the relative humidity variation needs
to be considered during method development, especially if the NIRS method is to be directly
applied at these different sites. To reduce the impact of these potentially important variabilities,
several spectral preprocessing techniques are available. However, these pre-processing techniques
are not always sufficient; an additional, valuable option is to update the calibration model using
new samples comprising these variabilities.

The addition of samples to the target class to create a robust model can be accomplished in
two ways. First, the empirical approach where the model is updated over time by adding samples
to include newly evolved variabilities. This empirical approach depends on stepwise addition of
newly available samples to the calibration set and rebuilding the model over time [159]. Another
approach can be taken by implementing risk-assessment concepts during method development.
According to ICH-Q9 guidelines, a risk-assessment can be conducted while developing the
calibration method, and factors which can be risks for spectroscopic method performance are
added into the target class during model development [154].

In addition to sample considerations for development of a suitable target class, the
boundary conditions are also important. The boundary around the target class decides if an
unknown sample is authentic or falsified. The CM method assumes that the target class forms one
cluster, with the boundary formed around this cluster. However, including spectrally different
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samples (e.g., samples with different moisture levels) may introduce multiple clusters within the
target class. This violates the assumption of the model by forming a binomial or multimodal
distribution in the model space. In addition, the boundary formed around the multiple clusters may
not include all potential calibrations samples, and the model will be more prone to rejecting
authentic samples. Therefore, the caveat of this approach is that without prior knowledge of the
shape of the underlying distribution of samples, satisfactory results may not be achieved.

This chapter explores the use of a support vector machine based method to resolve
boundary condition issues of a traditional CM method. Support vector machine methods create a
spherically shaped boundary around the samples. The boundary is typically described by a few
training objects which are mentioned as support vectors. It is possible to replace normal inner
products by kernel functions to obtain more flexible data descriptions. This method is often
referred to as a support vector data description (SVDD) approach, proposed by Tax et al [21]. This
method has been used for the detection of machine faults, outlier detection, etc., and has shown
similar results to the one-class support vector machine (OC-SVM) developed by Schölkopf et al
[22]. However, the SVDD method has not yet been evaluated for analyzing pharmaceutical
samples using spectroscopic data, particularly for authentication purposes.

The objective of this paper is to explore the performance of SVDD as a class-modeling
technique relative to that of the widely used SIMCA method in order to authenticate
pharmaceutical products. This study emphasized the suitability of these chemometric techniques
in the presence of seasonal variations. To demonstrate the capabilities of these methods, tablets
were prepared in-house (in the laboratories of the Duquesne University Center for Pharmaceutical
Technology) throughout a year’s worth of environmental variation. Although these samples were
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generated in the laboratory, this study provides direction for further development of an
authentication method using spectroscopic data.

2.2
2.2.1

Materials and Methods
Theory

2.2.1.1 SIMCA based Approach

SIMCA is extensively used as a class-modeling technique for authentication purposes. The
procedure for SIMCA first involves decomposing calibration samples using a PCA model with the
optimal number of principal components. Classification rules are then constructed to create a
decision boundary. Different versions of classification rules have been developed over time; this
is discussed extensively in existing literature [17, 103, 160]. However, in this study, one of the
most immediate and commonly used versions was applied for the SIMCA analysis. In this method,
the boundary around a training set of SIMCA is based on two distances: 1) score distance (SD)
and 2) orthogonal distance (OD). The SD is determined by computing the distance, in the space of
the PCs, between an unknown sample and a target group, commonly referred to as the Hotelling’s
𝑇 2. The OD is determined by calculating the unknown sample’s squared residual distance from
the model space, referred as the 𝑄 residual [17, 82]. Hotelling’s 𝑇 2 measures the information of
each sample within the PCA, or SIMCA model, and is calculated by Equation 1, where 𝑡𝑖 is the 𝑖th row of the 𝑇𝑘 , the 𝑛 by 𝑘 matrix of 𝑘 score vectors from the PCA model, and matrix of 𝑘 scores
vectors from the PCA model of 𝑛 number of target class samples and Λ- 1 is a diagonal matrix
containing the inverse of the eigenvalues associated with the 𝑘 eigenvectors (principal
components) retained in the model.
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The 𝑄𝑖 statistic is defined as the sum of squares of the residuals and can be calculated
according to Equation 2 where 𝑒𝑖 is the residual of sample i after applying the SIMCA model.

𝑇𝑖2 = √𝑡𝑖 𝛬−1𝑡𝑖𝑇

1

𝑄𝑖 = 𝑒𝑖 𝑒𝑖𝑇

2

A sample is assigned to a target class if the computed distances are shorter than a predefined
2
threshold value. These threshold values are based on 𝑇𝑙𝑖𝑚
and 𝑄𝑙𝑖𝑚 , which are the confidence

intervals for the model under consideration. Confidence limits for SD (referred to as 𝑇 2 in the
2
2
PLS_Toolbox and related literature) are given from Hotelling’s 𝑇 2 to obtain 𝑇𝑙𝑖𝑚
, i.e. (𝑇𝑙𝑖𝑚
=

𝐹𝑘,𝑛−𝑘 𝑘(𝑛 2 − 1)/(𝑛 − 𝑘) considering 𝑘 and (𝑛 – 𝑘) degrees of freedom, where 𝑘 is the number
of PCs and 𝑛 is the number of calibration samples for the target class.

The χ2 distribution is used for the squared residuals and confidence limits for the
orthogonal distance (OD, also referred to as Q in the PLS_Toolbox and related literature) are
computed by the Jackson and Mudholkar (JM) approximation.

2
The limit of Hotelling’s 𝑇 2 (𝑇𝑙𝑖𝑚
) and the limit of 𝑄 statistic (𝑄𝑙𝑖𝑚 ) values can be

calculated from the ratio between the corresponding statistic of the sample 𝑖 and the corresponding
2
2
limit at α = 0.05 [𝑒. 𝑔. , (𝑇𝑙𝑖𝑚
= 𝑇95%
and 𝑄𝑙𝑖𝑚 = 𝑄95% ] [17]. A more flexible boundary is

developed by a semi-circle with a radius of √2, which is mentioned as d; this d is calculated
according Equation 3.

2

𝑑 = √(

𝑄 2
𝑇2
) +( 2 )
𝑄𝑙𝑖𝑚
𝑇𝑙𝑖𝑚
68

3

Figure 2-1: Threshold boundary based on the confidence interval of Hotelling’s
𝑇 2 versus 𝑄 residual. The squared acceptance area is the green space in the graph,
where samples plotted at any point outside of this area are rejected. According to
this threshold, nearly every sample will be accepted, with only the green sample
being rejected. A more flexible boundary could be applied as shown by the semicircular area. Then, both green and red will be accepted. Figure is adapted from
López et al.[100] Copyright (2014) with permission from Elsevier.

This distance measure gives equal weighting to distance in the model space, i.e. scores
distance (SD or 𝑇 2) and residual space, i.e. orthogonal distance (OD or 𝑄). The outcome of this
boundary was depicted in Figure 2-1.

2.2.1.2 SVDD based Approach

The theory of SVDD has been extensively described in the literature [21, 161]. Therefore,
only a brief description of the concept of SVM in the framework of classification is given here.
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Figure 2-2: The hypersphere containing the target data (blue), described by the
center a and radius R. Five objects (red) are on the boundary. Three object (red)
xi is outside and has ξi > 0.

∅(𝑅, 𝑎, 𝜉 ) = 𝑅2 + 𝐶 ∑ 𝜉

||𝑥𝑖 − 𝑎||2 ≤ 𝑅2 + 𝜉,

3

𝜉≥0

4

The SVDD algorithm avoids the estimation of a complete probability density; it obtains a
data boundary by forming a circle or hyperplane around the data where 𝜇 is the data center and 𝑅
is the distance from the center to the hyperplane that forms the boundary around the samples
(Figure 2-2). However, it is not always possible to include all data within the boundary. Therefore,
this algorithm has adapted to tolerate errors for some objects that fall outside of the boundary.
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Usually, slack variables 𝜉, allow a probability that some of the training samples will be placed
outside the boundary. Samples which reside on the boundary (𝜉 = 0), or outside of the hypersphere
(𝜉 > 0), are referred to as support vectors. Development of the hypersphere is based on the
optimization of these support vectors, where the distance of each of the samples should be less
than or equal to 𝑅2 + 𝜉 . Therefore, mathematically, it is possible to define a structure error
function (∅) for an SVDD model with a constraint.

In Equation 4, 𝐶 shows the trade-off between the volume of the hypersphere (calculated by 𝑅 2 )
and the number of errors (𝜉) and therefore controls the fraction of samples lying outside the
boundary. The higher the 𝐶 value, the more samples are included in the model space. This 𝐶 can
also be expressed as “a fraction of target class samples rejected” by 𝐷 value which is defined in
Equation 5.

𝐷=

1
𝑛𝐶
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5

σ =1

σ =5

σ =25

Figure 2-3: Data description trained on a banana-shaped data set. The kernel is a
Gaussian kernel with different width sizes σ. Support vectors are indicated by the solid
circles; the dashed line is the description boundary (adapted from Tax et al. [160]).
Copyright (1999) with permission from Elsevier.

The C and D are related by 𝑛 which is defined as the number of samples in the calibration
set. 𝐷 has some analogy to confidence levels in distance-based classifiers. When 𝐷 = 0, no target
samples are misclassified, whereas 𝐷 = 0.05 means 5% of samples will be outside the boundary.
However, this number is an approximation. This optimization problem was further modified using
the Lagrangian method which simplified the calculation [21].

It is also possible to incorporate kernel functions into the model to create a non-linear
boundary (Figure 2-3) [21]. It provides additional dimensions which transform the shape of the
data. The shape of the boundary can be optimized using different kernel function, but most popular
is the Gaussian radial basis function (RBF),

𝐾(𝑥𝑖 , 𝑥𝑗 ) = 𝑒𝑥𝑝

−‖𝑥𝑖 − 𝑥𝑗 ‖
2σ2
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6

The broader the Gaussian, the smoother is the surface; hence, the radius of the RBF (or σ)
relates to how ‘bumpy’ the surface is, and varying this parameter can change the appearance of
boundaries between points. Using a small σ results in a sharp Gaussian that effectively forms a
boundary around each point (or occasionally neighboring points). Therefore, a small σ value may
overfit the model, whereas as σ increases, the model becomes smoother and more circular,
resembling a PCA or SIMCA models. It is essential to understand that the number of samples on
the boundary decreases as σ increases—this is because fewer points are required to model a smooth
boundary and so fewer SVs are required.

2.2.2

Figures of Merit

In the class-modeling approach, two validation parameters are used for performance
analysis. The goal of the method is to accept target class samples. This is referred to as the
sensitivity of the model. It describes the ability of the model to declare genuine samples. The
following formula calculates the sensitivity of the method (accepting genuine samples):

Sensitivity=TP/(TP+FN)

7

where TP and FN are true positive and false negative, respectively. If the model accepts
falsified samples, it needs further optimization.

The second measure of model performance is rejection of the non-target class samples.
This is called specificity. The specificity of the method (rejecting falsified samples) is used as a
validation parameter. The following formula calculates this parameter:

Specificity=TN/(TN+FP)

8
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where TN and FP are true negative and false positive, respectively.

To consider both factors simultaneously, the geometric average of these two parameters
were calculated. The average of sensitivity (Equation 7) and specificity (Equation 8) will be
indicated as average performance (see Equation 9).

Average performance= (Sensitivity + Specificity)/2

2.2.3

9

Sample Set

2.2.3.1 Sample Preparation

For this study, acetaminophen (APAP) was used as a model drug. The target formulation
was APAP (27.30%w/w), microcrystalline cellulose (MCC 200; 34.15% w/w), lactose (34.15%
w/w), hydroxypropyl methyl cellulose (HPMC; 3.90% w/w), and magnesium stearate (0.5% w/w).
Tablets were generated with a wet-granulation approach. First, granules containing APAP, HPMC,
and lactose were manufactured using a fluid bed granulator (model WSG 5, Glatt, Binzen,
Germany). Then, granules and extra-granular excipients (MCC 200, lactose, magnesium stearate)
were mixed in a 3.5 quartz V-blender for a total blend mass of 1 kg for 45 min. Target blending
time for homogeneity was tested using NIRS. The blends were subsequently compacted on a 38station rotary tablet press (Elizabeth-Hata International, Inc., North Huntingdon, PA, USA). The
target tablet weight was 350 mg.

To consider non-target class test samples during model development, another set of
samples containing low concentration of API (19% w/w) was manufactured. The shape and size
of both sets of tablets were the same.
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2.2.4

NIR Scanning

NIR reflectance measurements were acquired for both sides of each tablet over the
wavelength range of 925 to 1700 nm at a 6.38 nm increment, averaging 5000 scans (JDSU
MicroNIR). Before scanning, the tablets were precisely centered using the positioning iris,
standard on this instrument. A period of two weeks elapsed between compression and spectral
collection to allow the tablets to undergo viscoelastic relaxation.

All spectral data were analyzed in Matlab (version 8.6, MathWorks, Natick, MA) using
PLS_Toolbox (version 8.8, Eigenvector Research, Inc, Manson, WA) [162], and software
developed by the Duquesne University Center for Pharmaceutical Technology.

2.2.5

Reference Testing

Acetaminophen reference values for all compacts were determined using high-pressure
liquid chromatography (HPLC; Waters Alliance 2790, Milford, MA, USA), followed by
ultraviolet detection (Waters 2487). A method, modified from USP29-NF24 (“Acetaminophen
Tablets’’), was employed [41]. The mobile phase was water: methanol: acetic acid (80: 17: 3), and
the stationary phase was a 15 cm by 4.6 mm C18 column with 3μm packing. The detection
wavelength was 243 nm. The error of the reference measurement was estimated at 0. 83%.

2.2.6

Sample Considerations for Calibration, Test and Validation

During the study, a total of six granulations and fourteen tablet batches of the target
formulation were manufactured. There was significant variability in the particle-size distribution
of the granules and in the moisture content of the excipients and granules. These variabilities were
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observed because the environment of the laboratory in which the experiments were performed was
not controlled for humidity; during winter the air was dry (20–30% relative humidity (RH)).
During the summer months, typical RH was between 60 and 70%.

Samples prepared in the lab were used to investigate these seasonal spectral variabilities
and the subsequent effect on the model performance during spectroscopic analysis. Samples were
prepared using six different granules (containing different particle size distribution) and in
different seasons of the year (in the presence of different relative humidity).

The target class samples were developed from the target concentration, and the non-target
class product was prepared using a lower concentration of API, as mentioned previously.

Calibration, test, and validation sets were the sample sets used for the model development
process. The model was optimized using the test set which contained both target and non-target
class samples, whereas the calibration set contained only target class samples. Non-target class
samples were used during the optimization process to enhance the model performance (Figure 24) [163].
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Figure 2-4: Method development flow chart and considered samples.

Three calibration scenarios were created to demonstrate three conditions of calibration sets:

1) Basic: Samples prepared in the summer (lab humidity ~ RH65%) were added to the
calibration set. This set will be further mentioned as the “basic calibration set”.

2) Updated: The updated data includes the basic calibration set and additional samples
created during the winter, representing a real-life scenario in terms of the likely scenario for the
model update. This data set will hereafter be called the “updated calibration set.”

3) Risk-based: In this approach, samples prepared during the summer were stored in lower
humidity condition (~20% RH) to mimic the winter condition, and later added into the calibration
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sample set along with the samples of the basic calibration set. This will be henceforth described as
the “risk-based calibration set.”

Calibration sets for model development: Samples were considered for calibration set from
three scenarios mentioned above. Each of these calibration sets were used to generate SIMCA and
SVDD model. Test sets were used to optimize calibration model and validation sets were used to
measure the final performance. (Table 2-1).

Test sets for model optimization: Cross-validation was conducted using calibration sample
sets of target class samples. Samples of similar composition containing a low level of API
(19%w/w) were used as non-target class samples to optimize the model parameters.

Validation sets for performance evaluation: The model was challenged with the validation
set to test whether it could accommodate seasonal variabilities present in the independent target
class samples. Three batches of target class validation sample sets were generated from new
granules (that had not been present in the calibration set) and manufactured under summer, spring,
and winter conditions.

Table 2-1: Details of the modeling scenarios

Basic

Scenarios
Updated

High
Target

High+Low
Target

High+Low
Target

High+Low
Target+Low

High+Low
Target+Low

High+Low
Target+Low

High+Low
Target+Low

High+Low
Target+Low

High+Low
Target+Low

Risk-Based

Calibration Set
Moisture variations
API Concentration

Test Set
Moisture variations
API Concentration

Validation Set
Moisture Variation
API Concentration
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2.3
2.3.1

Results
Spectral Investigation and Exploratory Analysis

Samples were prepared using granules containing different particle size distributions and
created in different seasons of the year (containing different relative humidity conditions). Figure
2-5 shows the second derivative treated spectra of tablets. Figure 2-5A used the same granules
manufactured in two different seasons. Different spectral regions of the samples generated in the
summer (~60% RH) and in the winter (~25%RH) demonstrated intensity differences [164, 165].
The preprocessing method removed the effects of physical variation by eliminating the baseline
differences. However, the water bands around 1470 nm exhibited significant variability compared
to other regions of the spectra. This 1470 nm region represents primarily the combination bands
of water. This spectral change depicts the influence of moisture on the spectra [164, 165]. Figure
2-5B showed the spectral difference in the 1167 nm region due to APAP concentration differences;
here, the target concentration and low concentration tablets represented target class and non-target
class product, respectively.
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Figure 2-5: A) NIR spectra of different moisture conditions B) Two different
concentration levels of API.

A PCA algorithm was used to decompose the calibration spectra after SNV and meancentering treatment [81]. Figure 2-6A shows that the scores of the first two PCs, generated from
the basic-calibration set, are uniformly distributed. However, when the PCA algorithm was
applied to the updated and risk-based calibration scenario data (preprocessed), two clusters formed
in the PCA space (Figure 2-6B). This clustering indicates that variabilities were present across the
calibration set, mostly in the PC2 direction. As most of the samples were prepared and scanned in
the summer-season, the largest group contained summer-samples. Whereas, the smaller group
contained samples added from the winter-season (low humidity condition). Also, a boundary was
developed using a 95% confidence interval of PC1 and PC2 scores. It was observed that the
developed confidence interval in the PC space of the updated calibration model mostly excluded
samples from the smaller cluster (Figure 2-6B). Therefore, the samples that resided outside the
boundary were primarily from the winter season. Nevertheless, increasing the confidence interval
includes all samples within the boundary (Figure 2-6C).
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Figure 2-6: A) PCA of the basic calibration model with a 95% confidence interval,
B) PCA of the updated calibration model with a 95% confidence interval, and C)
PCA of the updated calibration model with a 99% confidence interval. Here the red
circles are samples, and the dashed line is the confidence interval.
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Table 2-2: Performance of the different modeling approaches

Different Models with
predefined threshold
𝟐

SIMCA (𝑻 & Q=0.95)
SIMCA (𝑻𝟐 & Q =0.99)
PCA-SVDD (D=0.05)
PCA-SVDD (D=0.01)
Spectral SVDD (D=0.05)
Spectral SVDD (D=0.01)

Sensitivity
0.5
0.5
0.5
0.5
0.5
0.5

Basic
Specificity
1
1
1
1
1
1

Average
0.75
0.75
0.75
0.75
0.75
0.75

Calibration scenarios
Updated
Sensitivity Specificity Average
0.67
1
0.83
1
0.92
0.96
1
1
1
1
1
1
1
1
1
1
1
1
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Risk-based
Sensitivity Specificity
0.85
1
1
0.6
0.93
0.98
0.94
0.94
0.93
1
0.93
1

Average
0.925
0.80
0.955
0.94
0.965
0.965

2.3.2

Model Performance of SIMCA and SVDD Methods

2.3.2.1 SIMCA Method Performance

While developing the SIMCA calibration model, several parameters were optimized.
Spectra were preprocessed and PCs were determined using independent test sets (containing both
target and non-target class samples) by maximizing the classification average performance of
sensitivity and specificity. The baseline correction method was required as a preprocessing method
to minimize batch-to-batch variabilities due to particle size differences. Standard normal variate
(SNV) helped to remove these variabilities. The number of selected PCs has a major impact on
the classification results. Adding more PCs into the model increases the complexity of the model,
which typically helps to reject non-target class samples. However, a more complex model means
that a higher amount of variation in the training set is considered; adding more PCs may result in
an over fitted model and a potential risk of rejecting target samples during routine analyses. Hence,
a model containing a minimum number of PCs to generate adequate specificity is preferable. This
approach is often referred to as a parsimonious approach [163].

After establishing a PCA model, an acceptance area is developed based on a threshold
value. In this study, the decision threshold is set at √2 which creates a semi-circle in Hotelling’s𝑇 2 and 𝑄 residual plot. This is based on a priori significance level of Hotelling’s 𝑇 2 and 𝑄 residual.

This significance limit for these two statistics are estimated based on the internally cross-validated
values of 𝑇 2 and 𝑄 residual associated with the calibration samples. In this study, two fixed
significance levels, 95% and 99%, were used to measure the performance.
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In Table 2-2, the performance of SIMCA models is shown. Here, it was observed that,
regardless of the significance level, the basic design scenario showed 100% specificity using 1 PC
(rejected all the non-target class samples). According to Figure 2-7A, these non-target class
samples have higher 𝑄 residual and Hotelling’s 𝑇 2 and resided outside the boundary. Non-target
class samples, containing a lower concentration of API, were separated from the target class.
However, the other critical parameter, sensitivity of the model, is 50%. The rejected target samples
have high 𝑄 residuals in the diagnostics plot (Figure 2-7A), which indicates that the target-class
samples in the validation set had unmodeled variance. This performance is not unexpected, as 50%
of validation target class samples were generated in the winter and had different moisture content.
The model accepted target class samples which were manufactured during the summer seasons
and had similar features of the basic calibration design set.

The updated calibration scenario (which was developed by adding winter samples to the
summer sample set) improved sensitivity compared to the basic set. This result indicated that to
improve model performance, winter samples are required in the calibration set. Moreover,
changing the threshold value from 0.95 to 0.99 further improved sensitivity. The diagnostic plot
in Figure 2-7B, showed that calibration samples prepared in the winter season had higher 𝑄
residuals and Hotelling’s 𝑇 2 relative to the samples prepared in the summer. While developing a
decision boundary using 95% CI, most of these winter samples resided near the boundary or
outside of the decision boundary. These samples are typically referred to as high-leverage samples.
Similar patterns were observed for the risk-based calibration model (Figure 2-7C). Changing the
significance level of Hotelling’s 𝑇 2 and 𝑄 residual to 99% placed these high leverage samples into
the decision boundary. This change in the significance level improved the sensitivity of the model
by accepting validation samples which were rejected in the previous model threshold. However, it
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is also important to understand that the specificity of the model decreased due to the change of the
significance level. Hence, with this higher significance level (99%), the model began to accept
non-target class samples (Figure 2-7D).

Figure 2-7: Diagnostics plots of SIMCA using 95% threshold value of Hotelling's 𝑇 2 and
𝑄 residuals of A) Basic calibration set, B) Updated calibration set, C) Risk-based
calibration set, and 99% threshold value of Hotelling's 𝑇 2 and 𝑄 residual of D) Risk based
calibration set. Here, red indicates the calibration samples from the target class, green
indicates validation samples from the target class, and blue indicates validation samples
from the non-target class.

Similar results were observed for the risk-based scenario. By including samples stored in
the low humidity condition, the sensitivity of the model improved. As the model also contained
samples stored at 11% RH, model performance improved by accepting validation samples
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generated in the winter. This was an efficient approach of method development as it included
moisture variabilities in the calibration set without considering samples generated during winter
seasons. Therefore, analysts were not required to wait to update the model until generating
samples, which is often a tedious process. However, this model also had high leverage samples;
changing the threshold value from 0.95 to 0.99 improved sensitivity but decreased the specificity
of the model by accepting non-target class samples.

2.3.2.2 SVDD Method Performance

In this study, the SVDD algorithm was applied to the PCA decomposed data and
preprocessed spectral data; these will be mentioned as PCA-SVDD and Spectral-SVDD
subsequently. Both approaches were optimized individually using the test set to obtain the best
possible results. During optimization, different factors such as the preprocessing method, the
number of PCs, and the parameters of SVDD (i.e., D and σ) were considered. Previous literature
suggested to fix the rejection fraction of the calibration model (D) according to a predefined value
and then to optimize σ. In this study, two D values: 0.05 and 0.01 were considered. These two
values represent the comparative performance of 95% CI and 99% CI of the method [166]. To
optimize σ for three calibration scenarios, a search was performed based on the test set. While
calculating the σ value, a series of values ranging from 0.1-2.5, with incremental steps of 0.1, was
used.

86

Figure 2-8: A boundary was developed using a support vector machine approach for
updated calibration samples. Each row represents different D values whereas each
column represents σ values.
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While developing the PCA-SVDD method, the first two principal components’ scores were
selected to develop the model for each calibration scenario. PCA-SVDD models were developed
by optimizing σ. The impact of the σ parameter on the boundary development of the updated
calibration scenario was visualized in Figure 2-8. Decreasing the σ value tightened the non-linear
boundary of the updated calibration scenario by exploiting a higher number of support vectors
(samples resided on the boundary) [21].

However, analysts should be cautious about the

unnecessary tightening of the boundary, which may increase risk of overfitting of the model. Also,
changing D values allowed more samples to reside outside the boundary, which is representing a
similar approach to the confidence interval of PCA or SIMCA. One crucial difference between the
decision boundary of SIMCA (based on the confidence interval) and PCA based SVDD analysis
was identified. In the SVDD approach, samples from both summer and winter samples resided
inside the boundary. However, while developing a SIMCA model based on the 95% CI, the model
excluded most samples from the winter season.

Performance of the different calibration scenarios is presented in Table 2-2. Basic
calibration scenarios of PCA-SVDD did not contain moisture variation in the calibration model,
and, therefore, failed to accept validation samples from different seasons. This performance is
comparable to the SIMCA modeling approach. However, the performance of PCA-SVDD
generated from updated and risk-based scenarios improved significantly relative to the SIMCA
approach. The developed PCA-SVDD model successfully accepted more target class validation
samples, compared to SIMCA, and demonstrated higher sensitivity. Additionally, the model
successfully rejected non-target class samples by projecting them outside the boundary. Therefore,
the PCA-SVDD algorithm improved the model performance of the NIRS method. The risk-based
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scenario also showed a similar trend to the updated approach. D values of both 0.01 and 0.05
showed improved performance compared to SIMCA.

Figure 2-9: Depiction of selected support vectors of updated calibration set
where the blue spectra are support vectors, red spectra are summer samples and
green spectra are winter samples. Particular section is magnified to visualize the
data clearly.

The Spectral-SVDD approach also showed improved prediction results compared to
SIMCA. Data is visualized in Figure 2-9. As the boundary was not possible to show for the
multivariate spectral data, support vectors were depicted using the preprocessed spectra.
According to Figure 2-9, the SVDD algorithm selected blue samples as support vectors from the
calibration sample set. These support vectors were chosen from both summer (red) and winter
(green) samples, indicating that the boundary was selected using both summer and winter sample
sets, unlike the SIMCA approach.
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2.4

Discussion and Summary

Traditional development of decision boundaries for CM models is based on the assumption
that there is a specific distribution that exists in the multivariate space (i.e., F- distribution or χ2
distribution on the Hotelling’s 𝑇 2 and 𝑄 residual space). Though these assumptions often vary in
different versions of SIMCA, analysts develop decision boundaries at a specific significance level
α (often set to 0.05) [17]. However, these assumptions are frequently violated as samples
containing spectral variabilities may introduce bimodal, multimodal, non-symmetric statistical
uncertainties, degrading model performance.

This work proposes the use of SVDD as a class-modeling technique using NIRS. Due to
distribution free boundary development, SVDD is a promising technique for use in both the
laboratory and field for solving the calibration development challenges described above. The most
important advantage of SVDD is that boundary samples are determined without relying on
distribution assumptions. Using a well-known example from NIRS (the effect of moisture on NIR
spectra), this chapter demonstrates the advantage of SVDD.

Though compared to the traditional SIMCA method, SVDD has not been widely used in
pharmaceutical applications of chemometrics. However, it has been proven useful for classmodeling applications. Moreover, the kernel feature allows the development of a non-linear
boundary around calibration samples, offering a significant analytical advantage compared to
traditional CM methods.

One challenge of the SVDD approach is the visualization of data. While it is impossible to
visualize the highly dimensional data, observation of selected samples as support vectors may
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provide valuable insights about the developed method. Another risk of using SVDD methods is
overfitting. Here in this study, independent samples were used as test and validation sets,
decreasing the risk of overfitting. However, analysts may not always have access to independent
samples for optimization. In that case, separating the training set into two sets might be an option.
To separate samples into two sets, randomization algorithms will ensure homogenous distribution
of the available samples.

Many studies have demonstrated the capabilities of different class-modeling techniques for
pharmaceutical samples, but the development of methods for validating such models is still in its
infancy. However, as regulatory bodies attempt to implement different spectroscopic techniques
in the field for routine surveillance, analytical methods must be validated to ensure that these
methods perform consistently during routine analyses. This work offers insight on 1)
understanding the physical and chemical variability of typical pharmaceutical tablets, required
knowledge for development of robust models, and 2) the advantages of SVDD methods for the
detection of falsified drugs using spectroscopic techniques.
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3 Chapter 3: Application of Class-Modeling Techniques
using Raman spectroscopy in the Presence of Moisture
Variation
3.1

Introduction

Raman spectroscopy has emerged as a promising tool for detection of falsified drug
products due to sharp peak features offering inherently good chemical specificity, the nondestructive nature of the method, and the flexibility in sampling interfaces.

One of the proposed uses of Raman spectroscopy is to detect active pharmaceutical
ingredient (API) in the test sample. A pure component spectrum collected from API and a spectrum
from the test sample may be utilized to determine correlation by a spectral matching algorithm.
Because 50% of the falsified products detected in a recent study did not have the claimed API or
contained the wrong API [27], this method was used to detect such falsified products.

In another approach, instead of using pure component spectra, samples collected from an
authentic manufacturer have been used to find the correlation between authentic and test spectra
[14, 35, 78-80]. Utilizing authentic sample spectra allows the analyst to verify the correct
formulation (including excipient composition) of the test sample. However, relying on the sample
spectrum to calculate correlation has drawbacks. One limitation is that pharmaceutical excipients
generally have less Raman signal compared to the API. Studies have showed that, since different
generic samples of a specific therapeutic group contain similar formulations ( i.e., excipient
compositions are often very similar to each other), Raman was unable to differentiate generic
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products using correlation values because of the inadequate signal intensity from different
excipients [14, 15]. This drawback of SM algorithms is also true when an analyst wants to detect
highly similar falsified products (samples containing the same API, but unique excipient
composition). Therefore, using class-modeling techniques can offer advantages of decreased false
positives and false negatives.

As an important step in development of any class-modeling technique, a calibration model
development effort is required. While developing Raman calibration methods, it is necessary to
ensure that models meet the required performance standards; in particular, the sensitivity and
specificity must meet predetermined validation criteria. One of the widely used class-modeling
algorithms, soft independent class modeling analogy (SIMCA), has been used to create models for
detection of falsified medicines [109, 151, 155]. Though this method allows the analyst to extract
relevant chemical and physical information about samples to get qualitative information, numerous
sources of spectral variability that occur during the method life-cycle may confound Raman
measurements and may ultimately decrease the sensitivity of the model (ability to accept targetclass samples). Therefore, to ensure long-term model performance, model sensitivity may be
enhanced by including such sources of spectral variability in the target-class. These sources of
variability may be identified during a risk assessment. Understanding the impact of such variability
on the spectra and the effect of these spectral changes on model performance is a critical part of a
sound model development process [151, 152].

Many sources of Raman spectral variability arise during the pharmaceutical manufacturing
process, including sampling error, analytical instrument instability, sample property variation and
environmental fluctuation. Sample variability may be introduced through raw material or process
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variability or as a result of sampling procedure: the time, location and method of sampling is often
at fault. Typically, lot-to-lot differences of incoming raw materials introduce new physical and
chemical variations [128, 129]. The consequence of these variations on Raman spectra may depend
on the sampling configuration, spectral collection modalities, etc. [130-132] As an example, the
effect of particle size variation in tablets has been compared for backscatter and transmission
Raman spectroscopy [133]. Because backscatter Raman generates most of the signal from very
near the tablet surface [167], particle size had a reduced impact relative to the transmission mode.
In the case of transmission measurements, photon propagation characteristics were more
influenced by particle size variation due to the effect of light scattering on the effective optical
path length. When particle size variability was not included in the calibration set, quantitative
model accuracy suffered. Spectral processing methods such as derivative, normalization, etc., were
applied to remove the baseline effect of particle size variation, thereby improving model
performance. Also, by matching particle size variability for both API and excipients in the
calibration, adequate quantitative predictions were obtained for independent test sets [1, 133-135].
A change of size, shape or density of tablets due to changes in the manufacturing process can also
introduce spectral variability [136, 137]. By adjusting laser power and accumulation time, or
enhancing density range in the calibration model, robustness can be enhanced against tablet size
and density variations [134, 136].

While the implementation of Raman in pharmaceutical applications has increased
dramatically over the past decades due to the improvement of instrumentation [54, 168, 169], one
continuing challenge, and a major source of spectral variability causing interference with the
Raman spectral signal, is fluorescence. Produced by emission of photons from low-lying excited
electronic states, fluorescence often masks the vibrational shift of Raman spectra. This effect
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occurs in a sample whenever the frequency of the excitation laser coincides with transition energy
from the ground to an electronically excited state. Different experimental strategies and instrument
modifications have been developed to overcome this problem [170]. By using excitation sources
in the near-infrared region coupled with multichannel detectors, modern dispersive Raman
spectrometers decrease the fluorescence background and provide adequate Raman intensity [171].
Different spectral preprocessing methods have been used to reduce the impact of fluorescence
signal on prediction results [172-175]. Moreover, model performance should be adequate as long
as both calibration and validation sets contain similar fluorescence background without
introducing other spectral disturbances [176].

One of the challenging sources of variability that analysts often encounter during
spectroscopic model development and deployment is environmental variability; for example,
relative humidity will often vary from the warehouses where raw materials are stored to the
facilities where products are manufactured. This can cause significant variability in the amounts
of water sorbed by pharmaceutical samples [177-179]. Additionally, falsified products are often
seized after being exposed to unknown storage conditions. Therefore, the impact of relative
humidity on model performance is critical and needs to be tested. Most often, Raman analytical
methods ignore the effect of moisture because Raman presents relatively weak water scattering.
However, because pharmaceutical samples exhibit fluorescence from active pharmaceutical
ingredient (API) [146] , excipient [173, 174], dyes [175], capsule shells [180], etc., the effect of
moisture as a fluorescence quencher needs to be considered [181]. This can introduce unwanted
spectral inconsistency across calibration and test samples. Nevertheless, there is not enough
literature evidence to show the moisture effect on Raman spectra. Therefore, influence of moisture
on Raman spectra was investigated, along with the model performance.
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The objectives of this chapter are to investigate the effect of moisture and fluorescence on
Raman spectroscopic analysis for pharmaceutical solid oral dosage forms. The effect of these
changes on Raman spectra and multivariate qualitative model performance was assessed. As
SVDD is a potential class-modeling technique, performance of this method was compared with
the SIMCA method during this investigation. Finally, strategies for the development of robust
qualitative calibration models were discussed.

3.2

Experimental Plans

In this chapter, two datasets were used to provide adequate understanding of the effect of
moisture on calibration model performance.

1) Dataset 1: Lab-based acetaminophen tablets- Acetaminophen tablets were manufactured
in the Duquesne University Center for Pharmaceutical Technology (DCPT).

2) Dataset 2: Artemether- lumefantrine combinations tablets- Artemether-lumefantrine
fixed dose combination tablets were collected from a generic manufacturer.

3.3

Dataset 1: Lab-based acetaminophen Tablets

Tablet were prepared at two scales of manufacturing for this data set, including:

A) Lab-scale tablets, to study the effect of moisture on Raman spectra.

B) Pilot scale tablets, to study the effect of moisture on Raman model performance.
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3.3.1

Lab Scale Tablets to Understand the Effect of Moisture on Raman Spectra

This experiment investigated the deleterious effects of water quenching on Raman spectra.
To demonstrate this, a formulation composed of acetaminophen, lactose, microcrystalline
cellulose (MCC), hydroxypropyl methylcellulose (HPMC) and magnesium stearate was used.

Granules of acetaminophen (APAP; Mallinckrodt Inc., Raleigh, NC, USA), HPMC
(Pharmacoat 606, Shin-Etsu Chemical Co. LTD, Tokyo, Japan) and lactose (modified spray-dried;
Foremost Farms USA, Rothschild, WI, USA) were manufactured using a fluid bed granulator
(model WSG 5, Glatt, Binzen, Germany). The active containing granules were mixed with extragranular MCC (MCC; Avicel PH 200, FMC Biopolymer, Mechanicsburg, PA, USA), lactose and
magnesium stearate (Fisher Scientific, Waltham, MA, USA) in a bin blender. The mixture
comprised of the aforementioned components were blended in a 3.5-quart V-blender (total mass
of 1 kg) for 45 min. NIRS was used to demonstrate homogeneity at the target blending time.

The tablets were generated on a Carver automatic tablet press (Model 3887. 1SD0A00,
Wabash, IN, USA) using a 13 mm die and flat-faced punches. Target tablet weight was 700 mg.
A five by three level, two factors [active content (19.11%, 23.21%, 27.30%, 31.40% and 35.49%
w/w; and excipient ratio levels 2, 1, 0. 5)] full factorial design was created. The use of a fullfactorial experimental design provided orthogonality between the active ingredient and the
excipient ratios. While it would have been possible to have all other components vary
independently from the active ingredient, the use of excipient ratio helped to reduce the number of
design points, as summarized in the design (Table 3-1). After allowing the tablets to undergo
viscoelastic relaxation (two weeks), they were placed in environmental chambers at room
temperature. The four chambers equilibrated with a relative humidity (RH) of 11% (saturated
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lithium chloride), 32% (saturated magnesium chloride), 52% (saturated magnesium nitrate) and
75% (saturated sodium chloride). Tablets were left to equilibrate in each chamber, beginning with
the lowest moisture level. Once the mass of tablets had equilibrated in the 11% RH chamber, they
were analyzed and moved to the 32% RH chamber. The equilibration and analysis were repeated
for each chamber. Tablets were moved from low to high relative humidity to simplify the
experimental design and reduce the experimental period.

Table 3-1: Design for lab-scale tablets to vary API and excipients level
IntraMicroExtraDesign Acetamino- HyproMagnesium Excipient
granular crystalline granular
#
phen
mellose
Stearate
ratio
lactose
cellulose
lactose
1
19. 11
2. 73
5. 46
51. 77
20. 43
0. 50
2. 0
2
23. 21
3. 32
6. 63
48. 65
17. 70
0. 50
2. 0
3
27. 30
3. 90
7. 80
45. 53
14. 97
0. 50
2. 0
4
31. 40
4. 49
8. 97
42. 41
12. 24
0. 50
2. 0
5
35. 49
5. 07
10. 14
39. 29
9. 51
0. 50
2. 0
6
19. 11
2. 73
5. 46
38. 83
33. 37
0. 50
1. 0
7
23. 21
3. 32
6. 63
36. 49
29. 86
0. 50
1. 0
8
27. 30
3. 90
7. 80
34. 15
26. 35
0. 50
1. 0
9
31. 40
4. 49
8. 97
31. 81
22. 84
0. 50
1. 0
10
35. 49
5. 07
10. 14
29. 47
19. 33
0. 50
1. 0
11
19. 11
2. 73
5. 46
25. 89
46. 31
0. 50
0. 5
12
23. 21
3. 32
6. 63
24. 33
42. 02
0. 50
0. 5
13
27. 30
3. 90
7. 80
22. 77
37. 73
0. 50
0. 5
14
31. 40
4. 49
8. 97
21. 21
33. 44
0. 50
0. 5
15
35. 49
5. 07
10. 14
19. 65
29. 15
0. 50
0. 5
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Fluorescence quenching effect

To understand the nature of spectral change due to fluorescence quenching, spectra of pure
components were collected in the presence of water and molecular gases, oxygen (O 2) and nitrogen
(N2). To investigate the impact of water, pure component compacts were created by compressing
approximately 700 mg of each material in the Carver press. Then, these pure component compacts
were stored in the four aforementioned humidity conditions to observe the effect of moisture on
Raman spectra. In addition, spectra were collected in the presence of O2 and N2 using custom gas
chambers.

3.3.2

Pilot scale Tablets to Understand the Effect of Moisture on Raman Model
Performance

In this experiment, the blends were compacted on a 38-station rotary tablet press
(Elizabeth-Hata International, Inc., North Huntingdon, PA, USA). The stations were tooled using
3/8 in. (9.5 mm) diameter, round biconvex punches and the corresponding dies. Only two stations
were tooled to facilitate the collection of the tablets post ejection. Three tablets were collected
every minute for 20 min. The turret speed was left constant at 30 rpm, and the target compression
force was 8000 kp. The target tablet weight was 350 mg. HPLC was performed on the tablets to
ensure uniformity of blend and tablets.

During the course of the study (from June 2014 - March 2015), a total of six granulations
and fourteen tablet batches were manufactured using the target formulation. A large variability
existed in the in the moisture content of the excipients and granules. These variabilities were
observed because the environment of the laboratory in which the experiments were performed was
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not controlled; during the winter the air was dry (20–30% relative humidity (RH)), but during the
summer months it was typical to observe a RH between 60% and 70%. Based on the seasonal
differences, samples are categorized as summer, spring and winter samples. Both calibration and
test sets included all these three seasonal samples.

3.3.3

Raman Data Collection

Raman spectra were collected on a TRS 100 (Cobalt Light Systems Ltd., Abington,
Oxfordshire, UK) for analysis of compacts. The transmission spectrometer is equipped with a
diode laser operating at 830 nm as the radiation source, a long pass spectral filter and a
thermoelectrically cooled CCD camera for the detector. All compacts were scanned over the
wavenumber range of 38-2400 𝑐𝑚 −1. The measurements were conducted at room temperature
(approximately 24ºC). Parameters were tuned according to the tablet scale: exposure time for pilot
and lab scale tablets were 0.5 seconds and 1.3 seconds, respectively. Five accumulations were
collected per spectrum with a laser power of 0. 6W.

The effect of O2 and N2 gasses on the spectra of powdered samples was evaluated with a
RamanRxn2TM backscattering spectrometer (Kaiser Optical Systems, Inc, Ann Arbor, MI, USA)
and iCRaman software (version 4. 1, Mettler Toledo, Columbus, OH, USA). A fiber-coupled
PhAT probe (HoloGRAMS version 4. 0, Kaiser Optical Systems Inc., Ann Arbor, MI, USA) was
equipped with a 400-mW laser at 785 nm. The diameter of laser spot size was 6 mm. Accumulation
time was 3 seconds, and the spectral range was 38-2400 cm−1 .
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3.3.4

Model Evaluation

In order to evaluate class-model for authentication purpose and to determine the potential
impact of moisture variation, both SVDD (see Section 2.2.1.2) and SIMCA (see Section 2.2.1.1.)
was applied [109]. The capability of a model developed at one moisture level to predict the target
class of compacts stored at other relative humidity levels was tested. The sensitivity (see Section
2.2.2) was used to evaluate the effect of moisture variability on model performance. Various
diagnostic plots were employed to understand the underlying causes of model performance.

3.3.5

Results and Discussions

3.3.5.1 Effect of Moisture Variability on Raman Spectra using Lab-based Acetaminophen
Tablets

Figure 3-1: Raw spectra of calibration tablets at different moisture conditions:
11% RH (red), 32% RH (blue), 52% RH (green), and 75% RH (magenta).
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Figure 3-1 shows spectral baseline changes when tablets were exposed to four different
moisture levels (11% (red), 32% (blue), 52% (green) and 75% (magenta) RH). It can be observed
that increasing the water content in the tablet leads to a decrease in the fluorescent background.

Figure 3-2: Raw spectra of a tablet (target formulation) exposed to repeat scans
over eight weeks to test the photobleaching effect.

Mechanistically, the decrease in fluorescence intensity was caused by the deactivation of
the excited-state fluorophores in contact with certain molecules (e.g., water in this study) in the
sample. These molecules are referred to as quenchers [39]. This spectral change, due to the
presence of water, was much more significant than the effect of photobleaching (due to successive
exposure of the sample to the laser). The effect of photobleaching is illustrated in Figure 3-2, where
a tablet was stored at a relative humidity 52% and scanned repeatedly over eight weeks. With an
increasing number of scans and storage time, there was a small decrease in the baseline due to
photobleaching.
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Figure 3-3: Pure component raw spectra of A) acetaminopen, B) hypromellose, C) lactose, D) magnesium stearate, and
E) microcrystalline cellulose stored in four different humidity conditions (11% RH, 32% RH, 52% RH and 75% RH in
red, blue, green and magenta respectively)
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To understand the source of spectral variation in the presence of moisture, a variety of

compacts were prepared using pure components; the compacts were then exposed to different
moisture levels. Figure 3-3 reveals that MCC and HPMC compacts demonstrated a significant
decrease in the baseline with increasing water adsorption, which may be due to fluorescence
quenching. However, APAP, lactose and magnesium stearate spectra demonstrated very small
changes in the different conditions. This is likely due to the absence of fluorescence with these
three pure components. The results indicate that the primary source of spectral variation in the
prepared samples was from MCC and HPMC, with water acting as a quencher. In Figure 3-4,
fluorescence quenching for MCC and HPMC was demonstrated in the presence of oxygen, a
known quenching agent in cellulosic materials [42]. Previous studies demonstrated that, due to the
presence of lignin in the fiber component, a large number of pulp and paper samples exhibit laser
induced fluorescence (LIF). However, in the presence of molecular oxygen, lignin caused LIF
contributions to Raman spectra were significantly decreased [182]. Figure 3-4 shows that due to
the presence of O2, the spectral baseline of MCC changed over time. But, when spectra were
collected in the presence of N2 or air, quenching was reduced. This result suggests that
fluorescence decreases dramatically in the presence of the quenching agent O 2. A small spectral
change was observed with MCC in the presence of air due to the continuous laser exposure. This
provides another demonstration that the effect of photobleaching was less than that of quenching
associated with moisture. Acetaminophen and lactose spectra demonstrated limited spectral
change due to the lack of fluorophores.
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Figure 3-4: Raman spectra collected in the presence of molecular gas A)
MCC in presence of O2, B) MCC in presence of N2, C) MCC in presence
of air, D) Acetaminophen in presence of O2.

The effect of fluorescence quenching on spectral baseline has been shown to vary with the
content of both fluorophores and moisture. To characterize the impact of these two factors, spectral
slope and intensity was observed for raw spectra. The slope of the spectra was calculated from a
simple least-squares regression between Raman shift and Raman intensity. Three Raman shifts
(276, 750, 1404 cm−1 ) were chosen from the spectra to calculate this slope. The slope values are
displayed in Table 3-2, where results from four moisture levels and three excipient ratios (2:1, 1:1
and 0. 5:1 of MCC: lactose) are presented.
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First, the amount of fluorescent components affected the baseline intensity, as anticipated.
Fluorescence intensity decreased with a decreasing amount of MCC (for a given moisture level).
This change was reflected in the slope. Second, the moisture content had a significant impact on
the baseline: the Raman intensity decreased with increasing water content (for a given compact
composition), causing a dramatically reduced slope with increasing moisture content (Table 3-2).
These results emphasize the quenching effect of water on Raman spectra.

Table 3-2: Effect of fluorescent containing material and moisture on Raman spectra

MCC: Lactose
Ratio

2

1

0. 5

%RH

RS=276 cm-1

RS=750 cm-1

RS= 1404 cm-1

Slope (Calculated from least square)

Intensity count

Intensity count

Intensity count

A. U.

11

85896

47659

14711

35593

32

59688

33290

10039

24824

52

34189

19205

5590

14300

75

22719

12889

3585

9567

11

81946

45242

13930

34008

32

56868

31702

9737

23565

52

33534

18615

5531

14001

75

24557

13951

3982

10287

11

61985

34349

11061

25462

32

42609

23625

7491

17559

52

27139

15339

4803

11168

75

22087

12424

3659

9214

RS= Raman Shift.
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3.3.5.2 Effect of Sample Moisture Variability on Qualitative Model Performance using Pilot
Scale Acetaminophen Tablets

The observed spectral variations due to the presence of water had a significant impact on
qualitative model performance using SIMCA and SVDD model. Performance was evaluated by
developing three models, prepared in winter, summer and spring, where relative humidity was
varied from 15%-75% RH. These models were then used to predict sensitivity of three test sets
corresponding to the three seasons.

A number of preprocessing methods such as baseline weighted least squares,
normalization, mean centering, derivative, and detrending were evaluated to eliminate the baseline
changes of the full spectral range described before. Random block cross-validation (five blocks)
was used to determine the most suitable spectral pre-treatments and model complexity (number of
principal components for SIMCA and C and σ for SVDD). An optimization was independently
conducted based on the minimization of cross-validation error. Savitzky-Golay first derivative
(window size-31, polynomial order-2) followed by normalization to unit area and mean-centering
was chosen for all models. Derivative methods were helpful to remove baseline variations and
normalization decreased the intensity of variations introduced due to the fluorescence quenching
or any physical differences between calibration and test sets.

As shown in Table 3-3, both SIMCA and SVDD models offered good sensitivity for
samples from the same moisture levels, where the preprocessing method was successful at
removing fluorescent baseline variability. However, poor results were achieved for prediction of
samples from unique moisture levels; error statistics increased with increasing range between the
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moisture levels of calibration and test sets. Figure 3-5 presents Hotelling’s 𝑇 2 and 𝑄 residual plots
for spring calibration model. The reconstruction error for summer and winter test sets was higher,
indicating that the lack of robustness of the calibration model to moisture variability.

Table 3-3: Effect of sample moisture variability on test set predictions: Lab Scale Tablet

SIMCA
Summer
Summer
0.95
Test Set Sensitivity Spring
0
Winter
0

Spring
0.75
0.84
0
SVDD
Summer
Spring

Test Set Sensitivity

Summer
Spring
Winter

0.95
0
0

0.7
0.93
0

Winter
0
0.75
1

Global
1
1
1

Winter

Global

0
0.8
1

1
1
1

Global models include all of the expected variability in the calibration set. In this case,
calibration sets from three seasons were combined to facilitate the creation of robust model:
sensitivity for the test set at the different humidity levels are provided in Table 3-3. The global
model demonstrated a lower prediction error compared to models created at unique humidity
conditions

3.4

Dataset 2: Artemether- Lumefantrine Combinations Tablets

The World Health Organization (WHO) introduced artemisinin-based combination therapy
(ACT) as first-line therapy to decrease the falciparum malaria, which was adapted by most
countries [183]. Successful prevention and control of malaria can be achieved by ensuring the
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quality of ACTs and other antimalarials. However, one-third of anti-malaria medicines from
malaria-endemic countries failed the quality test, which is alarming for the prevention of malaria
[184]. Different fast screening processes have been proposed to test pharmaceutical tablets at
different stages of the supply chain. Raman spectroscopy has been used to test the quality of
artemether-lumefantrine fixed-dose combination products [146].

Figure 3-5: Hotelling’s 𝑇 2 vs. 𝑄 residual plot was generated from different
seasonal conditions of test tablets (summer (red), spring (green), winter (blue)) ,
which were projected on the calibration set (spring (black)).
However, as artemether has a high fluorescent background while using Raman
spectroscopy, model performance may deteriorate due to the fluorescent quenching in the presence
of moisture [146]. Therefore, it is hypothesized that, for artemether-lumefantrine samples, it is
essential to consider moisture throughout the method development process. Artemetherlumefantrine tablets produced by generic manufacturers were used as a model drug to evaluate the
influence of moisture variation on tablet’s spectra and model performance.
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3.4.1

Sample Collection

Anti-malarial drugs were obtained from a government registered pharmacy in Dhaka,
Bangladesh. A total of 56 artemether-lumefantrine tablets, manufactured by Square
pharmaceutical Ltd. (Lumetram®) were collected. Packaging was visually inspected to avoid any
fraudulent activities, and the batch numbers were confirmed with the manufacturer for
authenticity. Further, to independently verify the active ingredient in the manufacturers' standards,
pure components of artemether (J&K Scientific San Jose, CA), and lumefantrine (Combi-block,
San Diego, USA) were used.

3.4.2

Samples Scan

Raman data were collected using a RamanRXN2 spectrometer (Kaiser Optical Systems,
Inc, Ann Arbor, MI, USA) and iC Raman software (version 4.1, Mettler Toledo, Columbus, OH,
USA). The spectrometer was equipped with a 785 nm laser excitation and a fiber-coupled PhAT
probe (HoloGRAMS version 4.0, Kaiser Optical Systems, Inc, Ann Arbor, MI, USA) with a 6 mm
spot size. One accumulation with 5 s integration times were acquired over the range of 150–1,890
cm−1 at 1 cm−1 increments. A dark scan was subtracted, and the cosmic ray filter and intensity
calibration options were selected. Tablets were positioned at the end of the probe unit using an inhouse machined copper sample holder with a 10 mm diameter. The sample holder was threaded
into the end of the PhAT probe tube so as to provide a fixed distance from the laser source to each
sample. This reduces error related with repositioning and re-focusing. To decrease stray light
effects while collecting samples spectra, a black cap was kept over the top of the sampling
interface. The average of spectra from both sides of each tablet was used for calibration
development and testing, respectively.
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3.4.3

Samples Preparation to Investigate the Effect of Moisture

Three chambers were used with target relative humidity (RH) of 15% (saturated solution
of lithium chloride), 50% (magnesium nitrate) and 70% (sodium chloride). A total of 15 Tablets
were left to equilibrate in each chamber. The equilibration of the mass over storage time at each
RH condition was used as an indicator of stability. Tablets were moved from low to high relative
humidity to simplify the experimental design and reduce the experimental period. Both sides of
the tablets were scanned 5 times using the same parameters described above.

3.4.4

Testing the Effect of Moisture on Model Performance

Individual classification models were constructed from each sample set equilibrated at a
single relative humidity. Test samples stored at the alternate relative humidity conditions were
predicted. When the moisture level is different between calibration and test sets, method sensitivity
should be challenged. Moreover, depending on the performance of sensitivity, the effect of
moisture variance should be accounted for during method development.

3.4.5

Results and Discussions

3.4.5.1 Moisture Effect on Artemether-Lumefantrine Tablets

Sample spectra of artemether-lumefantrine collected using Raman spectroscopy showed
high fluorescence background (Figure 3-6). These spectral features were similar to the
acetaminophen tablet dataset. Raw spectra of two pure components were collected. Here,
artemether showed strong fluorescent background and peak features were suppressed. However,
lumefantrine had sharp peak features and fluorescence background was absent.
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Figure 3-6: Raman spectra of artemther-lumefantrine combination.

Figure 3-7: Pure component spectra of A) artemether and B) lumefantrine.

Spectral variations were observed due to the presence of water in the tablet. As both
samples and pure components were placed in different humidity chambers, fluorescence
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quenching was observed due to the presence of water in the samples (Figure 3-8). It was also
revealed that this quenching effect was prominent in the artemether (Figure 3-9).

Figure 3-8: Spectra of tablets collected from three humidity conditions

Figure 3-9: Moisture variation of artemether and lumefantrine in different humidity conditions.
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3.4.5.2 Model Performance in Presence of Moisture Variations

Models developed at individual moisture levels accepted target class samples stored at
similar moisture levels. However, the models failed to predict test sets collected at other moisture
levels. This study resembled the previous acetaminophen studies described in this Chapter (using
Raman) and Chapter 2 (using NIRS). The error statistics became higher in different humidity
conditions, due to the increment of the difference of moisture level between calibration and test
sets (Table 3-4). This was largely because of fluorescence quenching and resulted increase of
baseline change. Therefore, Raman qualitative model performance decreased due to the lack of
robustness.

Table 3-4: Model performance of artemether-lumefantrine tablets in different
moisture conditions
SIMCA

Test Set Sensitivity

Test Set Sensitivity

11%
52%
75%

11%
1
0
0

11%
52%
75%

11%
1
0
0

52%
0.3
0.95
0
SVDD
52%
0.4
0.925
0

114

70%
0
0.4
1

Global
0.9
1
1

70%
0
0.2
1

Global
1
1
1

The effect of these spectral variabilities was observed in multivariate space described by 𝑄
residual and Hotelling’s 𝑇 2 (Figure 3-10). The 𝑄 residual values for the low moisture level of
calibration set and high moisture level for the test set indicated that this test set has different
spectral shape compared to the calibration set (Figure 3-10A). Global models including moisture
variability showed improved performance by reducing 𝑄 residual (Figure 3-10B). This global
model is often considered as a risk-based model. In this case, calibration sets from three relative
humidity levels were combined to facilitate the creation of a global model. This global model
demonstrated a lower prediction error compared to the models created at unique humidity
conditions. Moisture variabilities can cause density changes of tablets which may also have effect
on the spectra. Baseline correction and derivative methods were conducted to remove this
interference.

Figure 3-10: Hotelling’s 𝑇 2 vs. 𝑄 residuals plots were generated from calibration
plot (A) 11% RH samples (black), 52% RH samples (red) (B) global RH samples
(black), 52% RH samples (red).
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Changes of relative humidity often cause polymorphic changes in API or excipients.
However, this formulation did not demonstrate such a risk. Also, as the drug is stable over the
proposed humidity range, stability was not an issue for the considered formulation.

3.5

Summary and Conclusion

It is difficult to preemptively identify all sources of variation that will be encountered
during the pharmaceutical life-cycle. The experimental approach in this study provides an example
of how a simple phenomenon like

moisture variability, arising from such phenomena as

inconsistent environmental conditions, can, through fluorescence, significantly affect spectral
baseline and model performance. Both SVDD and SIMCA methods were tested in this work using
a global modeling approach to demonstrate opportunities for the creation of robust models for
laboratory and production scale tablets.

In this study, the presence of components containing 1) fluorophores and 2) moisture,
negatively affected model performance. Pharmaceutical raw materials, including excipients and
APIs, often contain fluorescent components. In Dataset-1, lignin in the microcrystalline cellulose
caused

laser induced fluorescence [182, 185]. In Dataset-2, artemether showed a strong

fluorescence background. Moreover, variable moisture content also introduced spectral variance
for these two datasets. The water content of tablets will often vary between and within different
tablet batches, depending on the relative humidity conditions during production, packaging,
storage and analysis. Water may be sorbed by samples very quickly depending on the relative
humidity of the environment and material attributes [34]. While it is likely that the relative
humidity of the laboratory may be controlled, it is very unlikely that the same environmental
conditions will be observed in the field analysis. Analysts may need to test the suspected samples
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which have been exposed to a different humidity condition. This is particularly true in situations
where spectroscopic method development takes place at one geographic and climatic location and
routine use of the method occurs elsewhere [177].

It is typically beyond the capacity of an analyst to eliminate sample components or strictly
control the sources of variability. Understanding the effect of variabilities such as moisture and
fluorescence during multivariate calibration model development will facilitate the generation of
models which are robust against these variations. In the present study, the effect of fluorescence
background was reduced by preprocessing the spectra. However, when calibration and test sets
contained different moisture content, prediction performance was degraded. These findings
regarding the effect of moisture on the Raman spectra should be useful information for method
development. This is true for both SVDD and SIMCA algorithms.

Though both SVDD and SIMCA algorithms performed satisfactorily after adding moisture
variations in the calibration model, SVDD showed promising results. This study highlighted the
usefulness of the SVDD algorithm for Raman spectroscopic techniques as a class model for
pharmaceutical tablet authentication system. This was the first use of SVDD and Raman
spectroscopy for tablet authentication.

117

4 Chapter 4: Developing a SVDD Method with Non-Target
Class Samples to Detect ‘Highly Similar’ Acetaminophen
Tablets Collected from Global Sources
4.1

Introduction

The development and implementation of class modeling typically occurs in two stages,
including 1) building a target class by generating a decision boundary around the target class
samples, and 2) evaluating a test samples to determine method sensitivity and specificity, based
on whether the sample resides inside or outside of the established multivariate decision boundary.

Typically, development of a decision boundary for a SVDD model does not rely on samples
from the non-target class. Method development using only target class samples is known as a ‘oneclass SVDD’ approach. In such a case, the model reaches an optimal condition by achieving the
best sensitivity (ability to accept target class samples).

However, samples from the non-target class can be used to optimize the model [21].
Including non-target class samples during modeling improves the description of the target class by
defining a tighter boundary around the target class data in the areas where non-target objects are
present. In contrast with the target class samples residing within the boundary, the non-target class
samples should be outside of the multivariate boundary. This type of method development is
feasible when several datasets from extraneous classes are available. These new non-target class
samples enable the calculation of an additional figure of merit — specificity (the rejection of
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objects from the non-target class). Understanding model specificity reduces the risk of accepting
false samples.

While developing a spectroscopic authentication method using a SVDD algorithm, the
non-target class samples should be a true representation of falsified drugs.

The pharmaceutical literature reports pharmaceutical products, including pure components
and finished dosage forms, could be falsified in various ways. Primary methods of falsification
involve altered composition of final dosage forms. This includes, but is not limited to, intentional
adulteration of pharmaceutical ingredients, tablets prepared without active pharmaceutical
ingredient (e.g., using only excipients), tablets manufactured using the wrong API, and tablets
generated with the correct API, but unusual compositions of excipients. In practice, the most
difficult samples to detect using spectroscopic methods could be the last category, which are often
generated using similar manufacturing techniques. Therefore, during authentication model
development, analysts should select non-target class samples which have similar compositions and
have similar spectral features to the target class. Spectral matching algorithms would be one
appropriate method to evaluate the spectral similarity between target and non-target class samples
during development of a SVDD method.

In this chapter, it is proposed that an appropriate non-target class of samples is essential for
optimizing a SVDD method. To prove this, challenging samples (which are difficult to distinguish
between non-target class and target class) from various producers containing identical API and
similar excipient compositions were considered. Highly similar acetaminophen tablets collected
from China, India, and Bangladesh were used in the study.
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4.2
4.2.1

Materials and methods
Sample collection

Tablet formulations containing acetaminophen were obtained from outlets readily
available to tourists or visitors in Bangladesh, India, and China (Figure 4-1). The tablets were
uncoated, intact and blister-packed. All tablets contained 500 mg of APAP according to the label.
Samples which had similar size and shape were only considered in this study (Figure 4-2). Nine
different manufacturers’ samples were collected from these three countries. The tablets were
collected from different batches, 10 tablets per batch. Details are presented in Table 4-1.

Figure 4-1: Samples were collected from India, Bangladesh, and China.
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Figure 4-2: Image of the tablets from different manufacturers (M1-M9).

Table 4-1: Characteristics of tablets from different manufacturers (M1-M9).

Manufacturer

Tablet

APAP

APAP Percentage in the

Code

Weight

amount

tablet

M1

558.3

500

89.55

M2

599.7

500

83.37

M3

582.7

500

85.81

M4

577.7

500

86.55

M5

557.3

500

89.71

M6

582.3

500

85.86

M7

554.0

500

90.25

M8

590.7

500

84.65

M9

545.7

500

91.63
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4.2.2

Confirming the Chemical Similarity of Samples using Raman Spectroscopy:

Raman spectra were collected by following the protocol mentioned in section 3.3.3 .

Figure 4-3: Raman spectra of different manufacturers’ samples and APAP.

The presence of acetaminophen in each product was confirmed using Raman spectroscopy.
The spectra are observed in Figure 4-3. Here, the spectra were stacked to demonstrate the presence
of API. Tablet spectra were compared in the fingerprint region (1850–400 cm−1 ), to verify the
presence of API. The spectral correlation was calculated by comparing each of the sample spectra,
with the acetaminophen spectrum. All products showed correlation coefficient values greater than
0.95, confirming the presence of acetaminophen (see section 1.3.3.1.2).
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4.2.3

NIR Measurement

NIR spectra were acquired in the range of 1550–1950 nm with a 10 nm wavelength
increment using a portable NIR ONE Sensor (Spectral Engine, VTT, Finland). Measurements were
carried out in diffuse reflectance mode. For analysis, the entire spectral region (1550-1950 nm) is
utilized because it is difficult to foresee at which wavelength alien objects will manifest deviations
from the genuine sample. Each time, both sides of the tablets were scanned to increase the sample
representation. Replicas were averaged before the analysis.

4.3

Figures of Merit

The following formula (Equation 1) calculate sensitivity of the method (accepting genuine
samples):

Sensitivity=TP/(TP+FN)

1

where TP and FN are true positive and false negative, respectively. If the model accepts
falsified samples, the model needs further optimizations.

The Specificity of the method (rejecting falsified samples) is used as validation parameter.
The following formula (Equation 2) calculates this parameter:

Specificity=TN/(TN+FP)

2

where TN and FP are true negative and false positive, respectively.
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4.4
4.4.1

Theory
Unsupervised analysis (PCA)

The Principal Component Analysis (PCA) method projects multivariate spectra into lowdimensional space, which emphasizes the variabilities present in the collected spectral data
although they do not precisely aim to identify them [81, 82]. PCA decomposes the multivariate
response arranged in an 𝑋 matrix into a product of two new matrices as indicated in the following
equation 3:

𝑋 = 𝑇𝑘 𝑃𝑘𝑇 + 𝐸

3

Where 𝑇𝑘 is the matrix of scores which represent how samples relate to each other, 𝑃𝑘 is
the matrix of loadings which contain information about how variables relate to each other, k is the
number of factors included in the model and E is the matrix of residuals, which contains the
information not retained by the model. The reader is referred to the works of Wold et al. [81] and
Martens & Naes [82] for a more detailed discussion of PCA.

4.4.2

SVDD

See Section 2.2.1.2.

4.4.3

Spectral correlation method

The spectral correlation method compares two spectra under study. This algorithm
considers the two spectra as two vectors, and then calculates correlation between these vectors
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(Equation 4) [67]. This spectral correlation (𝑆𝐶) method is often mentioned as a similarity and is
the equivalent of measuring the cosine of the angle between two spectra.

𝑆𝐶 = 100 ∗ √[(𝑆𝑎𝑚𝑙𝑒1𝑚 ∙ 𝑆𝑎𝑚𝑝𝑙𝑒2𝑚 )2 ]/[(𝑆𝑎𝑚𝑝𝑙𝑒1𝑚 ∙ 1)(𝑆𝑎𝑚𝑝𝑙𝑒2𝑚 ∙ 𝑆𝑎𝑚𝑝𝑙𝑒2𝑚 )]
Here 𝑆𝑎𝑚𝑝𝑙𝑒1𝑚 and 𝑆𝑎𝑚𝑝𝑙𝑒2𝑚 is the 𝑚𝑡ℎ absorption value in the spectra. 𝑆𝐶 measures the
similarity between the spectra, and 𝑆𝐶 values range from 0 (poorest match possible) to 1 (perfect
match).
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4

4.5

Experimental Strategy

Acetaminophen tablets manufactured by nine generic manufacturers produced in three
countries were used to demonstrate the proposed model development approach. In this study, the
calibration model was first developed using M1. After that, the model was optimized and validated
with both target and non-target classes (using M2-M9). Figure 4-4 displays a flow diagram of the
protocol.

Figure 4-4: Method development flow path. Relative to the contemporary process
analytical method development cycle which typically includes target class samples,
proposed SVDD method will be optimized using both target class and non-target class
samples
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4.6
4.6.1

Result
Spectral Investigations and PCA Analysis

Raw spectra failed to reveal significantly unique features of different sample sets. Baseline
shifting in the raw spectra was caused due to sample positioning variability. A standard normal
variate (SNV) method removed the baseline shifting associated with sample positioning
variability. Figure 4-5 shows the preliminary differences where primary variations were observed
in 1650-1850 nm and 1900-1950 nm.

Figure 4-5: SNV treated spectra from nine different manufacturers.

While using the PCA algorithm, different preprocessing methods and their combinations
were tested. To distinguish product from different manufacturers, the most efficient preprocessing
methods were SNV following the second order Savitzky Golay derivative, using a second-order
polynomial with a 5-point window and mean-centering. These combination of different
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preprocessing methods further removed baseline shifts and sharpened the spectral peaks. Principal
component analysis (PCA) was applied to different manufacturers’ samples (M1-M9). The results
show that 4 PCs describe 97.46% of data variation. The score plots presented in Figure 4-6
demonstrated that M9, M2, M4, and M5 were well separated from M1 (target class). However,
other groups showed substantial overlapping, in the plot of PC1 vs. PC2 scores. When considering
the plots generated using subsequent PCs, it is possible to separate other classes from the target
class. However, the close location of different groups indicated the high similarity of samples from
different manufacturers. In this case, PCA alone would not be adequate to consistently discriminate
all tablets from the target class.

Figure 4-6: A combined PCA model including all the calibration
and test manufactures.
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4.6.2

SVDD Model Performance:

The spectra of 30 samples from M1 manufacturer were used for the calibration model
development. Then, 20 more samples from M1 were used for sensitivity calculation. Additionally,
20 samples from each of the other eight manufacturers (M2-M9) were considered as non-target
class samples for optimization and for use as the validation sets. These non-target class samples
were used for the assessment of specificity. Among these eight manufacturers (M2-M9), one was
used to optimize the model and the other seven were used for validation purposes. Therefore, a
total of eight models were developed using optimization sets to calculate specificity. For each nontarget class, a total specificity is computed along with seven partial specificities, one for each nontarget class. The total specificity is the average of the seven partial specificities (Table 4-2).
Column one contains the non-target class names used for optimization. The second and third
columns show the number of support vectors and selected σ, respectively. The other eight columns
present the partial specificities, calculated separately for each non-target class. Mismatches (total
specificity less than 90%) are bold marked in column 9.
Table 4-2: Performance of SVDD using NIR spectroscopy

Non-target
class
M2
M3
M4
M5
M6
M7
M8
M9

D= 0.01
No o
of
σ
SV(s)
2
0.3
2
0.23
2
0.23
2
0.245
2
0.27
3
0.21
2
0.3
2
0.3

Validation specificity
Partial specificity
M2

1
1
1
1
1
1
1

M3

M4

M5

0.65 0.15 0.45
1
1
1
1
0.9 0.55
0.7 0.25 0.8
1
1
1
0.65 0.15 0.45
0.65 0.15 0.45
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M6

M7

0.91
0
1
0.63
1
0.63
1
0.54
0.5
1
0.91
0
0.91
0

M8

M9

1
1
1
1
1
1
1
1

1
1
1
1
1
1
1

Total
specificity
0.59
0.95
0.95
0.86
0.75
1.00
0.74
0.59

It can be seen that values of total specificity obtained for the models which used M2, M5,
M6, M8 and M9 as optimization sets are unsatisfactory. This result means that if these samples are
used as the non-target class to optimize the SVDD, the model could run the risk of having higher
false positives. This was observed in the Table 4-2. Such models failed to reject the rest of the
classes (M3, M4, M7). However, three models which used M3, M4 and M7 to optimize the model
reliably distinguished between target and the non-target class samples. Among these, M7 worked
best as that model rejected all non-target class samples. Figure 4-7 shows that M2 is spectrally
different than the calibration spectra, whereas M7 is highly similar.

Figure 4-7: Spectral comparison of calibration set (M1), and non-target classes
(M2 and M7)

Therefore, it can be concluded that the selection of a pertinent non-target class set for the
SVDD can significantly influence the results of classification. This experiment suggests that to
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reject “highly similar” samples using the SVDD method, it is essential to use highly similar nontarget class samples for model optimization. This creates a model that is sensitive to non-target
class test samples that are “highly similar” to target class samples.

4.7

Non-Target Class Sample Selection:

A correlation coefficient was calculated to automatically select a suitable non-target class
set for model optimization of falsified drug detection. This effort defined a method for setting
quantitative criteria for selection of ideal non-target class samples which would help to optimize
the model. Figure 4-8 showed the correlation coefficient values between the calibration set and
different non-target class sets. All of the samples exhibited a correlation of more than 0.95.
However, among these, non-target class, M7, showed the highest correlation with the target class,
M1. This correlation value between M1 and M7 was similar to the correlation values of different
batches of M1 (as different batches of M1 were used as calibration and test sets). Because of this,
it was difficult to separate M7 from M1, when other sample sets (M2-M6, M8 and M9) were used
to optimize the model. Therefore, M7 was the ideal non-target class candidate to be used for
optimizing the SVDD model.
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Figure 4-8: Spectral correlation coefficient values between the calibration set
and different manufacturers’ samples sets (M2-M9) including a unique batch of
a calibration set (M1).

Figure 4-9: Workflow of a method development for a spectroscopic
authentication system.
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The final workflow for falsified detection is proposed in Figure 4-9. To obtain better
performance, a SVDD model will be optimized using a non-target class sample. Before applying
the SVDD algorithm, these non-target class samples can be selected using a simple mathematical
treatment, such as correlation coefficient, for testing similarity between the target class and nontarget class.

4.8

Discussion and Conclusion:

It is understood that a spectroscopic system for authentication of pharmaceutical products
will require modern chemometric tools. The SVDD method was used with both target and nontarget class samples to demonstrate an approach for development of an authentication method. The
proposed SVDD method differs from a conventional two-class classification method because the
SVDD defines a closed boundary around target-class samples, whereas traditional two-class
support vector machine methods develop a boundary between these two classes. Furthermore, the
method does not require a strict representative sample of the target distribution; a calibration set
with extreme objects is acceptable, even desirable. However, it is also important to understand that
an effort to reduce false positives (accepting falsified samples) can result in an increase in false
negatives (rejecting authentic samples). With the presence of non-target class samples used for
model optimization, the boundary is developed rationally.

In this chapter, it was observed that exploiting non-target class samples during model
development is useful for optimization of SVDD models. Adding non-target class samples in the
method development process enabled the investigators to optimize the boundary of the SVDD
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model based on both sensitivity and specificity parameters. Selecting appropriate non-target class
samples to optimize the model requires a quantitative approach such as spectral correlation
calculation.

Figure 4-10: Modeling of a banana-shaped data set (blue) using non-target
classes: green (A) and yellow (B, C).
Figure 4-10 demonstrates the importance of careful non-target class sample selection. In
Figure 4-10A, when green samples are used as the non-target class, the spherical boundary around
the banana shaped target class data (blue) is appropriate to reject these green samples. However,
if yellow samples (which are closer to the target class blue samples than the non-target class green
samples) are used as non-target class samples, the spherical boundary is inadequate to reject these
non-target class yellow samples (Figure 4-10B). Therefore, model optimization using ideal nontarget class samples is required. After model optimization, an appropriate non-linear boundary
could be developed. This tighter boundary is seen in Fig 4-10C, around the target-class data, which
allows the model to distinguish non-target class (yellow objects), seen outside the boundary.

The finding from this study emphasized that to develop a spectroscopic method with the
help of chemometric methods, analysts should consider a pertinent test set and validation. Without
utilization of appropriate samples to optimize the model, the method will not perform adequately.
This proved the hypothesis mentioned in section 1.2.
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5 Chapter 5: Application of Experimental Design to
Generate Synthetic Non-Target Class Samples and the
Effect of Raw Material Variability of the Target Class on
the Class- Model Performance
5.1

Introduction

Development of class-modeling methods typically involves two stages. Initially, the model
should be developed using a calibration data set containing representative variations of target-class
samples; ideally, these samples should contain all possible sources of product variation. In
Chapters 2 and 3, the effect of moisture variation on NIR and Raman spectroscopy was discussed.
After an initial calibration model development, the model is then optimized using various complex
test sets, an approach that is highlighted in Chapter 4. Therefore, for proper model performance,
the optimization set (or test set) should include both authentic target class and non-target class
samples originating from alternative classes (see Figure 4-4).

One of the challenges of model development that has not been adequately addressed in the
literature is to find appropriate falsified samples to consider as an alternate class. Notably, it is
crucial to test the ability of the model to recognize samples which have a highly similar
composition to the target class. These falsified samples are often referred to as “high quality”
falsified products [15]. It is often difficult to find these alternate classes to be used in model
development.
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Researchers have proposed several strategies to collect alternate classes of samples.
Products manufactured by competitors can be a potential source of the non-target class sample.
Rodionova et al. used competitors’ products as a non-target class to optimize the decision boundary
for the SIMCA-DD method and successfully improved model performance by adjusting the
boundary area [186]. In the previous chapter of this dissertation, the SVDD method was optimized
using legitimate analogs of the target class; this approach demonstrated good performance.
However, samples from different manufacturers may not always be available, especially for brand
products (which have a high risk of falsification). Another group of researchers proposed the use
of samples stored in higher humidity conditions [13]. However, a high-water content may change
physico-chemical structures of the samples significantly, which may not be appropriate to be
considered as “high quality” falsified products.

One potential strategy to overcome this challenge is to generate synthetic samples in the
lab using statistical experimental design, or design of experiments (DOE), which can be a useful
statistical tool to explore the capability of spectroscopic identification of falsified products
containing unique chemical compositions. DOE is useful to gain understanding about which nontarget class samples are spectrally similar to the target class samples.

Synthetic samples, generated in the lab, can provide progress in resolving another
challenge of method development; namely to collect a fully representative calibration set
accounting for possible future variations in the target class. Using a material sparing approach,
potential sources of product variation such as moisture deviations, variabilities from raw material
sources, etc., can be added into the calibration model. In Chapters 3 and 4, laboratory generated
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samples with significant moisture variation were used to improve model performance. Likewise,
the effect of raw material variabilities can be addressed.

It is understood that the change in chemical composition or physical variations due to raw
material variability may exhibit a unique inherent response with different analytical techniques.
For example, NIR spectra involve a combination of absorbance and scattering properties of light
and exhibit response to both chemical and physical changes in pharmaceutical products. Raman
spectroscopy, on the other hand, is very sensitive to fluorescence; this is a major source of spectral
variability causing interference with the Raman spectra. Fluorescence is produced by the emission
of photons from low-lying excited electronic states, and often masks the vibrational shift of Raman
spectra [59]. Different pharmaceutical samples exhibit fluorescence arising from various active
pharmaceutical ingredients [146] , excipients [173, 174], dyes [175], capsule shells [180], etc. As
anticipated, samples generated using different excipient compositions should have a different
response for Raman and NIR spectroscopy. Therefore, non-target class samples will be different
based on the anticipated chemical response of the analytical method used to detect falsified
samples. Likewise, the impact of physical variability will also typically be different for NIR and
Raman spectroscopy. This chapter will evaluate such phenomena.

The objectives of this chapter include:

1. To demonstrate the usefulness of DOE during spectroscopic model development with
class-modeling techniques such as SIMCA and SVDD.

2. To use raw material variability to demonstrate the importance of creating representative
training sets in development of robust models.
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3. To explore the effect of DOE and raw material variability on NIR and Raman models
for false-sample identification.

5.2
5.2.1

Materials and Methods
Target Class Samples

The model drug product is a 350 mg tablet containing Acetaminophen (APAP;
Mallinckrodt Inc.,Raleigh, NC, USA) at 50% w/w active pharmaceutical ingredient (API),
microcrystalline cellulose (MCC; Avicel PH 200, FMC Biopolymer, Mechanicsburg, PA, USA)
at 15% w/w lactose (modified spray-dried; Foremost Farms USA, Rothschild, WI, USA), Starch
at 15% w/w (Pharmacoat 606, Shin-Etsu Chemical Co. LTD, Tokyo, Japan), cross carmellose
sodium (Pharmacoat 606, Shin-Etsu Chemical Co. LTD, Tokyo, Japan) at 4% w/w and magnesium
stearate (Fisher Scientific, Waltham, MA, USA) at 0.50% w/w as excipients. Colloidal silicon
dioxide, at 0.50% w/w, is used to improve APAP flow before combining with the excipients.

Materials were dispensed by weight (Data Range, model no AX504DR, Mettler Toledo,
Columbus, OH) and were transferred to a bin blender. In total, 1kg of material was weighed and
the nominal weights for all constituents were adjusted to the observed mass data to calculate actual
concentration. Blending was performed at the Duquesne University Center for Pharmaceutical
Technology with a 5.5-L bin blender (L.B. Bohle LLC, Warminster, PA, USA) with DeltaV
(Emerson Process Management, Equipment & Controls, Inc., Lawrence, PA, USA) controls.

Blend Monitoring: Lab scale blends with a total mass of approximately 1 kg were created
for NIR data collection. The fill ratio of these blends in the 5.5-L bin blender was less than 60%.
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The top sensor was set to collect spectra when inverted to assure that each scan had powder directly
in front of the sensor. At 15 rpm, the scans were collected at 4 s intervals. Pure component and
granule scans were collected by filling the blender for 45 mins. Diffuse reflectance NIR spectral
data was collected using the MicroNIR-W spectrometer (Viavi Inc., USA). It uses a linear variable
filter (LVF) technology, with an InGaAs detector (900–1,700 nm), a pair of integrated vacuum
tungsten lamps, and provides wireless capability. This spectrometer was attached to the lid of the
blender and rotated with the blender while running the process. Spectra were collected with 16 coadditions averaged for a single scan with an integration time of 0.033 s. The dark and light
reference scans are internal for the top sensor and were collected once daily. Different blend end
point criteria were tested using moving block standard deviations. Mixtures were assumed to be
homogeneous when standard deviation reached a minimum value.

5.2.2

Sample Considerations for Non-Target Class using Design of Experiment (DOE):

The goal of this effort was to create non-target class products containing identical API
concentration but different excipient composition to the target class. As three diluents (lactose,
starch and MCC) are the primary excipient compositions, the ratio of these three components was
varied. A fully balanced, three-constituent mixture design composed of MCC, lactose and starch
were used to generate the appropriate formulation (excipient ratio) for tablets (Figure 5-1). Total
composition of these three excipients were kept at 45% w/w of the target formulation because the
target tablet contains 45% w/w diluent. Simplex centroid design was used to change the
composition of these three excipients in the formulation. Table 5-1 summarizes the design. Figure
5-1 represents different types of alternate class products [187]. The tablets were generated using
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Presster (Model 5869, Norwood, MA) by a 10 mm die and flat-faced punches. The target tablet

rch
Sta

Lac
t os
e

weight was 350 mg. Thirty replicate tablets per level were created to test the performance.

MCC 200

Figure 5-1: Samples generated using different excipients compositions.

Table 5-1: Seven different formulations were generated using a mixture experimental
design

Formulation 1
Formulation 2
Formulation 3
Formulation 4
Formulation 5
Formulation 6
Formulation 7

APAP

Lactose

MCC
200

Starch

Croscarmellose
sodium

50
50
50
50
50
50
50

0
0
22.5
0
15
22.5
45

0
22.5
0
45
15
22.5
0

45
22.5
22.5
0
15
0
0

4
4
4
4
4
4
4

Colloidal
Sillicon
Dioxide
(Aerosil 200)
0.5
0.5
0.5
0.5
0.5
0.5
0.5

Magnesium
Stearate

0.5
0.5
0.5
0.5
0.5
0.5
0.5

Grey color row: Target class formulation which was used for calibration model development and
unique batches of Formulation 5 was used as test set.

5.2.3

Target Class Samples Containing Raw Material Variabilities

Raw material variations were simulated by changing the vendors of starch (Table 5-2). The
particle size of these starches was the same according to the vendors’ information. Other
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components of the target formulation remained unchanged. In total, two batches were prepared.
These batches will be further referred as R1 and R2.

Table 5-2: Raw material variations

5.2.4

Design Name

Starch
vendor

R1

EM Solution

R2

Colorcon

NIR Spectral Collections

NIR reflectance measurements for both sides of each tablet were acquired over the
wavelength range of 925 to 1700 nm at a 6.38 nm increment averaging 5000 scans (JDSU
MicroNIR). Prior to scanning, the tablets were precisely centered using the positioning iris
standard on this instrument.

All spectral data were analyzed in the Matlab environment (version 8.6, MathWorks,
Natick, MA) using the PLS_Toolbox (version 8.8, Eigenvector Research, Inc, Manson, WA) and
software developed by the Duquesne University Center for Pharmaceutical Technology.

5.2.5

Raman Spectral Collection

Raman spectra were collected by following the protocol mentioned in section 3.3.3 .
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5.2.6

Theory

5.2.7

Spectral Investigations

Spectral investigations were conducted using below mentioned methods:

1. Spectral matching: See Section 4.4.3
2. Principal component analysis: See Section 4.4.1

5.2.8

Class-Model

The chemometric model for this study was developed using SIMCA and SVDD. Details
of the methods are reported in earlier section of this document.

1. SIMCA: See section 2.2.1.1
2. SVDD: See section 2.2.1.2.
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Experimental Strategy
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Reject nontarget class
MCC 200

Design of experiment

NIR and
Raman

Spectrometer
Authentication
System

Model Performance
-SIMCA
-SVDD

Accepts
target class
Raw material variability

Figure 5-2: Flow chart of experimental plan.
The goal of authentication is to reject non-target class samples and accept target class
samples. This study generated sample formulations using DOE to identify suitable compositions
for meeting the goals of the experiment. Raw materials from two different vendors were used to
generate variations in the target class samples. Both NIR and Raman spectroscopy data were
collected, and multivariate models were developed (Figure 5-2).
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5.3
5.3.1

Results
Near-Infrared Spectroscopy

Figure 5-3: Preprocessed NIR spectra of A) samples of different formulation
generated using DOE, B) pure component spectra of different components of
tablets, and C) samples of target class using two different raw material vendors.
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5.3.1.1

Spectral investigations

NIR spectra from the unique formulation design points are shown in Figure 5-3A. To
understand the source of variation, the spectra of pure components are shown in Figure 5-3B. As
lactose, MCC, and starch are cellulosic excipients, spectral similarity is expected for these
components; dissimilarity from APAP is noticeable in Figure 5-3B. Moreover, the excipients’
peaks dominate the longer wavelength regions. Therefore, spectral variation for the various DOE
samples are observed primarily in the excipient dominated regions. Figure 5-3C shows the raw
spectra of two different sample sets (R1 and R2, correlating with the formulations created from
two unique sources of starch).

Figure 5-4: Spectral correlation of target class (F-5) with samples containing
different chemical and physical variations.

Spectral correlation: Spectral correlations between the calibration set (target class (F5))
and different design points are shown in Figure 5-4. The highest correlation values were observed
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for test sets of F5 (different batch), R1, and R2; because there were no chemical differences of
these formulations with the target class. However, different chemical design points showed lesser
correlations. Other design points, F3 and F4 showed the highest correlation values with the target
class, F5.

As described in Chapter 2, spectral correlation is useful for distinguishing different classes
of samples. If the spectral correlation value from testing meets a specific threshold value, then the
sample is declared as the target class to verify the product empirically. Several studies have
suggested using 0.95 as a threshold value to distinguish different classes of samples (see Section
1.3.3.1.2). That means if the matching threshold value is 0.95 between two sample sets, these
samples are considered equivalent. However, it is obvious that the threshold may change if samples
are highly similar. For example, in this study, the threshold should be higher than 99.98, as the
closest non-target class samples have this correlation value.

Figure 5-5: The scores plot of a combined PCA model of different design
points.
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Principal component analysis (PCA): Preliminary PCA was performed on the entire data
set. It reveals both similarities and differences in tablets produced by various formulations of DOE
and raw material variations. The PCA model with two PCs explains 95.54% of the total variance.
The PCA model showed minimal variation for sample spectra derived from R1 and R2
formulations (containing different sources of starch). The preprocessing method removed the
spectral deviation arising from variation in physical factors. In the scores plot (Figure 5-5), it was
observed that F3 and F5 samples sets were overlapped despite the chemical variations being
significantly different between these two sets.

5.3.1.2 Class-Model Performance of NIRS:

SIMCA model performance: As noted, Formulation 5 was considered to be the target
class. A total of three batches of this formulation were included into the calibration model to
incorporate the batch to batch variabilities. Model performance was observed using DOE and
samples having raw material variations.

At first, SIMCA was developed using one PC and a 95% confidence interval threshold of
Hotelling’s 𝑇 2 and 𝑄 residual (Figure 5-6A). The model successfully rejected F1, F2, F4, F6, and
F7, but failed to reject F3. Hotelling’s 𝑇 2 and 𝑄 residual plots explained the failure of rejecting
F3. Low 𝑄 residual values showed that this formulation overlapped with the calibration sample
set, whereas other formulation design points were located far from the calibration set. The model
developed using PC1 successfully accepted test sets R1 and R2, except for two samples from R1.
Hotelling’s 𝑇 2 and 𝑄 residual plots showed that genuine samples manufactured using different
vendors resided inside the target-class boundary (Figure 5-6(A-B)). After increasing the
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confidence interval to 99%, the model accepted only one of these samples (Figure 5-6 (C-D)).
However, with the new boundary, the model also started to accept the F4 design point, as F4 is the
second nearest design point after F3.

To reject all non-target class design points, a SIMCA model with one PC was not sufficient,
even though it accepted samples containing raw material variability. Next, two PCs (explaining
95.54% of total variance) were used to develop a SIMCA model. After adding PC2, the model
became more specific and rejected all formulations. Figure 5-7(A-B) revealed that F3 now had
higher Hotelling’s 𝑇 2 and 𝑄 residuals compared to the previous PCA model. However, after
adding two PCs, the model started to reject samples with raw material variabilities, which were
four R1 and seven R2 samples. Nevertheless, increasing the confidence interval from 95% to 99%
improved the sensitivity of the model (Figure 5-7 (C-D)). The SIMCA model with 99% CI
accepted all samples with raw material variability.

Using cross-validation to select the number of PCs can be another option. Here, crossvalidation suggested three PCs for the SIMCA model. However, a SIMCA model developed using
three PCs is unnecessary, as the model already rejected all formulations using fewer PCs.
Therefore, a model with two PCs showed the best performance (Table 5-3).
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Figure 5-6: Model diagnostics plots of SIMCA model, which was developed using the first PC, (A) Threshold was
developed using 95% CI. B) Magnified version of plot A, C) Threshold was developed using 99% CI, D) Magnified
version of plot C.
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Figure 5-7: Model diagnostics plots of SIMCA model, which was developed using first two PCs, (A) Threshold was
developed using 95% CI, (B) Magnified version of plot A, (C)Threshold was developed using 99% CI, D) Magnified
version of plot C.
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Table 5-3: Performance of SIMCA model using NIRS
Calibration approaches

Different Models with
predefined threshold

1 PC

2 PCs

Sensitivity

Specificity

Average

Sensitivity

Specificity Average

SIMCA (𝑻𝟐 & Q=0.95)

0.96

0.84

0.9

0.81

1

0.905

SIMCA (𝑻𝟐 & Q =0.99)

0.98

0.78

0.88

0.97

1

0.985

SVDD model performance: In this study, the SVDD algorithm was applied to the
preprocessed spectral data, including Savitzkay-Golay derivative and normalization. Here, two D
values, 0.05 and 0.01, were considered. A series of σ values were applied with incremental steps
of 0.1. The best performance was obtained from a σ value of 0.9. The performance of the different
approaches is summarized in Table 5-4. Both threshold values of D rejected all of the non-target
class samples. Support vectors were visualized in Figure 5-8. Formulation 4 was plotted to show
the similarity with target class samples.

Table 5-4: Performance of SVDD model using NIRS.

σ =0.9
Different models with
predefined threshold
Spectral SVDD (D=0.01)
Spectral SVDD (D=0.05)

Sensitivity

Specificity

Average

No. of SVs

0.89
0.867

1
1

0.945
0.9335

6
3
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A

B

C

Figure 5-8: A) Depiction of selected support vectors of the calibration set where the blue spectra are support vectors
and red spectra are calibration samples B) Calibration set (red), R1 and R2 sample sets (cyan). C) Calibration set
(red) and F4 design point (green)
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5.4
5.4.1

Raman Spectroscopic Methods
Spectral Investigations

A

B

Figure 5-9: A) Spectra of different design points of pharmaceutical formulations,
B) Raman spectra of pure components, (C) Spectra of two batches of samples.

In this experiment, the API showed a Raman signature in tested samples. Figure 5-9 shows
that Raman spectra of different formulation design points were dominated by the API
(acetaminophen or APAP) because the aromatic ring of APAP is a strong Raman scatterer
compared to the polar excipients. Therefore, Raman is very useful to identify the API, in this case,
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since it exhibits several characteristic bands that are directly correlated with the molecular structure
of the substance of interest.

The other dominating spectral source is the fluorescence background of MCC. While this
formulation has a high drug load, the APAP is detectable. For products with a low drug load, the
Raman spectra of the API may be masked by the fluorescence of the excipients.

Spectral correlation: The spectral correlation value of F5 is displayed in Figure 5-10. It
was observed that F2 and F6 showed the highest correlation with the target F5 formulation. Due
to the strong fluorescence signal, MCC was the main reason for this similarity. In Figure 5-10, F6
showed the nearest correlation value. The second nearest formulation was F2.

Figure 5-10: Spectral correlation of target class (F-5) with different design
points.
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Figure 5-11: The scores plot of a PCA model which was developed combining
all formulations.

Principal component analysis (PCA): The total spectral range was used to analyze the
data. Data were preprocessed using SNV and mean-centering. The PCA plot (Figure 5-11) shows
that the first two PCs explained 89.4% of the total variance. Similar to the spectral correlation
value, F2 and F6 resided near the target formulation, F5. From Figure 5-9, it is observed that F2
and F6 have similar spectral features to F5 (target class, F5) due to the presence of fluorescence
background. Samples containing raw material variabilities (R1 and R2) overlapped with F5. This
indicates that Raman was insensitive to the raw material variability in the present study.

5.4.2

Class-Model Performance

SIMCA: Similar to the NIR model, Formulation 5 was used as the target class. Two batches

of Formulation 5 were included in to the calibration model. Sensitivity and specificity were
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observed using samples containing raw material variabilities (R1 and R2) and DOE samples (F1,
F2, F3, F4, F6 and F7).

Using Raman spectra, the first SIMCA model was generated from one PC and a 95%
confidence interval threshold of Hotelling’s 𝑇 2 and 𝑄 residual. In this case, the model
appropriately rejected all non-target class formulation design points, except 7 samples from F6.
Hotelling’s 𝑇 2 and 𝑄 residual plots explained the failure of rejecting these samples. As
Formulation 6 had low 𝑄 residual values, these samples resided inside the boundary (Figure 5-12
(A-B)).

While F6 contained MCC which had similar fluorescence background compared to F5
(target class samples), it was observed that the model developed using PC1 successfully accepted
the test sets R1 and R2, except 11 samples. After increasing the confidence interval to 99%, the
model accepted nine of these eleven samples, improving the sensitivity of the model (Figure 5-12
(C-D)). However, increasing this boundary also influenced the model to begin accepting more
samples from the F6 design point, meaning specificity was decreased.

Next, a SIMCA model using two PCs (which explains 89.4% of total variances) was used
to develop the SIMCA model. After adding PC2, the model became more specific and rejected all
formulations (Figure 5-13 (A-B)). However, after adding two PCs, the model rejected more
samples of R1 and R2; as a result, sensitivity decreased significantly. Increasing the confidence
interval from 95% to 99% improved the sensitivity of the model. However, the SIMCA model
with 99% CI also started to accept non-target class samples of F6 (Figure 5-13 (C-D)).
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Figure 5-12: Diagnostics plots of SIMCA model, developed using the first PC, (A) Threshold was developed
using a 95% CI, (B) Magnified version of plot A, C) Threshold was developed using 99% CI, D) Magnified
version of plot D.
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Figure 5-13: Model diagnostics plots of SIMCA model which was developed using first two PCs, (A) Threshold
was developed using 95% CI, (B) Magnified version of plot A, C) Threshold was developed using 99% CI, D)
Magnified version of plot C.
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Raman showed satisfactory performance with the use of one PC. This indicates that Raman
spectroscopy does not rely on an extra direction of variations to identify non-target class samples
compared to the NIRS. Therefore, Raman model was less complex, and sharp spectral features of
Raman may help to identify different non-target class samples. But, this observation may vary
depending on the API and excipient signals of different formulations.

Table 5-5: Performance of SIMCA model using Raman spectroscopy.

Different Models
with predefined
threshold
SIMCA
(𝑻𝟐 & Q=0.95)
SIMCA
(𝑻𝟐 & Q =0.99)

Calibration Approaches
1 PC

2 PC

Sensitivity

Specificity

Average

Sensitivity

Specificity

Average

0.972

0.84

0.906

0.4

1

0.7

0.961

0.905

0.933

0.6

0.95

0.775

SVDD: In this study, the SVDD algorithm was applied to the preprocessed spectral data.
A Savitzky-Golay derivative and normalization was applied to the data. Here, two D values, 0.05
and 0.01, were considered. A series of σ values were applied with incremental steps of 0.1.

Performance of the different approaches is described in Table 5-6. Both threshold values
of D rejected all non-target class samples. Support vectors were visualized in Figure 5-14A. Raw
material did not show variations with the target class samples (Figure 5-14B). Therefore, model
was successfully accepted these samples. Formulation 6 was plotted to show the similarity with
target class samples (Figure 5-14C). There are slight variations observed between target class and
F6 in the lower wavelength regions (around 200 cm−1 ), which enabled the rejection of this
formulation. Therefore, the SVDD model performance was comparable to the SIMCA model.
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A

B

C

Figure 5-14: A) Depiction of selected support vectors of the calibration set where the blue spectra are support vectors
and red spectra are calibration samples, B) Calibration set (red), R1 and R2 samples (cyan), C) Calibration set (red)
and F6 design point (green).
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Table 5-6: Performance of SVDD model using Raman spectroscopy.
σ =0.25
Different Models with
predefined threshold
Spectral SVDD (D=0.01)
Spectral SVDD (D=0.05)
5.5

Sensitivity Specificity
0.9333
0.8667

0.9167
0.9778

Average

SV

0.925
0.922

3
4

Discussion and Conclusion

The proposed DOE approach allows an analyst to test the developed method against
various non-target class samples. Given the flexibility of designing samples, analysts should be
able to create samples containing the identical API but different excipient composition, as this may
be the most challenging condition to detect. Rationally designed samples, defined by DOE, are
helpful for identifying which non-target class samples are spectrally similar to the target class
samples, and which samples pose a risk in terms of potential method failure.

In this study, CM model using NIRS struggled to separate F3 as non-target class samples,
whereas CM model using Raman failed to separate F6 as non-target class samples. NIR
spectroscopy is sensitive to the C-OH bond, causing starch, lactose, and MCC to have similar
spectral features. F3 showed the highest similarity to F5, and therefore, F3 has a higher risk of
increasing the false positives (reduced model specificity). However, for Raman spectroscopy, F6
was a challenging formulation. Both F2 and F6 contained a higher amount of MCC, similar to the
target class, F5. Because F6 had lactose in its formulation, it had a more significant peak intensity
than the starch. This caused F6 to be the closest non-target class sample. Therefore, using F6
formulation was critical for the development of a successful model.
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Moreover, these lab generated non-target class samples have similar solid fraction, size,
shape, etc., compared to the target class. Therefore, physical factors demonstrated minimum effect
on the spectra in this case.

Although the implementation of DOE requires more samples, this approach offers
significant benefit in that it will help to minimize the risk of model failure. Using small scale labbased samples reduces the burden of sample preparation and makes the model development more
efficient.

In this study, changing excipient vendors did not have a significant impact on model
performance. However, in general, switching to a different vendor can result in several physicochemical changes, including moisture variation, particle size variability, etc.

Another source of variation, lot-to-lot variability of excipients, can also be a factor to be
modeled. It is expected that the inter-manufacturer variabilities will be more significant than the
batch to batch variability of an individual manufacturer (intra-manufacturer variability). However,
it is difficult to preemptively identify all sources of variability that might be introduced by different
manufacturers during the pharmaceutical life-cycle. The experimental approach of this study
provided an example of the effect of manufacturer and lot-to-lot variabilities on sample spectra
and model performance.

Having appropriate non-target class samples is critical for model development. These nontarget class samples challenged both SIMCA and SVDD. Typically, a model developed using more
PCs in the SIMCA model can separate challenging samples which resided near to the target class.
However, using samples containing more PCs unnecessarily separates samples containing raw
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material variability from different vendors. Nevertheless, the model that is developed using a
fewer number of PCs may appropriately accept the samples with variability in raw material
supplier. Careful model development will prevent unnecessary rejection of target class samples
(false negatives) or incorrect authentication of falsified products (false positives). This model
optimization becomes logical in the presence of statistically representative non-target class
samples and target class samples containing foreseeable variations in the model.
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6 Chapter 6: Onsite Implementation of Portable
Spectrometers to Analyze Commercially Available
Pharmaceutical Products
6.1

Introduction

This chapter discusses the use of portable spectrometers to analyze pharmaceutical
products in health care settings. Researchers have been using two portable spectrometers to collect
data in two different pharmacies over a span of a few months. Theses pharmacies are located in
the city of Pittsburgh. Various brand and generic products were selected based on a previous
history of falsification. Results from the testing of two products are reported here.

To accomplish this project, a comprehensive data collection protocol was developed. This
protocol was used during the feasibility studies to verify the spectral collection methodology and
for the collection of data to improve the understanding of factors that influence the product spectra.
The effect of sample positioning, lot-to-lot variability, variations from manufacturing site change,
and the impact of wavelength range on the performance of two different spectrometers are reported
in this chapter.

Different multivariate methods, including, principal component analysis (PCA),
Hotelling’s 𝑇 2 and 𝑄 residual statistics were used to develop understanding of the source of
spectral variations. Finally, the collected data were used to develop and validate qualitative
authentication methods using chemometric models. The model will be included in a cloud-based
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data management system to implement a real-time authentication technique. This study will
provide direction for the detection of falsified medicines in different locations worldwide.

The objectives of this chapter include:

(1) Evaluate the effect of sample positioning.

(2) Evaluate the possible sources of spectral variation while collecting data from
commercial samples.

(3) Compare the effect of spectral wavelength ranges on method performance using two
different spectrometers.

(4) Develop NIRS models for the analysis of tablet authenticity.

6.2
6.2.1

Materials and Methods
NIR Instrumentation

Currently, a variety of portable NIR spectrometers are available from different
manufacturers. Whereas each technology has its own strengths and weaknesses, micro electromechanical systems (MEMS) technology was chosen for this work because of the advantages of
fast data acquisition rate, affordability, and lack of moving parts.

The NIR ONE Sensor (Spectral Engine, VTT, Finland) uses the patented Micro Electro
Mechanical System (MEMS) Fabry-Perot Interferometer, which is a fully programmable optical
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filter with a single-element InGaAs detector. This compact spectrometer has a window made by
quartz for a sample surface system.

Two spectral ranges were utilized with two different devices (Figure 6-1).

1) Diffuse reflection spectra were recorded in the wavelength range of 1550–1950 nm. This
will be mentioned as SWL-NIR (Short Wavelength NIR) in the rest of the chapter.
2) Diffuse reflection spectra were recorded in the wavelength range of 2000–2450 nm. This
will be mentioned as LWL-NIR (Long Wavelength NIR) in the rest of the chapter.

The spectrometers were connected to a laptop through a USB communication cable and
controlled using sensor control software developed by Spectral Engines Oy.

Apixaban
SWL-NIR
1550-1950nm
Atorvastatin
NIR
Spectrometers
Apixaban
LWL-NIR
2000-2450nm
Atorvastatin

Figure 6-1: Two NIR spectrometers were used to analyze two products,
including apixaban and atorvastatin.
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6.2.2

Sample Positioning Study

Sample orientation is critical; the instrument has a detector (red circles in Figure 6-2) at
the center of the sampling window and two lamps, one located on each side of the detector (yellow
circles in Figure 6-2). The spectrometers were marked using a straight line to facilitate sample
positioning. The marking is simulated in Figure 6-2. This line was drawn two ways:

A) Passes through the detector but perpendicular to the lamps ( Figure 6-2A) and

B) Passes through the detector and lamps (Figure 6-2B).

B

A

Detector
Lamp

Figure 6-2: Two orientations of the sample based on the drawn line which is, A)
Passes through the detector but perpendicular to the lamps, B) Passes through
the detector and lamps.

An oval shaped tablet was scanned six times with repositioning. Standard deviation was
calculated for these repeated measurements for both the SWL-NIR and LWL-NIR data.
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6.2.3

Sample Collection in Pharmacy

Two commercial tablets: apixaban (Eliquis, by Bristol-Myers Squibb) and atorvastatin
(Atorvastatin, by Apotex) were scanned at the pharmacies in Pittsburgh. A transportable station
was set up containing portable spectrometers and reference standards (Figure 6-3A-B)). Tablets
were collected from bottles stored in the pharmacy. From each bottle, 30 tablets were collected
and both sides of each tablet were scanned. All tablets were replaced in the bottle after completing
the analysis.

All of the calculations were performed using Matlab 8.6 (The Mathworks Inc, Natick,
MA), along with the PLS_Toolbox 8.8 (Eigenvector Research Inc, Wenatchee, WA) and other
analysis tools written at the Duquesne University Center for Pharmaceutical Technology for this
study.

A

B

Figure 6-3: Portable stations, A) A briefcase sized transportable system to carry spectrometers
and reference standards, B) Spectrometers and laptop controller in use at a pharmacy.
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6.2.3.1 Apixaban: Considered Samples

The label claim of apixaban was 5 mg. A total of nine lots of product were analyzed.
Among these lots, seven were manufactured in Switzerland and two were manufactured in the
USA. Table 6-1 summarizes the lot number, manufacturing site and expected dose of the analyzed
tablets.

Table 6-1: Detail of apixaban tablets
Molecule Product Name and Dose
Apixaban
Apixaban
Apixaban
Apixaban
Apixaban
Apixaban
Apixaban
Apixaban
Apixaban

ELIQUIS 5MG
ELIQUIS 5MG
ELIQUIS 5MG
ELIQUIS 5MG
ELIQUIS 5MG
ELIQUIS 5MG
ELIQUIS 5MG
ELIQUIS 5MG
ELIQUIS 5MG

Lot No
AAY3155
AAY4017
AAK9028
AAT0949
AA22725
AA28472
AA28448
KK2981
KL2418

Manufactured
Location*
Switzerland
Switzerland
USA
USA
Switzerland
Switzerland
Switzerland
Switzerland
Switzerland

*It was mentioned in the label that the respective products were from USA and Switzerland.

6.2.3.2 Atorvastatin: Considered Samples

The label claim for atorvastatin tablets tested in the project was 40 mg. A total of fourteen
lots of products were scanned. All of these lots were manufactured in Canada. Table 6-2
summarizes the lot number, manufacturing site and expected dose of the analyzed tablets.
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Table 6-2: Details of the atorvastatin tablet
Molecule

Product Name and Dose

Lot No

Atorvastatin
Atorvastatin
Atorvastatin
Atorvastatin
Atorvastatin
Atorvastatin
Atorvastatin
Atorvastatin
Atorvastatin
Atorvastatin
Atorvastatin
Atorvastatin
Atorvastatin
Atorvastatin

ATORVASTATIN 40MG
ATORVASTATIN 40MG
ATORVASTATIN 40MG
ATORVASTATIN 40MG
ATORVASTATIN 40MG
ATORVASTATIN 40MG
ATORVASTATIN 40MG
ATORVASTATIN 40MG
ATORVASTATIN 40MG
ATORVASTATIN 40MG
ATORVASTATIN 40MG
ATORVASTATIN 40MG
ATORVASTATIN 40MG
ATORVASTATIN 40MG

NW6364
PJ2815
PJ9375
NK2915
NT7727
NT7700
3088695
3070915
PC4481
C805309
18230211
PK0500
PT5469
PK1767

6.3
6.3.1

Manufactured Location
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada

Results and Discussion
Sample Repositioning Study

Spectral variation was observed among different rescans of oval-shaped tablets in both “A”
and “B” orientations, whereas round-shaped tablets showed minimum variation, with repositioning
as expected. Therefore, the spectral behavior of oval shaped tablets is reported. The bulk of the
spectral variations, due to repositioning, took the form of a change in spectral baseline.

For the oval-shaped tablet, the average standard deviation of SWL-NIR absorbance intensity for
the orientation “B” was 0.15, whereas for the orientation “A”, it was 0.05. For the LWL-NIR
spectrometer, average standard deviations were 0.07 and 0.02 for “B” and “A” orientations
respectively. From this study, it was found that orientation “A” produces higher spectral variations
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compared to the orientation “B” for oval-shaped tablets. This was true for both SWL-NIR and
LWL-NIR spectrometers. Therefore, orientation B was used to analyze all oval shaped tablets in
the further research. However, from the data, it was also observed that the SWL-NIR spectrometer
was more sensitive for repositioning of tablets relative to the LWL-NIR spectrometer. A number
of data preprocessing techniques such as the standard normal variate (SNV) transformation,
multiplicative scatter correction (MSC), Savitzky–Golay (SG), etc., can be applied to mitigate this
variation.

Exploratory sample analysis

6.3.1.1 Apixaban

Spectral behavior of various batches of apixaban tablets were observed for SWL-NIR and
LWL-NIR spectrometers in Figure 6-4A and Figure 6-5A respectively. These spectra were SNV
and second derivative Savitzky–Golay treated. From preprocessed spectra, significant spectral
variances was observed among different batches. Primarily, the two batches prepared in the USA
(blue and green spectra) were different from the batches prepared in Switzerland. Spectral
differences were pronounced in SWL-NIR spectra compared to the LWL-NIR spectra. These
variations may evolve from different factors such as raw material variabilities, manufacturing
variabilities, moisture variabilities, etc. However, a detailed history of sample preparation or
manufacturing conditions was not available.

Based on the spectral features of the pure component spectra, it is assumed that the site-tosite variation is likely due to some difference in the excipients (Figure 6-4B, Figure 6-5B). The
spectral features were varied around ~1670 nm (Figure 6-4A). Excipients such as lactose
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anhydrous, microcrystalline cellulose and sodium lauryl sulfate (SLS) all exhibit peaks in that
same region. It is assumed that the contribution from these three components may change between
the manufacturing sites. Further analysis might reveal the true source(s) of variation.

Figure 6-4: A) Preprocessed SWL-NIR spectra of different batches of apixaban,
B) SWL-NIR spectra of major components of apixaban tablets.
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Figure 6-5: A) Preprocessed LWL-NIR spectra of apixaban, B) LWL-NIR
spectra of major components of apixaban tablets.
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Figure 6-6: A) Scores plot of different batches of apixaban, B) Loadings plot of
PCA analysis of apixaban using SWL-NIR spectrometer.

A two component PCA model captured nearly 95.99% of the spectral variation (Figure 66). The first PC explained nearly 74.87% of the variance. For SWL-NIR, the PCA analysis
revealed cluster formation of PC 1 and PC 2 plot (Figure 6-6A). Though subtle differences were
observed in the spectra due to the site differences, the PCA plot highlights the manufacturing site
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variation, as displayed in Figure 6-6. As different batches were produced in the USA and
Switzerland, the clusters were primarily due to the manufacturing site variations.

Further analysis was conducted by developing a PCA calibration model using only samples
manufactured in Switzerland (Figure 6-7). When the USA samples were projected on the PCA
model, the nature of the clusters in the manufacture sites were apparent (Figure 6-7B). Also, the
diagnostics plots showed the high Hotelling’s 𝑇 2 and 𝑄 residuals. (Figure 6-7C). The 𝑄
contribution plot emphasizes the important variables generated by the unmodeled variation in the
model. It was apparent from the 𝑄 contribution plot that high 𝑄 residual was observed around
~1670 nm, which confirmed the previous findings of excipient variations (Figure 6-7D).
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Figure 6-7: SNV treated spectra of product from two manufacturing sites. Using
these data, a PCA model was developed where Switzerland lots were used for
calibration, and USA manufactured samples were projected. B) Scores plot of
PC1-PC2, C) Plots of Hotelling’s 𝑇 2and 𝑄 residuals, D) Plots of Q contribution.
Data were collected using the SWL-NIR instrument.

A two component PCA model explained 81.48% of the LWL-NIR spectral variance. The
first PC explained 57.89% of the spectral variance (Figure 6-8). Unlike the SWL-NIR PCA model,
the PC scores of the LWL-NIR model appeared to be less related to site differences as the data
from two sites were overlapped (Figure 6-8A). However, when the PCA model was developed
using samples generated in the Switzerland site, projected USA samples resided outside the
calibration space (Figure 6-9). This difference between the two manufacturing sites was also
observable using LWL-NIR spectra.
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Both the SWL-NIR and LWL-NIR PCA models demonstrated the potential effect of
manufacturing site on the prediction model. Samples from two different manufacturing sites
should be included in future calibration models as controlled variation. This strategy would cause
little effect on the sensitivity (ability to accept target class samples) of the model performance.

In summary, both repositioning studies using the standard deviation data and the
exploratory analysis using PCA models suggested that LWL-NIR measurements are less sensitive
to sample positioning error and manufacturing site change relative to the SWL-NIR measurements.
However, careful data preprocessing method and sample considerations are required while
developing model.
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Figure 6-8: A) Scores plot of different lots of apixaban, B) Loadings plot of
PCA analysis of apixaban using LWL-NIR spectrometer.
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Figure 6-9: A) SNV treated spectra of products from two manufacturing sites.
Using these data, a PCA model was developed where Switzerland lots were used
for calibration, and USA manufactured samples were projected on PCA model,
B) Scores plot of PC1-PC2, C) Plot of Hotelling’s 𝑇 2 and 𝑄 residuals, D) Q
contribution plots. Data were collected using the LWL-NIR instrument.
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6.3.1.2 Atorvastatin

Figure 6-10: A) Preprocessed SWL-NIR spectra of atorvastatin, B) SWL-NIR
spectra of major components of atorvastatin tablets.

Different lots of atorvastatin tablets (SNV transformed and second derivative SavGol
treated) are shown in Figure 6-10 and 6-11. Unlike apixaban, minimum spectral variations of
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different wavelength regions were observed. Major components of these tablets were plotted, as
seen in Figure 6-10B and 6-11B.

Figure 6-11: A) Preprocessed LWL-NIR spectra of atorvastatin B) LWL-NIR spectra
of major components of atorvastatin tablets.
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The PCA scores (Figure 6-12A) and loadings (Figure 6-12B) of the SWL-NIR spectra
confirmed the minimum variations among different batches, as different groups overlapped. Two
PCs explained 92.6% of the spectral variation.

Figure 6-12: A) Scores plot of different lots of atorvastatin, B) Loadings plot of
PCA analysis of atorvastatin using SWL
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The PCA loadings and scores for the LWL-NIR spectra are shown in Figure 6-13 . The
first PC explained nearly 66.85% of the spectral variance, and the second PC explained an
additional 19.04% of the spectral variance.

Figure 6-13: A) Scores plot of different lots of atorvastatin, B) Loadings plot of
PCA analysis of atorvastatin using LWL spectrometer.

The two-axis plot of the PC scores does not show any significant clustering in the data.
The model can be developed using any lots, as no particular attention is required for this product.
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6.3.2

Multivariate Model Development: Calibration Set Considerations

Including appropriate samples into the calibration set is an essential element of a
multivariate method development process. Section 6.3.3. in this chapter evaluated several
important elements of method development while collecting spectra of commercial products. It
was observed that spectral variation due to manufacturing site change was prominent. Lot-to-lot
variability within sites was less than the spectral variability associated with site differences.
Spectral range was also important to consider, as the degree of variation changed based on the
wavelength regions. Regardless of the spectrometers used in this study, samples collected from
multiple batches and multiple manufacturing sites (if available) were used in the calibration set to
provide a sufficiently broad range of variation to develop a robust target class. Also, tablets were
scanned with a consistent orientation, as discussed in Section 6.3.2.

The next section focuses on the model performance of the NIRS authentication method.

6.3.3

Method Development and Performance

6.3.3.1 Apixaban

Sample considerations and model development: The calibration model developed for the
authentication of apixaban tablets used 150 samples drawn from five production batches including
data from both production sites. The calibration datasets are summarized in Table 6-3 and Table 6-

4.
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Table 6-3: Summary of apixaban calibration and validation sets

Samples (n)
Batches (n)
Model Type
Preprocessing
Spectral range (nm)
D

SV numbers

SWL-NIR
Calibration Test
Val-1 Val-2 Val-3
150
60
90
30
30
5
2
3
1
1
SVDD, SIMCA on Spectra
SNV + Second derivative + Normalize
1550-1950
0.01
0.2
3

Table 6-4: Summary of apixaban calibration and validation

Samples (n)
Batches (n)
Model Type
Preprocessing
Spectral range (nm)
D

SV numbers

LWL-NIR
Calibration
Test
Val-1 Val-2 Val-3
150
60
90
30
30
5
2
3
1
1
SVDD, SIMCA on Spectra
SNV + Second derivative + Normalize
2000-2450
0.2
0.2
3

To optimize the model, independent target (samples from unique batches) and non-target
class samples were used to test the model. One new lot of 5 mg apixaban product was used as
target class test samples. These tablets were used to ensure the highest specificity of the model. A
new batch of samples containing a lower concentration of API (2.5 mg) was used as non-target
class samples to ensure the highest sensitivity of the model. The SVDD model parameters, both D
and  were optimized accordingly (Table 6-3 and Table 6-4).
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A combination of SNV, second derivative and normalization was chosen based on
maximum average performance of sensitivity and specificity. The preprocessed calibration spectra
are shown in Figure 6-14A. The calibration model used three samples as support vectors (depicted
in Figure 6-14A as blue spectra).

The validation data consisted of three sets of samples.

The first validation set was target-class samples. This validation set (Val-1) consisted of
90 samples of target class samples from three batches containing apixaban (5mg). These batches
were manufactured at two different facilities (one in the USA and two in Switzerland).

The second and third validation sets were non-target class samples. The second validation
set (Val-2) consisted of 30 commercial samples containing a low dose of apixaban (2.5 mg). The
third validation (Val-3) set consisted of 30 laboratory scale samples manufactured at the Duquesne
University Center for Pharmaceutical Technology (DCPT) using MCC and apixaban. The purpose
of the third validation set is to provide an additional test of the specificity using samples including
a similar amount of apixaban (5mg) but different excipient composition.

Validation Method Performance: Method validation (with a validation set) was
conducted after the optimization of the model (using a test set). The validation performance was
evaluated based on the following two key performance criteria: sensitivity and specificity. The
specificity was tested using different batches of target class samples (Val-1), and the sensitivity
(ability to reject non-target class samples) was tested using two sets of samples: 1) low dose
apixaban tablets (Val-2) and 2) lab based simulated falsified products (Val-3).
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Table 6-5: Validation performance of apixaban calibration model

SVDD
SIMCA

SWL- Apixaban
LWL- Apixaban
SWL- Apixaban
LWL- Apixaban

Sensitivity
Val-1
0.9111
0.8667
0.76
0.8

Specificity
Val-2
0.8667
0.7812
0.81
0.6

Specificity
Val-3
1
1
1
1

Figure 6-14: SWL-NIR spectra of calibration set with A) support vectors, B) validation set
1, C) validation set 2, and D) validation set 3.

During validation, it was observed that this method successfully rejected all samples from
Val-3 set, while rejection of Val-2 was less obvious. The reason for the difference in performance
was explained in Figure 6-14 (C and D). It was observed that the Val-3 set (Figure 6-14C) was
spectrally significantly different from the target class samples. However, Val-2 is highly similar
to the target class which means that the model failed to reject all samples (Figure 6-14D). It is
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important to mention that while the Val-2 set was from the same manufacturer, and contained
similar compositions, it was challenging for the model to reject all samples from Val-2. This result
was confirmed using a diagnostic plot of Hotelling’s 𝑇 2 and 𝑄 residuals. All of the Val-3 (cyan
dots) have high 𝑄 residuals and Hotelling’s 𝑇 2 compared to the Val-2 (blue dots) (Figure 6-15).
The higher values of these two statistical parameters indicated the successful rejection of Val-3
compared to Val-2.

Figure 6-15: A PCA diagnostics plot of validation sets with the
calibration set. Spectra were collected using SWL-NIRS.

It was observed that SVDD performed better than SIMCA for authentication of
pharmaceutical samples. As, adding different manufacturing sites into the calibration set generated
clusters in the calibration space, SIMCA model suffered to provide optimum performance.
However, SVDD showed better sensitivity by accepting Val-1 samples, though they were
generated in two manufacturing sites. Appropriate preprocessing methods helped to improve
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performance. It was observed that combination of SNV, second derivative and normalization
showed the best performance compared to other combination of routines. This preprocessing
decreased the impact of sources of variability such as sampling variability and correcting for
pathlength variation. These overall improved model performances.

Similar performance was observed for LWL-NIR. The results showed comparable patterns
because spectral behavior and diagnostic statistics were similar, as shown in Figure 6-16 and
Figure 6-17.

Figure 6-16: LWL spectra of calibration set with A) Support vectors, B)
Validation set 1, C) Validation set 2, and D) Validation set 3
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Figure 6-17: A PCA diagnostics plot of validation sets with the calibration
set. Spectra were collected using LWL-NIR spectrometer.

6.3.3.2 Atorvastatin

Sample considerations and model development: For atorvastatin, SNV, 2nd Derivative
and normalization preprocessing methods were chosen based on the performance. An independent
test set (defined below) was used to optimize the model performance. Spectra of the preprocessed
calibration set are shown in Figure 6-18A, along with samples which were selected as support
vectors (blue spectra).

Model development for authentication of atorvastatin used 150 target class samples drawn
from production batches (40 mg). The test set was samples from different batches of product to
provide independence. Samples manufactured by three other generic manufacturers were used as
the non-target class product to optimize the model. The calibration datasets are summarized in
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Table 6-6 and Table 6-7. The validation samples consisted of three subsets of samples selected
from production scale and lab scale samples.

Table 6-6: Summary of atorvastatin calibration and validation sets.
SWL-NIR
Calibration Test Val-1 Val-2 Val-3
Samples (n)
150
30
90
90
30
Manufacturers (n)
1
2
1
3
1
Batches (n)
5
1
3
3
1
Model Type
SVDD, SIMCA on Spectra
Preprocessing
SNV + Second derivative + Normalization
Spectral range (nm)
1550-1950
D
0.01
0.15

SV numbers
8

Table 6-7: Summary of atorvastatin calibration and validation sets.
LWL-NIR
Calibration Test Val-1 Val-2 Val-3
Samples (n)
150
30
90
90
30
Manufacturers (n)
1
2
1
3
1
Batches (n)
5
1
3
3
1
Model Type
SVDD, SIMCA on Spectra
Preprocessing
SNV+ Second derivative + Normalize
Spectral range (nm)
2000-2450 nm
D
0.01
0.2

SV number
6
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Figure 6-18: SWL-NIR spectra of calibration set with A) support vectors, B) validation set 1, C)
Validation set 2, and D) validation set 3.

The first validation set (Val-1) consisted of 30 samples, including one batch of target class
samples. As atorvastatin is a generic product, samples available from other manufacturers were
used as the validation set. Three different manufacturers products (M1-Atorvastatin 40 mg from
Mylan Pharmaceutical, M2-Atorvastatin 40 mg from Lannett Company Inc., M3- Atorvastatin 40
mg from Dr Reddy’s Laboratories) were included in the second validation sets (Val-2). The third
validation (Val-3) set consisted of one batch of laboratory scale samples manufactured using MCC
with atorvastatin. Validation datasets are summarized in Table 6-6 and Table 6-7.

Validation Method Performance: Performance of the atorvastatin model was observed
using three validation sets. The SVDD model successfully accepted all samples in the target class
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validation set (Val-1). Although Val-3 was significantly different than the Val-2 samples (Figure
18C-D) the model successfully rejected other non-target class validation sets (Val-2 and Val-3).
Among the three manufacturers of Val-2, Man-2 was close to the target class samples whereas
other alternative class samples (M1 and M3) were demonstrated to reside far from the target class
samples (Figure 19). Similar spectral behavior (LWL-NIR) of these samples was observed in
Figure 6-20 and Figure 6-21. Samples collected using different spectrometer showed good
performance.

Table 6-8: Validation performance of atorvastatin calibration models

SVDD
SIMCA

SWL- Atorvastatin
LWL- Atorvastatin
SWL- Atorvastatin
LWL- Atorvastatin

SensitivityVal-1
1
1
1
1

Specificity
Val-2
1
1
1
1

Specificity
Val-3
1
1
1
1

Figure 6-19: SWL-NIR spectra of calibration sets with three
manufacturers samples of validation set 2.
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Figure 6-20: LWL-NIR spectra of calibration set with A) support vectors, B) validation set 1,
C) validation set 2, and D) validation set 3.

Figure 6-21: LWL-NIR spectra of calibration sets with
three manufacturers samples of validation set 2.
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6.4

Summary

The goal of an authentication technique is to predict target class samples accurately and to
reject non-target class samples. However, many challenges exist in the development of an NIR
based classification technique, including the broad spectral features of NIR spectrometers in
general, and the unwanted sensitivity to physical variability. In Chapters 2 and 3, it was observed
that moisture is a critical factor to consider during multivariate method development. In the current
chapter, it was observed that sample manufacturing site change created spectral variation. Spectra
acquired from multiple manufacturing sites were pooled for qualitative model development.
Including samples from unique manufacturing sites in the calibration sample set created bimodal/
multimodal distribution in the calibration space, violating the assumptions of the traditional
parametric distribution-based SIMCA method. Hence, these studies used a non-parametric
distribution-based method, the support vector data description (SVDD) algorithm, provided a more
robust class. The SVDD method proved to be a useful class-modeling technique for portable NIRS
to monitor tablet quality in pharmacies. Additionally, including non-target class samples was
critical to the development of robust multivariate models.

This study also explored the impact of positioning error. This was effectively mitigated
using a specific sample orientation system and spectral preprocessing techniques. It was also
observed that a longer wavelength range spectrum was less sensitive to sample positioning and
manufacturing site than a shorter wavelength range spectrum.

This chapter reemphasized the value of using a pertinent calibration model and the SVDD
algorithm to develop a robust spectroscopic authentication system, as proposed in the hypothesis.
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7 Chapter 7: Summary
As the spread of falsified drugs is increasing worldwide, it is often difficult for regulatory
authorities to surveil falsified products at various locations in the pharmaceutical supply chain.
Using portable spectrometers (i.e., Near-Infrared (NIR) and Raman spectrometers) may help to
remove this barrier. Rapid screening of pharmaceutical products by these analytical tools is an
effective way to enhance consumer safety. However, the use of such techniques is not
straightforward due to the multivariate nature of the collected data and the significant variety of
potential factors influencing the analytical measurements. To overcome the challenge of current
multivariate methods using spectroscopic data, this dissertation compiled three critical elements
(see Figure 7-1).

Spectroscopic
techniques (NIRS,
Raman)

ü Different NIR and Raman
spectrometers.
ü Wavelength range.
ü Sensitivity to external factors.
ü Sample composition sensitivity

Pharmaceutical samples:
calibration and
validation sets
Authentication
system

ü Understanding variabilities (FN).
ü Highly similar samples (FP).
ü DOE based samples

Multivariate
Methods
ü Limitations of current method.
ü Advanced algorithm.
ü Careful optimization.

32
Figure
7-1: Different elements of this dissertation involved with development of a
spectroscopic authentication system and accomplished steps (✓). Combination of these three
areas enabled development of a successful authentication system. (FN: False Negative, FP:
False Positive)
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Three elements regarding the project include:
1) While developing a spectroscopic authentication method, the specific advantages and
disadvantages of each spectroscopic techniques should be considered by the analyst.
A variety of NIR and Raman spectroscopic equipment was explored to understand the
sensitivity of these spectrometers to different physico-chemical variations such as
moisture and chemical composition.
2) To achieve consistent performance during routine analysis of pharmaceutical samples,
calibration and validation sets should include the spectral variation which may arise
during routine analysis. Moreover, during model development, the analyst should use
highly similar samples to reduce false positives. If these highly similar falsified samples
are not readily available, using DOE to generate simulated falsified samples should
serve the purpose.
3) Using a support vector machine based calibration method avoids the typical
assumptions required with more traditional methods regarding data distributions.
Moreover, the SVDD method was demonstrated to offer improved capability for
detecting highly similar non-target class samples.

These elements combinedly explored in different experiments of this dissertation.

In Chapter 2, a NIR spectroscopic-based class-modeling calibration technique was
described. While developing a spectroscopic method for detecting false-samples, several
challenges associated with the method development were addressed. One of those challenges is
the sensitivity of spectrometers toward unwanted variabilities such as moisture, manufacturing
site, instrument parts change, etc. Tablets containing Acetaminophen, MCC, lactose, HPMC, and
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magnesium stearate were generated using a pilot-scale manufacturing system over different
seasons of the year. Since the lab did not have controlled humidity conditions, samples generated
during different seasons were exposed to different humidity levels. Initially, the calibration model
was developed in the winter season; the model used to predict validation sets was developed in the
summer season. As the season was different between calibration and validation sets, the model
failed to accept the target-class samples, indicating a degradation of the model performance when
moisture variance was unaccounted for. To resolve this, the model was updated to include summer
samples in the calibration set. However, moisture variance in the newly added samples led to
significant extrapolation compared to the original experimental domain, defined by the previously
collected samples (during the winter). Therefore, adding summer samples to the calibration set
created a binomial/multimodal distribution, violating the assumptions of traditional parametric
distribution-based SIMCA modeling techniques. Hence, this chapter suggested using a nonparametric distribution-based method, support vector data description (SVDD), to develop a robust
NIR class-modeling technique for the detection of falsified samples. Performance of SVDD was
evaluated and compared with the traditional SIMCA approach. The SVDD method demonstrated
superior performance relative to the SIMCA method for detection of falsified samples. Hence,
when a binomial/multimodal distribution exists in the calibration model, SVDD is a useful classmodeling technique for monitoring tablet quality.

In Chapter 3, the influence of moisture variation on the performance of Raman
spectroscopy for class modeling was evaluated. Although water is a weak Raman scatterer,
moisture variability has an indirect effect on analytical model performance because many
pharmaceutical components have artifacts in the form of baseline variation associated with
fluorescence quenching. This chapter investigated the deleterious effects of water quenching on
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the prediction accuracy of a multivariate calibration algorithm developed using Raman
spectroscopy. To demonstrate this phenomenon two sets of tablets were used, 1) lab based
acetaminophen tablets containing lactose, MCC, HPMC, and magnesium stearate, and 2)
commercially produced artesunate tablets, which is an anti-malarial agent often falsified by
fraudulent manufacturers. Tablet moisture variation was introduced by placing samples in a variety
of humidity chambers. Significant spectral effects arising from fluorescence were identified in the
Raman spectra due to moisture variation and fluorescence related spectral variability. This caused
substantial degradation of the prediction performance for target class samples. Thus, the work
demonstrated that accounting for moisture variation during method development reduced the
prediction error of the SVDD and SIMCA based class-models.

Requirement of appropriate non-target class samples during multivariate authentication
system development was highlighted in Chapters 4 and 5. In Chapter 4, it was shown that to
enhance spectroscopic performance using the SVDD algorithm, non-target class spectral data are
critical for model optimization. This is important for the model which is developed to identify
challenging falsified drugs. It was demonstrated that using non-target class data can further tighten
the decision boundary around the target class samples, thereby improving model performance.
Moreover, if the non-target class samples are highly similar to the target class, the model exhibited
the desired performance. For this study, acetaminophen tablets were collected from different parts
of the world, which were manufactured by various producers. Tablet size, shape, and weight were
analogous, and the products demonstrated similar spectral features. Among the nine
manufacturers’ tablets, samples from one manufacturer were used to develop a target class, and
the eight other data sets were used for model optimization and validation. The model was
optimized using one product as a non-target class and demonstrated successful prediction of the
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other non-target class samples. Furthermore, optimization of the decision boundary minimizes the
false positives.

In Chapter 5, predictions models for highly similar non-target class products were
developed using DOE. Both NIR and Raman spectrometers were used to scan the samples. It was
demonstrated that the critical non-target class samples were unique for the two different analytical
techniques. These DOE based samples were useful to improve the model performance, and they
resolved the critical issue of limited accessibility to actual falsified drug products.

The insight gained from Chapters 2 through 5 was used to develop a spectroscopic
authentication method for use in the health care setting or other remote testing sites. In Chapter 6,
portable spectrometers were used to scan different commercial products in two local pharmacies.
A protocol was developed to collect data from available products. This study also highlighted the
requirement of careful considerations of calibration samples and the use of an advanced algorithm
for the actual modeling. The developed model performed successfully by accepting target class
samples and rejecting non-target class samples at the local pharmacies in Pittsburgh.

This dissertation emphasizes the importance of 1) applying critical prior knowledge
regarding pharmaceutical products, pharmaceutical manufacturing/processing, analytical
methodology, and chemometric techniques, and 2) the application of a specific modern approach
to develop a successful spectroscopic authentication system. Combining all these pieces gives a
unique insight to direct the analyst during development of an authentication method.
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Figure 7-2: A schematic diagram of a possible cloud-based
data management and model application of spectroscopic
techniques.
Future applications of this project will include developing a cloud-based platform. The
developed model will be stored in a cloud-based server, facilitating effective management of
models and data for the analyst in the field. It will enable a global product tracking system, from
manufacturers to the rural clinics which will address the scourge of falsified drugs. Moreover, a
combination of an enhanced modeling approach, utilizing critical prior knowledge, will provide
the prescription for the solution to the current crisis of falsified drugs in the developing countries.
Also, this can be a potential application for IoT based testing of pharmaceutical products and
enhanced supply chain integrity in developed countries.
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